

WO 2005/037989

PCT/US2003/024918

EXAMPLE 32

CONSTRUCTION OF 2H7 scFv IgG FUSION PROTEINS WITH HINGE MUTATIONS

5 A 2H7 scFv IgG fusion proteins are constructed with the first cysteine residue and the second cystein in the IgG1 hinge region substituted with a serine residue to provide MTH (SCC) and MTH (CSC). The template for introduction of the mutations is a polynucleotide encoding 2H7 scFv WTH WTCH2CH3 (SEQ ID NO:___). The oligonucleotide introducing the mutations are 5' PCR primer oligonucleotides HIgGMHcys1 (SEQ ID NO:___) and HIgGMHcys2 (SEQ ID NO:___). The constructs are prepared as described in SEQ ID NO:___). The encoding polynucleotides of the mutants are presented in SEQ ID NOs:___) and the polypeptide sequences are provided in SEQ ID NO:___).

Additional representative sequences of the present invention are as follows:

15

HuIgG1 wild type hinge, CH2, CH3

tctgatcaggagcccaaatcttgtgacaaaactcacacatgccaccgtgccagcacctgaactcctggggggaccgtcagtcttctctt
ccccccaaaaccaaggacaccctcatgatctcccggaccctgaggtcacatgcgtgggtggacgtgagccacgaagaccctgag
20 gtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgaggaggagcagtacaacagcacgtaccgtg
tggtcagcgtctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctccagcccc
atcgagaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacaccctgcccccatccgggatgagctgaccaaga
accaggtcagcctgacctgcctgtgcaaaaggcttctatccagcgacatcgccgtggagtgaggagcaatgggcagccggagaa
ctacaagaccacgcctcccgtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggg
25 gaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

HuIgG1 wild type hinge, CH2, CH3

sdqepkscdkthtcppcpapellggpsvflfpkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvev
hnaktkpreeqynstyrvvsvltvlhqdwlngkeykckvsnkalpapietkiskakgqprepqvylppsrdeitknqvsitclvkgyf
30 psdiavewesngqpennykttppvl dsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispkg

Llama IgG1 hinge, CH2, CH3

tgalcaagaaccacatggaggatgcacgtgcccnacgtgcccncaatgccnngcncnngaactnccaggaggc
ccttctgtctttgtcttcccccgaaacccaaggacgtcctctccatttttgaggccgagtcacgtgcgttgtagtgacgtcggaagaaa

WO 2005/037989

PCT/US2003/024918

gaccccgaggtcaatttcaactggatatattgatggcgttgaggtgcgaacggccaafacgaagccaaaagaggaacagttcaacagcacg
taccgctgtgtcagcgtcctgcccattccagcaccaggactggctgacggggaaggaattcaagtgcagggtcaacaacaagctctccc
ggccccatcgagaggaccatctccaaggccaaagggcagaccgggagccgcaggtgtacacctggccccacaccgggaagaac
tgccaaggacaccgtgagcgttaacatgcctgggtcaaaggctctaccagctgacatcaacgttgagtggcagaggaacggtcagccg
5 gagtgcagagggcacctacgccaacacgcccccacagctggacaacgacgggacctaactctctacagcaagctctcgggtgggaaga
acacgtggcagcggggagaaaccttaacctgtgtgtgatgcatgagggcctgcacaaccactacaccagaaatccatcacccagttt
cgggtaaataagtaatactaga

Llama IgG1 hinge, CH2, CH3 (In figure 23 as Llama IgG1)

10 ephggctcpqcpapelpggpsvfvfpkpkdvlslsgrpevtcvvvdvgkedpevnfnwyidgvevrtantk
pkeeqfnstyrvvsvlpihqdwltgkefkckvnnkalpapiertiskakgqtrepqvylaphreelakdtvsvtclvkgfypadin
ewqrngqpesegtyantppqlndgtyflysrlsvgkntwqrgetltgvvmhealhnhytqksitqssgk

Llama IgG2:

15 tgatcaagaacccaagacacaaaaaccacaaccacaaccacaaccacaaccacaaccatctacaacagaatccaagtgtcccaatgtccag
cccctgagctctctgggagggccctcagttctatcttcccccgaaacccaaggacgtcctctccattctgggagggccgaggtcacgtg
cggtgtgtagacgtgggccaggaagaccccgaggtcagttcaactgggtacattgatggcgctgaggtgcgaacggccaacacgagggc
caaaagagggaacagttcaacagcacgtaccgctgggtcagcgtcctgcccattccagcaccaggactggctgacggggaaggaattcaa
gtgcaaggtcaacaacaagctctccccggccccatcgagaagaccatctccaaggccaaagggcagaccgggagccgcaggtgta
20 caccctggccccacaccgggaagagctggccaaggacaccgtgagcgttaacatgcctgggtcaaaggcttctaccacctgatatcaacg
ttgagtggcagaggaatgggcagccggagtcagagggcacgtacgccaccacgccacccagctggacaacgacgggacctaactctct
ctacagcaagctctcgggtggaaagaacacgtggcagcagggagaaaccttcacctgtgtgtgatgcacgagggccctgcacaaccact
acaccagaaatccatcacccagttctgggtaaataagtaatactaga

25 *Llama IgG2*

Dqepktpkpqpqpqpnppteskepkcpapellggpsvfvfpkpkdvlslsgrpevtcvvvdvgqedpev
sfnyidgaevrtantrpkeeqfnstyrvvsvlpihqdwltgkefkckvnnkalpapiektiskakgqtrepqvylaphreelakdt
vsvtclvkgfypdinveqwrngqpesegtyatppqlndgtyflysklsvgkntwqqgetftcvvmhealhnhytqksitqssgk

30 *Llama IgG3 Fc*

tgatcaagcgcaccacagcgaagacccagctccaagtgtcccaatgccaggccctgaactccttgaggggcc
cacggtctctatcttcccccgaaagccaaggacgtcctctccatcacccgaaaacctgaggtcacgtgcttgggtggacgtgggtaaag
aagacctgagatcgagttcaagctggctcggatgacacagaggtacacacggctgagacaaagccaaaggaggaacagttcaaca

WO 2005/037989

PCT/US2003/024918

gcacgtaccgcgtggtcagcgtcctgcccattccagcaccaggactggctgacggggaagggaattcaagtgaagggtcaacaacaagct
ctcccagcccccatcgaggaccatctccaaggccaaagggcagacccgggagccgcaggtgtacacctggccccacaccgggaa
gagctggccaaggacaccgtgagcgtaacctgcctggtaaaaggcttctccagctgacatcaacgttgagtgaggaggaatgggca
ggcggagtcagaggcacctacgccaacacgcccacagctggacaacgacgggacctactctctacagaaactctccgtggga
5 aagaacacgtggcagcaggagagaagtcttcacctgtgtggtgatgcagaggctctacacaatcactccaccagaaatccatcaccag
tcttcgggtaaatagtaatctagaggggcc

Llama IgG3 Fc

dqahhsedpsskcpkcpPELLGGPTVFIppkakdvlsitrkpevtclwwtwvkktrsssswsvddtevh
10 etkpkeeqfnstyrvsvlpqhqdwtgkefkckvnnkalpapiertiskakgqtrepqvytlaphreelakdtvsvtclvkgtffpadi
nvwqrngqpeseqtyantppqlndgtyflysklsvgkntwqqgevfctvmmhealnhstqlksitqssgk

15

HuIgG1 wild type hinge

gatcaggagcccaaatctgtgacaaaactcacacatgccaccgtgccagca

HuIgG1 wild type hinge

dqepksedkthtppcpa

20

HuIgG1 H2, wild type hinge with leu at second position (results from BglI site)

gatctggagcccaaatctgtgacaaaactcacacatgccaccgtgccagca

HuIgG1 H2, wild type hinge with leu at second position.

25

dlepksedkthtppcpa

NT

HuIgG1 wild type CH2

cctgaactcctgggggaccgtcagtcttctctcccccaaaacccaaggacaccctcatgatctccggacccc
30 tgaggtcacatgcgtggtggtggacgtgagccacgaagacctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatg
ccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatgg
caaggagtacaagtgcaggtctccaacaaagccctccagcccccatcgagaaaaccatctccaagccaaa

WO 2005/037989

PCT/US2003/024918

HuIgG1 wild type CH2 AA

pellggpsvflfpkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvvs
vltvlhqdwlngkeykckvsnkalpapiektiskak

5

NT HuIgG1 wild type CH3

gggcagccccgagaaccacaggtgtacacctgcccccatccgggaggagatgaccaagaaccaggtcagcc
tgacctgcctgggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaagaccac
gcctcccgtgtggactccgacggctccttctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttca
10 tgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga

AA HuIgG1 wild type CH3

gqprepqvylppsreemtknqvsltlvkgfypsdiavewesngqpennykttppvlstdgsfflyskltvdk
15 srwqqgnvfscsvmhcalhnhytqkslspspk

NT HuIgG1 mutated hinge (C-C-C→S-S-S)

gatcaggagcccaaatcttctgacaaaactcacacatccccaccgtccccagca
20

AA HuIgG1 mutated hinge (C-C-C→S-S-S)

dqepkssdkthtsppspa

25 Mutant hinge, but wild type CH2 and CH3—reads from the hinge+Ig tail,
HIgG1MTH WTCH2CH3:

tgatcaccccaaatcttctgacaaaactcacacatctccaccgtcctcagcacctgaactcctgggtggaccgtcagt
cttcctcttcccccaaaacccaaggacacctcatgatctcccgaccctgaggtcacatgcgtgggtggagctgagccacgaaga
ccctgagggtcaagttcaactgggtacgtggacggcggtggaggtgcataatgccagacaaagccgaggaggagcagtacaacagcacg
30 taccgtgtgggtcagcgtctcaccgtcctgcaccaggactgggtgaatggcaaggagtacaagtgaaggtctccaacaaagccctcca
gccccatcgagaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgccccatccgggatgagctga
ccaagaaccaggtcagcctgacctgctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccgga
gaacaactacaagaccacgcctcccggtgtgtggactccgacggctccttctctacagcaagctcaccgtggacaagagcaggtggca

WO 2005/037989

PCT/US2003/024918

gcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgat
aatctaga

Protein sequence: Mutant hinge, but wild type CH2 and CH3

5 dhpksdkthtsppssapellggpsvflfpkpkdtlmsrtpevtcvvdvshedpevkfnwyvdgvevhna
ktpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepvytlppsrdeltknqvsitclykgfyps
iavewesngqpennyktpvldsdgsfflyskltvdkrsrwqqgnvfscsvmhealhnhytqkslspsgk

LLG1-5'bgl 35 mer Llama IgG1 5'
10 5'-gtt gtt gat caa gaa cca cat gga gga tgc acg tg-3'

LLG2-5'bgl 32 mer, Llama IgG2-5'
5'-gtt gtt gat caa gaa ccc aag aca cca aaa cc-3'

15 LLG3-5'bgl 33 mer, Llama IgG3-5'
5'-gtt gtt gat caa gcg cac cac agc gaa gac ccc-3'

LLseqsense 19mer, llama sequencing primer
20 5'-ctg aga tcg agt tca gct g-3'

LLseqAS 19 mer
5'-cct cct ttg gct ttg tct c-3'

NT
25 **2H7 scFv llama IgG1**

aagcttgccgcatggattttcaagtgacagatttcagcttctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctctccagctcagcaatcctgtctgcatctccaggggagaaggacacaatgacttgaggccagctcaagtgttaagtacat
gcactgggtaccagcagaagccaggatcctccccaaacccctggatttatgccccatccaacctggcttctggagtcctgctcgttcagt
gcagtgggtctgggaccttactctctcacaatcagcagagtgaggctgaagatgctgccacttactgcccagcagtgagggtttaacc
30 caccacgttcgggtgctgggaccaagctggagctgaaagatggcggtggctcggcggtggatctggaggaggtgggagctctca
ggcttatctacagcagcttggggctgagctggtagggcctggggcctcagtgaaatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggtaaagcagacacctagacaggcctggaatggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaaggggcaaggccacactgactgtagacaaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg

WO 2005/037989

PCT/US2003/024918

gtctatttctgtgcaagagtgggtactatagtaactcttactggacttcgatgtctggggcacagggaccacggtcaccgtctcttgatca
 agaaccacatggaggatgcacgtgcccnacgtgcccncaatgccnngcnccngaactnccaggaggcccttctgtcttcttcccccc
 gaaacccaaggacgtcctctccattttggaggccgagtcacgtgcgttgtagtgagcgtcggaaagaaagaccccagggtcaattcaac
 tggatatattgatggcgttgaggtgcgaacggccaatacgaagccaaaagggaacagttcaacagcacgtaccgcgtggtcagcgtcctg
 5 cccatccagcaccaggactggctgacgggggaaggaattcaagtgaaggtaacaacaaagctctccggcccccacagaggacca
 tctccaaggccaaaggcgagacccgggagccgaggtgtacacctggccccacaccgggaagaactggccaaggacaccgtgagc
 gtaacatgcctggtcaaaggcttctaccagctgacatcaacgttgagtgagcagaggaaacggtcagccggagtcagagggcacctacgc
 caacacgccccacagctggacaacgacgggacactctctctacagcaagctctcggtgaggaaagacacgtggcagcgggggaga
 aaccttaacctgtgtggtgatgcatgaggccctgcacaaccactacaccagaaatccatcaccagctctcgggtaaatagtaatttaga
 10

AA 2H7 scFv llama IgG1

mdfqvqifsfllisasviiargqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiyapns
 lasgvparfsgsgsytstisrveadaatyccqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
 15 mscasgytftsynmhwwkqtrqglewigaiypngdtsynqkfkgtatltvdkssstaymqlssltedsavyfcarvvyysns
 ywyfdvwtgtttvtssdqephggctcpqcpapelpggsvfvfpkpkdvlsifggrvtcvvvdvgkkdpevnfnwyidggev
 rtantkpeeqlnstyrvsvlpiqhqdwtgkefkckvnnkalpapiertiskakgtrepqvylaphreelakdivsvtclvkgfyp
 adinveqwrngqpeseqgyantppqlndgtyflysklsvgkntwqrgetltcvvmhealnhhytqksitqssgk
 20

NT 2H7 scFv llama IgG2

aagcttgccgccatggatttcaagtgcagatttccagcttctgtaatacagtgcttcagtcataattgccagaggaca
 aattgttctctccagcttccagcaatcctgtctgcatctccaggggagaaggtcacaatgacttgaggccagctcaagtgttaattacat
 gcaactggtagcagagaagccaggatcctcccccacccctggatttatgcccatccaacctggcttctggagtcctgtctgcttcagtg
 25 gcaagtgggtctgggaccttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgagggtttaacc
 caccacgcttcgggtgctgggaccaagctggagctgaagatggcggtggctcggcggtggtggatctggaggaggtgggagcttca
 ggcttatctacagcagcttggggctgagctggtaggctggggcctcagtgagatgtcctgcaaggcttctggctacacattaccagtt
 acaatatgcactgggtaaagcagacacccagacaggcctggaatggattggagctattatccaggaaatggtgatacttctacaatcag
 aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
 30 gtctatttctgtgcaagagtgggtactatagtaactcttactggacttcgatgtctggggcacagggaccacggtcaccgtctcttgatca
 agaaccaagacacaaaaaccacaaccacaaccacaaccacaaccacaaccatctacaagaatccaagtgcccaaatgtccagcccctg
 agctcctgggaggggccctcagcttctatcttccccgaaacccaaggacgtcctctccatttctgggaggcccagggtcacgtgcgttg
 gtagacgtgggccaagggaagaccccagggtcagttcaactggtagattgatggcgtgaggtgcgaacggccaacacaggccaaaag

WO 2005/037989

PCT/US2003/024918

aggaacagttaacagcacgtaccgctgggtcagcgtcctgccatccagcaccaggactggctgacggggaaggaattcaagtgcaa
ggtaacaacaaagctctccggcccccacgagaagaccatctccaaggccaaaggcgagaccgggagccgcaggtgtacacct
ggccccacaccgggaagagctggccaaggacaccgtgagcgtaacatgcctggtaaaaggcttciaccacctgatatcaacgttgagt
ggcagaggaatgggcagccggagtcagagggcacgtacgccaccacgccacccagctggacaacgacgggacctactctctaca
5 gcaagctctcggtaggaagaacacgtggcagcaggagaaaccttcacctgtgtggtgatgcagaggccctgcacaaccactacacc
cagaatccatcacccagctctcgggtaaatagtaattctaga

AA

2H7 scFv llama IgG2

0 mdfqvqifsfllisasviiargqivlsqpailsaspgkvmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparifsgsgtsysltisrveadaatyycqwsfnptfagtkleldggsgsgsgsgsgssqaylqqsgaelvrpgasvk
msckasgytfsynmhwwkqtpqrqglewigaiypngdtsynqkfkkgkatltvdkssstaymqlssltedsavyfcarvvyysns
ywyfdvwgtgtvtvssdqepktpkpqpqpqpnppteskepckpapellggpsvfifppkpkdvlisgrpevtcvvvdvgqed
pevsfnwyidgaevrtantrpkeeqfnstyrvsvlpiqhqdwtgkefkckvnnkalpapietiskakgtrepvytlaphreela
15 kdtvsvtclvkgyppdinwvqrngqpesegtyatppqlndngtyflysklsvgkntwqqgetftcvvmhealhnhytqksitqss
gk

NT

2H7 scFv llama IgG3

20 aagcttgccgcatggattttcaagtgcagattttcagcttcctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctctccagctctcagcaatcctgtctgcattctccagggagaaaggtcacatgacttcagggccagctcaagtgttaagttacat
gcactgggtaccagcagaagccaggtatcctcccaaacctggatttatgccccatccaacctggcttctggagtcctgctcgttcagtg
gcagtgggtctgggacctcttactctctcacaatcagcagagtgaggctgaagatgctgccacttattactgccagcagtgaggatttaacc
caccacgftcgggtgctgggaccaagctggagctgaagatggcggtggctcggcggtgggtggatctggaggagtgaggagctctca
25 ggcttatctacagcagctctggggctgagctggtgaggcctggggcctcagtgaaagatgctcgaaggcttctggctacacattaccagtt
acaatatgcactgggtaaagcagacacntagacaggcctggaatggattggagctatttatccaggaaatgtgtatacttctcacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgag
gtctatttctgtgcaagagtgggtactatagtaactcttactggtactcgtgtctggggcacagggaaccggcaccgtctctctgatca
agcgaaccacagcgaagacccagctccaagtgtcccaaatgccaggccctgaactccttgaggggccacgggtcttcatcttcccccc
30 gaaagccaaggagctcctctccatcacccgaaaacctgaggtcagctgctgtggtgacgtgggtaaagaagacctgagatcaggttc
aagctggctcgtggtgacacagaggtacacacggctgagacaaagccaaggaggaacagttcaacagcacgtaccgcgtggtcagc
gtctgccccatccagcaccaggactggctgacggggaaggaattcaagtgaaggtcaacaacaaagctctccagcccccatcgagag
gaccatctccaaggccaagggcagacccgggagccgaggtgtacacctggccccacaccgggaagagctggccaaggacaccg

WO 2005/037989

PCT/US2003/024918

tgagc gtaacctgcctgggtcaaaggcttctcccagctgacatcaacgttgagtgagcagaggatgggcagccggagtcagagggcacct
acgccaacacgccgccacagctggacaacacgggacctaacttctctacagcaactctcgtgggaaagaacacgtggcagcaggg
agaagtcttcacctgtgtggtgatgcacgaggtctacacaatactccaccagaaatccatcaccagctctcgggtaaatagtaatactag
agggc

5

AA

2H7 scFv llama IgG3

mdfqvqifsfllisasviiargqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyccqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytfsynmhvwkqtrqglewigaiypngdtsynqkfkkgkatltvdkssstaymqlssltedsavycarvvysns
ywyfdvwgtgtvtvssdqahshsedpsskcpkcpellggptvfifppkakdvlsitrkpevtclwwtwvktlrsssswsvddt
evhtaetkpkkeeqfnstyrvvslpiqhqdwtgkefkckvnnkalpapiertiskakgqtreppvytlaphreelakdtsvtclvkf
fpadinvwqrngqpeseqyiantppqlndngtyflysklsvgkntwqqgevtcvvmhealnhstqksitqssgk

15

2H7+Completely WT IgG tail:

2H7 scFv WTH WTCH2CH3

Nucleotide sequence:

aagcttgccgcatggatttcaagtgcagattttcagcttctgtaatactgcttcagtcataattgccagaggaca
aattgttctctcccagctcagcaatctgtctgcatctccagggagagaaggtcacaatgacttcagggccagctcaagtgttaattacat
gcactgggtaccagcagaagccaggtatctccccaaacctggatttatgcccatccaacctggcttctggagtcctctgctcgttcagt
gcagtgggtctgggaccttctactctcacaatcagcagagtgaggctgaagatgctgccacttattactgccagcagtgagggtttaacc
caccacagcttgggtgctgggaccaagctggagctgaagatggcggtgctcggcggtggtgagctggaggagggtgggagctctca
ggcttatctacagcagcttggggtgagctgggtgaggcctggggcctcagtgaaagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggttaaagcagacacctagacagggcctggaatggattggagctattatccaggaaatgggtatacttctacaatcag
aagttcaagggcaaggccactgactgtagacaaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgtgtactatagtaacttctactgttactcgtctggtggggcacagggaccacgggtcaccgtctctctgatca
ggagcccaaatctgtgacaaaactcacacatgccaccgtgccagcacctgaactcctggggggaccgtcagcttctcttccccca
aaaccCaaggacacctcatgatctccggaccctgaggtcacatgcgtggtggagctgagccacgaagacctgaggtcaagtt
caactgggtacgtggagcgcgtggaggtgataatgccaagacaaagccgaggaggagcagtaaacagcacgtaccgtgtggtcagc
gtctcaccgtctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctccagccccatcgagaa
aacaatctcaaagccaaaggcagccccgagaaccacaggtgtacacctgccccatcccggtgagctgaccaagaaccaggtc
agcctgacctgcctggtcaaaggcttctatccagcgacatcgccgtggagtgaggagcaatgggcagccggagacaactacaaga

30

WO 2005/037989

PCT/US2003/024918

ccacgcctcccggtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccggtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

2H7+Completely WT IgG tail:

5

2H7 scFv WTH WTCH2CH3

Protein sequence

mdfqvqifsfllisasviiargqivlsqpailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyccqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsymbhwwkqprqglewigaiypngdtsynqkfkqkatltvdkssstaymqllsitsedsavfyfcarvvyysns
10 ywyfdvwtgtttvtvssdqepkscdkthtppcpapelggpsvflfppkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrldeltnqvslclvk
gfypsdiavewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispk

NT

15

CD80 transmembrane domain and cytoplasmic tail (+restriction sites)

goggatccttcgaacctgctcccatcctgggccattaccttaatctcagtaaatggaattttgtgatatgctgcctgacc
tactgctttgccccaaagtgcagagagagaaggaggaatgagagattgagaagggaagtgtacgcctgtataaatcgat

AA

20

CD80 transmembrane domain and cytoplasmic tail

adpsnllpswaitlisvngifviccltycfaprerrrrmerlrresvrpv

NT

25

40.2.220 VL (anti-human CD40 scFv #1--VL)

aagcttatggattttcaagtcagattttcagcttctgctaatactgcttcagtcataatgtccagaggagtcgacatt
gttctgactcagctccagccaccctgtctgtgactccaggagatagagctctcttctcagggccagccagagtattagcgactacttac
actggtatcaacaaaatcacatgagctccaaggcttctcatcaaatatgcttccattccatctctgggatccctccaggttcagtggcagt
ggatcagggtcagatttactctcagtatcaacagtggtgaacctgaagatgttggaattattactgtcaacatggtcacagctttccgtggac
30 gttcgggtggaggcaccaagctggaaatcaaacgg

AA

40.2.220 VL (anti-human CD40 scFv #1--VL)

WO 2005/037989

PCT/US2003/024918

mdfqvqifsfllisasvimsrgvdivltqspatlsvtpgdrvslsruasqsisdylhwyqqkshesprllikyashsi
sgipsrfsfgsgsgsdftlsinsvepedvgiyycqhgshfpwtfgggtkleikr

NT

5 40.2.220 VH (for anti-human CD40 scFv #1--VH)

cagatccagttgggtgcaatctggacctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttctg
ggatgccttcacaactactggaatgcagtggtgcaagagatgccaggaaagggttgagtggttggtgataaacacccactctg
gagtgccaaaatatgtagaagacttcaaggacggttgccttctcttggaaacctctgccaactgcataattacagataagcaacctcaa
gatgaggacacggctacgtatttctgtgtgagatccgggaatggaactatgacctggcctactttgcttactggggccaaggacactggt
10 cactgtctctgatca

AA

40.2.220 VH (for anti-human CD40 scFv #1--VH)
qiqlvqsgpelkkpgetvriskasgyafttgmqvwqempgkglkwigwintplwsakicrrlqgrfafslets
15 antaylqisnlkdedtatyfcvrsngnydlayfaywgqgtlvtvs

NT

40.2.220 scFv (anti-human CD40 scFv #1)
20 aagcttatggattttcaagtcagatcttctcagcttctcctgataatcagtcgttcagtcataatgtccagaggagtcgacatt
gttctgactcagtcctccagccacctgtctgtgactccaggagatagagctctcttctcctgaggccagccagagattatgcgactacttac
actggatcaacaaaatcacatgagtcctcaaggcttctcatcaaatatgcttccatccatctctgggatccctccaggttcagtggcagt
ggatcagggtcagatttactctcagatcaacagtggtggaacctgaagatgttggaatttactgtcaacatggtcacagctttccgtggac
gttcggtggaggcaccaagctggaaatcaaacggggtggcggtggctcgggagggtgggtcgggtggcggggatctcagatcca
25 gttggtgcaatctggacctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttctgggtatgccttcacaactactgga
atgcagtggtgcaagagatgccaggaaagggttgagtggttggtgataaacacccactctggagtgccaaaatatgtagaaga
cttcaaggacggttgccttctcttggaaacctctgccaactgcataattacagataagcaacctcaaagatgaggacacggctacgtatt
tctgtgtgagatccgggaatggaactatgacctggcctactttgcttactggggccaaggacactggtcactgtctctgatca

AA

30 40.2.220 scFv (anti-human CD40 scFv #1

mdfqvqifsfllisasvimsrgvdivltqspatlsvtpgdrvslsruasqsisdylhwyqqkshesprllikyashsi
sgipsrfsfgsgsgsdftlsinsvepedvgiyycqhgshfpwtfgggtkleikrgggsgggsgggsgggsggiqlvqsgpelkkpgetvrisk

WO 2005/037989

PCT/US2003/024918

ckasgyaftttgmqwvqempgkglkwigwintplwsakicrrlqgrfafsletsantaylqisnlkdedtatyfcvrsngnydlayfa
ywgqgtlvts

NT

5 2e12 VL (with L6 VK leader peptide)

atggattttcaagtcagattttcagcttcctgctaatacagtcctcagtcataatgtccagaggagtcgacattgtgctc
acccaatctccagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgtgaatattatgtcacaagttt
aatgcagtggtaccaacagaaaccaggacagccacccaaactcctcatctctgctgcacccaacgtagaatctgggggtccctgccaggttt
agtggcagtggtgtgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaaagtaggaa
10 ggttccttgagcgttcggtggaggcaccaagctggaaatcaaacgg

AA

2e12 VL (with L6 VK leader peptide)

mdfqvqifsfllisasvimsrgvdivltqspaslavlqqratisrcasesveyyvtslmqwyqqkpgppkllis
15 aasnvsgvparfsgsgsgtdfslnihpveeddiamyfcqsrkvpwtfgggtkleikr

NT

2e12 VH (no leader peptide)

caggtgcagctgaaggagtcaggacctggcctgggtggcgccctcacagagcctgtccatcacatgcaccgtctca
20 gggttctcattaaccggctatggtgtaaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatgggggtgatggaa
gcacagactataattcagctctcaaatccagactgagcatcaccaaggacaactccaagagccaagtttctfaaaaatgaacagctctgcaa
actgatgacacagccagatactactgtgccagagatgggtatagtaactttcattactatgttatggactactggggcaaggaaacctcagtc
ccgtctcctca(gatctg)

25 AA

2e12 VH

qvqlkesgpglvapsqslsitctvsgfsltgygvnwvrppgkglewlgmiwgdgstdynsalksrslsitkdns
ksqvfikmnsldtdtaryycardgysnfhyvmdywgqgtsvtvss

30 NT

2e12scFv(+Restriction sites)

aagcttatggattttcaagtcagattttcagcttcctgctaatacagtcctcagtcataatgtccagaggagtcgacatt
gtgctcacccaatctccagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgtgaatattatgtca

WO 2005/037989

PCT/US2003/024918

caagtttaatgcagtggtaccaacagaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc
caggtttagtgagtcagtggtctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgcagcaaag
taggaagggttccttgacgttcggtggagggcaccaagctggaaatcaaacgggggtggcgggtggctcgggcggagggtgggtcgggtggc
ggcgggatctcaggtgcagctgaaggagtcaggacctggcctgggtggcgcctcacagagcctgtccatcacatgcaccgtctcagggttc
5 tcaftaacggctatggtgtaactgggttcgccagcctccaggaaagggtctggagtggtgggaatgatatgggggtgatggaagcaca
gactataattcagctctcaatccagactgagcatcaccaaggacaactccaagagccaagtcttcttaaaaatgaacagctctgcaactgat
gacacagccagatactgtgccagagatggttatagtaactttcattatgttatggactactggggtaaggaacctcagtcaccgtct
cctct(gatcag)

10 AA
2e12scFv
mdfqvqifsfllisasvimsgvdivltqspaslavslgqratiscrasesveyyvtslmqwyqqkpgppkllis
aasnvesgvparfsgsgsgtdfslnihpveediamyfcqsrkvpwtfgggtkleikrgggsgggsgggsgvqqlkespgplva
psqslsitctvsgfsltygvnwvrppgkglewlgmiwgdgstdynsalksrslitkdnsksqvfikmnsiqtdtdaryycardgys
15 nfhyvymdywgqgtsvtvss

10A8 is anti-CD152 (CTLA-4)
10A8 VL (with L6 VK leader peptide)
atggattttcaagtcagattttcagcttctgctaatcagtgcttcagtcataatgtccagaggagtcgacatccagatg
20 acacagctctccatcctcactgtctgcatctctgggaggcaaagtcacatcacttgcaaggcaagccaagacattaagaagtatataggtg
gtaccaacacaagcctggaaaagggtccaggtgctcatatattacacatctacattacagccaggcatccatcaagggtcagtggaagtg
ggtctgggagagattatccctcagcatcagaaacctggagcctgaagatttgcaactattattgtcaacagtatgataatctccattgacg
ttcggctcggggacaaagttggaaataaacgg

25 AA
10A8 VL
mdfqvqifsfllisasvimsgvdiqmtqspsslsaslggkvitokasqdikkyigwyqhkpkgprlliyyst
lqpgipsrfsgsgsgrdyslsirnlepediatyycqqydnpltfsggtkleikr

30 NT
10A8 VH (no leader peptide)
gatgtacagcttcaggagtcaggacctggcctcgtgaaaccttctcagtcctctgtctctcacctgctctgtcactggcta
ctccatcaccagtggtttctactggaactggatccgacagttccgggaaacaaactggaatggatgggccacataagccacgacggtagg

WO 2005/037989

PCT/US2003/024918

aataactacaacccatctctcataaatcgaatctccatcactcgtgacacatctaagaaccagttttcctgaagttgagttctgtgactactgag
gacacagctacatatctgtgcaagacactacggtagtagcgggagctatggactactggggtaaggaacctcagtcaccgtctcctctga
tca

5

AA

10A8 VII

dvqlqesgpglvkpsqslstcsvtgysitsgyfwnwirqfpgnklewmghishdgrnnynpslinrisitrdtsk
nqfflklssvttedatatyfcarhygssgamdywgqgtsvtvss

10

NT

10A8 scFv

aagcttatggattttcaagtcagattttcagcttcctgctaatacagtgcttcagtcataatgtccagaggagtcgacatc
cagatgacacagtcctccatcctcactgtctgcatctctgggaggcaaaagtcacatcacttgaaggcaagccaagacattaagaagtatat
aggttggtaccaacacaagcctggaaaaggtcccaggctgctcatattacacatctacattacagccaggcatcccatcaaggttcagtg
15 gaagtgggtctgggagagattatccctcagcatcagaaacctggagcctgaagataattgcaacttattattgtcaacagtatgataatctcc
attgacgttcggctcggggacaaagttggaataaaacggggtggcgggtggctcgggcgggtgggtgggtcgggcgggtggtatctgat
gtacagcttcaggagtcaggacctggcctcgtgaaaccttctcagctctctgtctctcacctgctctgactggctactccatcaccagtggtt
ctactggaaciggatccgacagtttccgggaaacaaactggaatggatgggccacataagccacgacggtaggaataactacaacccatc
tctcataaatcgaatctccatcactcgtgacacatctaagaaccagttttcctgaagttgagttctgtgactactgaggacacagctacatatt
20 ctgtgcaagacactacggtagtagcggagctatggactactggggtaaggaacctcagtcaccgtctcctctgatca

AA

10A8 scFv

mdfvqifsfllisasvimsrgvdiqmtqspsslsaslggkvitckasqdikkyigwyqhkpkgprlliyyst
25 lqpgipsrfsrgsgsgrdyslsirnlepediatyycqydnlpitfgsgtkleikrgggsgggsgggsgsdvqlqesgpglvkpsqslst
csvtgysitsgyfwnwirqfpgnklewmghishdgrnnynpslinrisitrdtsknqfflklssvttedatatyfcarhygssgamdywg
qgtsvtvssd

30

NT

40.2.220-hmIgG1-hCD80

aagcttatggattttcaagtcagattttcagcttcctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gttctgactcagtcctcagccacctgtctgtgactccaggagatagagctctcttctcagggccagccagagtaftagcgactacttac

WO 2005/037989

PCT/US2003/024918

actggtatcaacaaaatcacatgagctccaaggctctcatcaaatatgcttccattccatctctgggatccctccagggtcagtggcagt
ggatcagggtcagatttactctcagtatcaacagtgtggaacctgaagatgttgaatttattactgtcaacatggtcacagctttcgtggac
gttcggtggaggcaccaagctggaatcaaacggggtggcgggtgctcggcgagggtgggtcgggtggcgcgagatcagatcca
gttggtgcaatctggacctgagctgaagaagcctggagagacagtcaggatctcctgcaaggcttctgggtatgccttcacaaactactgga
5 atgcagtggtgcaagagatgccaggaaagggtttgaagtggattggctggataaacacccactctggagtgcacaaatgtagaaga
cttcaaggacggtttgccttctcttggaaacctctgccaacactgcataattacagataagcaacctcaaagatgaggacacggctacgtatt
tctgtgtgagatccgggaatgtaactatgacctggcctactttgcttactggggccaagggaactggtcactgtctctgtatctggagccca
aatcttctgacaaaactcacacatccccaccgtcccagcacctgaactcctggggggatcgtcagtcttctcttcccccaaaaccaag
gacacctcatgatctccggaccctgagggtcacatgcgtggtggtggacgtgagccacgaagacctgagggtcaagttcaactggtac
10 gtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtagacaacagcacgtaccgtgtggtcagcgtcctaccg
tctctgaccaggactggtgaatggcaaggagtagaagtgcaaggcttccaacaaagccctccagccccatcgagaaaacctctcc
aaagccaaagggcagccccgagaaccacaggtgtacacctgccccatcccggtatgagctgaccaagaaccaggtcagcctgacct
gcctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagacaactacaagaccacgcctcc
cgtgtgtgactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgtctcc
15 gtgatgatgaggtctgcacaaccactacacgcagaagacccctcctctcctcgggtaagcggatccttgaacctgtcccatctct
gggccattaccttaatctcagtaaatggaattttgtgatgtctgcctgacctactgctttgccccaaagatgcagagagagaaggaggaatg
agagattgagaagggaagtgtacgccctgtataaatcgtat

AA

20 40.2.220-hmIgG1-hCD80
mdfqvqifslisavimsrgvdivltqspatlsvtpgdrvsiscrasqsisdyllhwyqqkshesprllikyashsi
sgipsrfsrgsgsgsdftlsinsvepedvgiyyqchghsfpwtfgggtkleikrgggsgggsgggsgggsgqilvqsgpelkpkgetvris
ckasgyafttmqvwqempgkglkwigwintplwsakicrrlqgrfafsletsantaylqisnlkdedtatyfcvrsngnydlayfa
ywgqgtlvtvsdlepkssdkthtspspapellggssvflfppkpkdilmisrtpevtcvvdvshedpevkfnwyvdgvevhnakt
25 kpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeltknqvsltlvkgfypsdi
vewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealnhytqkslspsgkadpsnllpswaitlisvn
gifviccltycfaprerrrrerlrresvrpv

NT

30 2e12scFv- hmIgG1-CD80 fusion protein
aagcttatggattttcaagtgagattttcagcttctgctaatcagtgcttcagtcataatgtccagaggagtcgacatt
gtgctcacccaatctccagcttcttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgatattatgtca
caagtttaatgcagtggtaccaacagaaaccaggacagccacccaactcctcatctctgctgcatacaacgtagaatctggggctcctgc

WO 2005/037989

PCT/US2003/024918

caggtttagtggcagtggtgctgggacagactcagcctcaacatccatcctgtggaggaggatgatattgcaatgtattctgtcagcaaag
taggaagggttccttgacgttcggtggagggcaccaagctggaaatcaaacgggggtggcgggtggctcgggagggtgggtggc
ggcgatctcaggtgcagctgaaggagtcaggacctggcctggtggcgccctcacagagcctgtccatcacatgcaccgtctcagggttc
tcattaaccggctatggtgtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatgggggtgatggaagcaca
5 gactataatcagctctcaaatccagactgagcatcaccaggacaactccaagagccaagtttcttaaaaatgaacagltctgcaactgat
gacacagccagatactactgtgccagagatggtfataagtaactttcattactatgttatggactactgggggtcaaggaaacctcagtcaccgtct
cctcagatctggagcccaaatctctgacaaaactcacacatccccaccgtcccagcaccigaactcctggggggatcgtcagttctctc
ttcccccaaaaccaaggacacctcatgatctccggaccctgaggtcacatgcgtggtggtggagctgagccacgaagacctga
ggtcaagtccaactggtacgtggacggcgtggaggtgcataatgcaagacaaagccgaggaggagcagtaacagcacgtaccgt
10 gtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagcccc
catcgagaaaaccatctccaaagccaaaggcgagccccgagaaccacaggtgtacaccctgccccatcccggtgatgagctgaccaag
aaccaggtcagcctgacctgcctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagaaca
actacaagaccacgctccgtggtgactccgagcgtccttctctctacagcaagctcaccgtggacaagagcaggtggcagcagg
ggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaacgggatcct
15 tgaacctgtcccatcctgggccattaccttaatctcagtaaatggaattttgtgatgctgcctgacctactgctttgccccaaagatgcaga
gagagaaggagggaatgagagattgagaagggaaggtgtacgccctgtataaatcgat

AA

2e12scFv- hmtIgG1-CD80 fusion protein

20 mdfqvqifsfllisasvimsrgvdivltqspaslavslgqratisrasesveyyvtslmqwyqqkpgppkllis
aasnvesgyparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikrgggsgggsgggsgqvqlkesgpglva
psqslsitctvsgfsltygvnwvrpppgkglewlgmiwgdgstdynsalksrslsitkdnsksqvfikmnsqtdtdaryycardgys
nfhyvmdywgqgtsvtvssdlepkssdkthtspapellgssvflfppkpkdtlmisrtpetvcvvvdvshedpevkfnwyv
dgvevhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeltknqvsitc
25 lvkgfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslspsgkadpsnll
pswaitlisvngifviccltycfaprerrrrerlrresvrpv

NT

30 *10A8 scFv-hmtIgG1-CD80*

aagcttatggatttcaagtcagattttagcttctgctaatactgctcagtcataatgtccagaggagtcgacatc
cagatgacacagctctccatcctcactgtctgcatctctgggaggcaagtcaccatcacttgcaaggcaagccaagacattaagaagtatat
aggttggtaccaacacaagcctggaaaaggctccaggctgctcatatattacacatctacattacagccaggcatcccatcaagggtcagtg

WO 2005/037989

PCT/US2003/024918

gaagtgggtctgggagagattattccctcagcatcagaaacctggagcctgaagatattgcaactattattgtcaacagtatgataatcttcc
attgacgttcggctcggggacaaagtggaaataaaacgggggtggcgggtggctcgggcgggtgggtgggtcgggtggcggcgggatctgat
gtacagcttcaggagtcaggacacctggcctcgtgaaccttctcagtcctctctcacctgctctgctactggctactccatcaccagtggtt
ctactggaactggatccgacagttccgggaaacaaactggaatggatgggccacataagccacgacggttaggaataactacaacccatc
5 tctcataaatcgaatcctcactcgtgacacatctaagaaccagttttcctgaagttgagttctgtgactactgaggacacagctacatatt
ctgtgcaagacactacggtagtagcggagctatggactactggggtcaaggaaacctcagtcaccgtctcctctgatctggagccaaatctt
ctgacaaaactcacacatccccaccgtcccagcacctgaactcctggggggatcgtcagtccttctcttcccccaaaacccaaggacac
cctcatgatctcccgacccttgaggtcacatgcgtggtgggtgacgtgagccacgaagaccctgaggtcaagttcaactgggtacgtgga
cggcgtggaggtgcataatgccaagacaaagccgcggggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctg
10 caccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccatcgagaaaaccatctccaaagc
caaagggcagccccgagaaccacaggtgtacacctgccccatcccggtatgagctgaccaagaaccaggtcagcctgacctgacctg
gtcaaaggcttctatcccagcgacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaagaccacgcctcccgtgct
ggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatg
catgaggctctgcacaaccactacacgcagaagacctctccctgtctccgggtaaagcggatccttgaacctgctccatcctgggcca
15 ttaccttaatctcagtaaatggaattttgtgatatgctgacctactgctttgccccaaagatgcagagagagaaggaggaaatgagagatt
gagaagggaagtgtacgccctgtataaatcgat

AA

10A8 scFv-hmIgG1-CD80

20 mdfqvqifsfllisasvimsrgvdiqmtqspsslsaslggkvitckasqdikkyigwyqhkpkgprllyytst
lqpgiprsfsgsgsgrdyslsirnlepediatyycqydnlpitfgsgtkleikrgggsgggsgggsgsdvqlqespglvkpsqslst
csvtgysitsgfywnwirqfpgnklewmghishdgrnynpslinrisitrdtsknqfflklssvttedatyfcarhygssgamdywg
qgtsvtvssdlepkssdkthtspapellggssvflfppkpkdtlmsrtpcvvvdvshedpevkfnwyvdgvevhnaktkp
reeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeltknqvsitclvkgfypsdiave
25 wesngqpennyktpplvdsdgsfflyskltvdksrwqqgnvfscsvmhcalhnhytqkslspsgkadsnllpswaitlisvngif
viccltycfaprerrrrrrlresvrpv

NT

500A2-hmIgG1-CD80

30 atgtgtatacatctcagctccttgggctttactcttctggatttcagcctccagaagtacatagtgctgactcagactc
cagccactctgtcttaattcctggagaaaagtcacaatgacctgtaagaccagtcagaatattggcacaactcttactggtatcacaaa
aaccaaaggaggctccaagggtctcatcaagtatgcttcgagtcattcctgggatccctccagattcagtggcagtggttcggaaaca
gatttcactctcagcatcaataacctggagcctgatgatcggaaatttactgtcaacaaagtagaagctggcctgtcacgttcggctctg

WO 2005/037989

PCT/US2003/024918

gcaccaagctggagataaaacggggtggcgggtgctcggcgagggtgggtcgggtggcgggcgatctcaggtcaagctgcagcagt
ccgggtctgaactagggaacctggggcctcagtgaaactgtcctgcaagacttcaggtacatattcacagatcactatattcttgggtgaa
acagaagcctggagaaagcctgcagtgataggaaatgttatggtgaaatgggtgtacaagctacaataaaaaattccagggaaggc
cacactgactgtagataaaatctctagcacagcctacatggaactcagcagcctgacatctgaggattctgccatctattactgtgcaagaag
5 gccggtagcgacgggcatgctatggactactggggtcaggggatccaagttaccgtctcctctgatctggagcccaaatcttgcacaaa
actcacacatccccaccgtccccagcacctgaactcctgggggatcgtcagtccttcttcccccaaaaaccaaggacacctcatgat
ctcccggaacctgaggtcacatgcgtgggtgggacgtgagccacgaagacctgaggtaagttcaactggtagctggacggcgtgg
aggtgcataatgccaagacaaagccgcgggaggagcagtagacaacagcacgtaccgtgtggtcagcgtcctaccgtcctgcaccagga
ctggctgaatggcaaggagtacaagtgaaggctccaacaaagccctccagccccatcgagaaaaccatctccaaagccaaagggc
10 agccccgagaaccacaggtgtacacctgccccatccgggatgagctgaccaagaaccagggtcagcctgacctgctgggtcaagg
cttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagacaactacaagaccacgcctcccgctgctggactccg
acggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctatgctccgltgatgcatgaggc
tctgcacaaccactacacgcagaagagcctctccctgtctcgggtaaagcggatcctcgaacctgctccatcctgggccattaccta
ctcagtaaatggaattttgtgatgctgcctgacctactgcttggcccaagatgcagagagagaaggagggaatgagagattgagaagg
15 aaagtgtacgccctgtataaatcgat

AA

500A2-hmtIgG1-CD80

mlytsqllglllfwisasrdivltqtpatlslipgervtmtcktsqnigtilhwyhqkpkcaprailikyasqsigip
20 srfsgsgsetdftlsinnlepddigiycqqsrswpvtfgpgtkleikrgggsgggsgggsgqvkllqsgselgkpgasvklsccts
gyiftthyisvwwkqkpgeslwignvygnggtsynqkfqqkatltvdkisstaymelssltedsaiyycarrpvatghamdywg
qgiqvtvssdlepkssdkthtspapellggssvflfppkpkdtlmsirtpvtevvvdvshedpevkfnwyvdgvevhnaktkp
reeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietkiskakgqprepvytlppsrdeltknqvsltclvkgyfypsdiave
wesngqpennykttpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispgakdpsnllpswaitlisvngif
25 viccltycfaprerrrrnerlrresvrpv

NT

2H7 scFv MTH(SSS)WTCH2CH3

aagcttgcgcctatggattttcaagtgagattttcagcttctgctaatcagtgcttcagtcataattgccagaggaca
30 aattgttctctccagctctcagcaatcctgtctgcatctccagggagaaagtcacaatgacttgaggccagctcaagtgtaagttacat
gcactggtagcagcagaagccaggatcctccccaaccctggatttatgccccatccaacctggctctcaggatccctgctcgcttcagtg
gcagtggtctgggacctcttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgcagcagtgaggattttaacc

WO 2005/037989

PCT/US2003/024918

caccacacgttcggtgctgggaccaagctggagctgaaagatggcggtggctcgggcggggtggatctggaggaggtgggagctctca
ggcttatctacagcagctctggggctgagctggtgagggcctggggcctcagtgaaagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggtaaacgagacacctagacagggcctggaatggattggagctattatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
5 gtctatttctgtgcaagagtggtgtactatagtaactcttactggtacttcgactgtctggggcacagggaccacgggtcaccgtctctctgatca
ggagcccaaatcttctgacaaaactcacatccccaccgtcccagcacctgaactcctggggggaccgtcagcttctcttccccca
aancccaaggacaccctcatgatctcccgacccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagtt
caactggtacgtggacggcgtggaggtgcataatgccaagacaagccgcgggaggagcagtagaacagcacgtaccgtgtggtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaagccctccagcccccatcgagaa
10 aacaatctccaaagccaaaggcagccccgagaaccacaggtgtacaccctgcccccatcccggtatgagctgaccaagaaccaggtc
agcctgacctgctgtgtaaaaggcttctatccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaaga
ccacgctcccgtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtctccgggtaaatgatctaga

15 2H7 scFv MTH(SSS)WTCH2CH3 protein sequence:

mdfqvqifsfllisaviiargqivlsqspailsaspgekvmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsytisrveadaatyccqqsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytfsynmhwwkqtrqglewigaiypngdtsynqkfkkgatltvdksstaymqlssltedsavyfcarvvyysns
ywyfdvwtgtvtvssdqepkssdkthtspapellggpsvflfpkpkdltlmisrtpvctcvvdvshedpevkfnwyvdgv
20 evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietkiskakgqprepvytlppsrdeltknqvsltlvk
gfypsdiafewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhhealhnhytqkslsispkg

HuIgGMHncs1 (oligo for CSS)

gtt gtt gat cag gag ccc aaa tct tgt gac aaa act cac

25 HuIgGMHncs2 (oligo for SCS=ncs2)

gtt gtt gat cag gag ccc aaa tct tct gac aaa act cac aca tgc cca ccg

HuIgGMHncs3 (oligo for SSC=ncs3)

gtt gtt gat cag gag ccc aaa tct tct gac aaa act cac aca tct cca ccg tgc cca gca cct g

30

hIgGWT3xba (3' oligo for above mutation introduction)

gtt gtt tct aga tca ttt acc cgg aga cag gga gag gct ctt ctg cgt gta g

WO 2005/037989

PCT/US2003/024918

Vhser11: (oligo for Leu to Ser at VH11)

gga ggt ggg agc tct cag gct tat cta cag cag tct ggg gct gag tcg gtg agg cc

huIgG1-3' (3' oligo to amplify IgG1 C regions, 3' end of CH3)

5 gtc tct aga cta tca ttt acc cgg aga cag

huIgA/Gchim5 (oligo for pcr#1)

cca tct ccc tca act cca cct acc cca tct ccc tca tgc gca cct gaa ctc ctg

10 huIgAhg-5' (oligo for pcr#2)

gtt gtt gat cag cca gtt ccc tca act cca cct acc cca tct ccc caa ct

huIgA3'

15 gtt gtt tct aga tta tca gta gca ggt gcc gtc cac ctc cgc cat gac aac

2H7 scFv IgAH IGG WT CH2CH3, 2H7 scFv with IgA hinge and WT CH2 and CH3

aagcttgccgcatggattttcaagtgcagattttcagcttctgctaatacagtgcttcagtcataattgccagaggaca
20 aattgttctctccagctccagcaatcctgtctgtcatctccaggggagaaggtcacaatgacttgaggccagctcaagtgttaagttacat
gcactgggtaccagcagaagccaggatcctccccaaacctggatttatgccccatccaacctggcttctggagtcctgtctgcttcagtg
gcagtgggtctgggacctcttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgaggtttaacc
caccacgttcggtgctgggaccaagctggagctgaaagatggcgggtggctggcggtgggtgagctctggaggagtgaggagctctca
ggcttatctacagcagctctggggctgagctggtagggcctggggcctcagtggaagatgctcctgcaaggcttctggctacacattaccagtt
25 acaatatgcactgggtaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtggtgtactatagtaactcttactgttacttcgatgtctggggcacaggaccacggtcaccgtctctgatcagc
cagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgcccacctgaactcctggggggaccgtcagttt
tcctctccccccaaaaccaaggacacctcatgatctccggaccctgagggtcacatgcgtggtggtggacgtgagccacgaagacc
30 ctgaggtcaagttaactggtacgtggacggcgtggaggtgcataatgccaagacaagccggggaggagcagtacaacagcagcta
ccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaagccctccagc
ccccatcgagaaacaatctccaagccaagggcagccccgagaaccacaggtgtacacctgccccatcccggtatgagctgacc
aagaaccaggtcagcctgacctgcctggtcaaaggcttctatccagcgacatgcctggtgagtgaggagcaatgggcagccggaga

PCT/US2003/024918

AA

PCT/US2003/024918

mdfqvqifsflisaviiargqivlsqspailsaspgekvtmtcrasssvsynhwyqqkpgsspkpwiapsn
lasgvparfsgsgsgtsysltisrveadaatyccqqsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsynmhwwkqtrqglewigaiypngdtsynqkfkkgatltvdksstaymqslsitedsavycarvvyysns
5 ywyfdvwtgtttvssdqvpstpptpsptpspschprlsihrpaledlllgseailtctltglrdasgvtftwtpssgksavqgp
pdrdlcgcysvssvlpgcaepwnhgktftctaaypesktpltatlsksngtfrpevhlpppseelalnelvtltclargfspkdvlrvwlq
gsqelprekyltwasrqpsqgtttfavtsilrvaedwkkgdltfscmvgealplaftqktidrlagkpthvnvsvvmaevdgtcy

0 tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccc
cgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcc
tcagggtgcaccttcacctggacgccctcaagtgggaagagcgctgttaaggaccacctgacctgacctctgtggctgctacagcgtgt
ccagtgctcctgccgggctgtgccgagccatggaaacatgggaagaccttcacttgactgctgcctaccccagtgccaagaccccgttaa
ccgccaccctctcaaaatccggaaacacattccggcccaggtccacctgctgccgccggcgtcggaggagctggccctgaacgagct
15 ggtgacgctgacgtgcctggcacgtggcttcagcccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgaga
agtacctgacttgggcatcccggcaggagcccagccaggggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgagga
ctggaagaagggggacaccttctcctgcatggtggggccacgaggccctgccgctggcccttcacacagaagaccatcgacocgttggcgg
gtaaaccacccatgtcaatgtgtctgttgcacatggcggaggtggacggcacctgctactgataatctaga

Dqvpstptpspstptpspschprlsihrpaledlllgscailtctltglrdasgvftwtpssgksavqgppdr
dlcgysvssvlpgcaepwnhgktftctaaypesktpitltsksngntfipevhlpppseelalnelvtltclargfspkdvlvrwlqgsq
elprekyltwasrqpsqggtttfavtsilrvaaedwkkgdftscmvghéalplftqktidrlagkpthvnsvsvmaevdgtcy

agatctcaagaagatgaaaggattgttctgttgacaacaaatgtaagtgccccggattacttccaggatcatccgttc
ttccgaagatcctaattgaggacattgtggagagaaacatccgaattattgttctctgaacaacagggagaaalactctgatcccacctacc
attgagaaccagatttgtgtaccattgtctgacctcagctgtaaaaaatgtgatcctacagaagtggagctggataatcagatagttaactgcta
30 cccagagcaatatctgtgatgaagacagtgctacagagacctgtacacttatgacagaaacaagtgctacacagctgtgggtcccactcgtat
tatgtgtgtgtgagacaaaatggtggaacagccttaacccagatgcctgtatctgtactaatctaga

139

WO 2005/037989

PCT/US2003/024918

rsqederivldnkckcaritsriirssedpnediverniriivplnnrenisdptsplrtrfvyhlsdlsckkdptev
eldnqivtatqsnicdedsatetcytdrnkcytavvplvyggetkmvetaltpdacyp

HUJCH5nl (J chain 5' primer)

5 gtt gtt aga tct caa gaa gat gaa agg att gtt ctt

HUJCH3 (J chain 3' primer-antisense)

gtt gtt tct aga tta gtc agg ata gca ggc atc tgg

10 4 carboxy terminal amino acids deleted from IgA CH3
GTCY

IgAH IgAT4 Human IgA tail, truncated (3T1)-(missing last 4 amino acids from
carboxy terminus)

15 tgatcagccagltccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccc
cgactgtcactgcaccgaccggccctcgaggacctgctcttaggtcagaagcgatcctcacgtgcacactgaccggcctgagagatgcc
tcaggtgtcaccttcacctggagccctcaagtgggaagagcgctgttcaaggaccacctgacctgacctctgtggctgtacagcgtgt
ccagtgtcctgccgggctgtgccgagccatggaaccatgggaagaccttcacttgactgctgctaccccgagtccaagaccccgctaa
ccgccaccctctcaaatccggaacacattccggcccagggtccacctgctgccgccggcgtggaggagctggccctgaacgagct
20 ggtgacgctgacgtgcctggcacgtggcctcagcccaaggatgtgctggtcgtggctgcaggggtcacaggagctgccccgcgaga
agtacctgacttgggcacccggcaggagcccgagggcaccaccaccttgcgtgtgaccagcactactgcgcgtggcagccgagga
ctggaagaagggggacaccttctcctgcatggtgggcccagaggccctgccgctggccttcacacagaagaccatcgaccgcttggcgg
gtaaacccaccatgtcaatgtgtctgtgtcatggcggagggtggactgataatctaga

25 IgAH IgAT4 Protein sequence:

Dqpvpstppstpsptpspschprlsihrpaledlllgseailtctltglrdasgvftftwtpssgksavqgppdr
dlcgcyssvslpgcaepwnhgtfctaaypesktpltatlsksntfrpevhllpppseelalnelvtltclargfspkdvlvrlqgsq
elprekyltwasrqepsqgtttfavtsilrvaedwkkgtfscmvghealplafqtktidrlagkpthvvnsvvmaevd

30 HUIGA3T1 (Oligo 3': to delete 4 amino acids at carboxy end of IgA CH3)
gtt gtt tct aga tta tca gtc cac ctc cgc cat gac aac aga cac

HUIGA3T2: (oligo to delete 14 aa at end of IgA -T4)

WO 2005/037989

PCT/US2003/024918

gtt gtt tct aga tta tca ttt acc cgc caa gcg gtc gat ggt ctt

NT

2H7 scFv IgAH IgAT4

5 (2H7 scFv IgA 3T1 construct)--truncates the CH3 domain at the 3'end

aagcttgccgccatggatittcaagtcagatttcagcttcctgctaatactgcttcagtcataattgccagaggaca
aattgttctctcccagctccagcaatcctgtctgcattctccaggggagaagggtcacaatgacttcagggccagctcaagtgtaagttacat
gcactgggtaccagcagaagccaggatcctcccccacccctggatttatgccccatccaacctggcttctggagtcctgtcgttcagtg
gcagtggggtctgggacctcttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgagggtttaacc
10 caccacgcttcggtgctgggaccaagctggagctgaagatggcggtggctcggcggtgggtgatctggaggaggtgggagctctca
ggcttatctacagcagctctggggtgagctggtagggcctgggacctaggaagatgctctgaaggcttctggctacacattaccagtt
acaatatgcactgggtaagcagacacctagacagggcctggaattgattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaagggcacactgactgtagacaaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctcgcg
gtctattttctgcaagagtgggtactatagtaactcttactggacttctgatgtctggggcacaggaccacggtcaccgtctcttctgatca
15 gccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgacc
ggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgcaccttcacctgg
acgccctcaagtgggaagagcgtgttcaaggaccacctgacctctgtggctgctacagcgtgtccagtgctcctgccggggtgt
gccgagccatggaaccatgggaagaccttacttgcactgctgcctaccccgagtccaagacccccgtaaccgccacctctcaaaatcc
ggaaacacattccggcccgagggtccacctgctgccgccgctggaggagctggccctgaacgagctggtgacgtgacgtgcctgg
20 cacgtggctcagccccaaaggatgtgctggtctgctggctgcaggggtcacaggagctgccccgcgagaagtacctgacttgggcatccc
ggcaggagcccagccaggggcaccaccacctcgtgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacacct
tctcctgatggtgggccacgaggccctgccgctggccttcacacagaagaccatcgaccgcttggcggtgaaaccacccatgtcaatg
tgtctgttgcacgggaggtggactgataatctaga

25 AA

2H7 scFv IgAH-T4

mdfqvqifsfllisasviiargqivlsqpailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypasn
lasgvparfsgsgtsysltisrveadaatyycqwsfnppfagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytfsynmhwwkqtpqrqglewigaiypngdtsynqkfkgkatltvdksstaymqllsitedsavyfcarvvyysns
30 ywyfdvwgtgtvtvssdqpvpsptpspsptpspschprlsrlhrpaledlllgseailtctltglrdasgvtftwtpssgksavqgp
pdrldgcysvssvlpgaepwnhgktftctaaypesktpitatsksgntfrpevhllpppseelalnelvtltclargfspkdvlvrvlq
gsqelprekyltwasrqepsqgtttfavlrsilrvaaedwkkgtfscmvghealplafktidrlagkpthvnvsvvmaevd

WO 2005/037989

PCT/US2003/024918

14 amino acids deleted from IgAH-T4 (so that total of 18 amino acids deleted from wild type IgA CH3)

PTHVNVSVVMAEVD

5

IgAH IgA-T18 (Human IgA Tail truncated, 3T2)

Tgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgtgccaccc
ccgactgtcactgcaccgaccggccctcaggacctgtcttaggttcagaagcgcacactgcacactgaccggcctgagagatgc
ctcaggtgtcaccttcacctggagccctcaagtgggaagagcgtgttcaaggaccacctgaccgtgacctctgtggctgtacagcgtg
10 tccagtgtcctgccgggtgtgccgagccatggaaccatgggaagaccttcactgtcactgtcgtacctaccccgagtccaagaccccgcta
accgccaccctctcaaaatccggaacacattccggcccagggtccacctgtgccgccgccgtcggaggagctggccctgaacgagct
ggtgacgctgacgtgcctggcacgtggcttcagcccaaggatgtgctggttcgctggctgcaggggtcacaggagctgccccgcgaga
agtacctgacttgggcatcccgccaggagcccagccagggcaccaccaccttcgctgtgaccagcactatgcgcgtggcagccgagga
ctggaagaagggggacaccttctcctgcatgtgtggccacgaggccctgccgctggccttcacacagaagaccatgcaccgcttggcgg
15 gtaaa

IgAH IgA-T18 Protein sequence:

dqpvpstptpsptptpspschprlsrhpaeldlllgseailtctltglrdasgvtftwtpssgksavqgppdrd
icgcysvssvlpgcaepwnhgktftctaaypesktpitailsksgntfrpevhllpppseelalneivltclargfspkdvivrwlqgsqe
20 lprekyltwasrqpsqgtttfavtsilrvaedwkkgdftscmvghelplafktidrlagk

NT

2H7 scFv IgAH IgAT18: (Human IgA Tail truncated, 3T2.)

aagcttgcgcgatggattttcaagtgacagatttcagcttcctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctcctccagctcctcagcaatcctgtctgcactcctcaggggagaaaggtcacaatgactgcagggccagctcaagtgaagtacat
gcactggtaccagcagaagccaggatcctccccaaccctggatttatgcccatccaacctggcttctggagtcctgctcgttcagtg
gcagtggtgtggacctcttactctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgaggatttaacc
caccacgttcggtgctgggaccaagctggagctgaagatggcgggtgctcgggcgggtggatctggaggaggtgggagctctca
30 ggcttatctacagcagctgagggtgagctgggtgaggcctggggcctcagtgaaagatgtctcgaaggcttctggctacacattaccagtt
acaatatgcactgggtaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagtcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtggtgtactatagtaactcttactgtacttcgatgtctggggcacagggaccacggtcaccgtctctctgatca

WO 2005/037989

PCT/US2003/024918

gccaagtccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccgactgtcactgcaccgacc
ggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcaccttcacctgg
acgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgccgggctgt
gccgagccatggaacatgggaagaccttcacttgcactgtgcctaccccgagtccaagaccccgtaaccgccaccctctcaaaatcc
5 ggaaacacattccggcccgagggtccacctgctgccgccgccgtcggaggagctggccctgaacgagctggtgacgtgacgtgcctgg
cacgtggctcagcccaaggatgtgctggttcgctggctgcagggggtcacaggagctgccccgcgagaagtacctgactgggcatccc
ggcaggagcccgaccaggccaccaccaccttgcctgtgaccagcatactgcgcgtggcagccgaggactggaagaagggggacacct
tctcctgcatggtgggccacgaggccctgccgtggccttcacacagaagaccatcgaccgcttggcgggtaaa

0 AA:
2H7 scFv IgAH IgAT18:
mdfqvqifsfllisasviiargqivlsqpailsaspgekvmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgtsysltisrveadaatyycqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytfsynmhwwkqtrqglewigaiypngdtsynqkfkgtatltvdksstaymqlssltsedsavfcarvvyysns
15 ywyfdvwgtgtvtvssdqvpstppstpsptpspcchprlslhrrpaledlllgseailtctltglrdasgvtftwtpssgksavqgp
pdrldgcysvssvlpgaepwnhgktftctaaypesktp|tatlsksgntfrpevhllpppseelalnelvtltclargfspkdvlvrwlq
gsqelprekyltwasrqepsqgtttfavtsilrvaedwkkgdtfscmvghealplafqtktidrlagk

20 CTLA-4 IgG WTH WTCH2CH3 (Human-oncoMLP-CTLA4EC-hIgGWT)
Nucleotide sequence:
gcaacctacatgatggggaatgagttgaccttctagatgattccatctgcacgggcacctccagtggaaatcaagtg
aacctcactatccaaggactgagggccatggacacgggacttcatctgcaagtgaggctcatgtaccaccgccatactacctgggc
ataggcaacggaacccagatttatgtaattgatccagaacctgcccagattctgatcaacccaaatcttgtgacaaaactcacacatgccca
25 ccgtgcccagcacctgaactcctggggggaccgtcagttcttcttccccccaaaacccaaggacacctcatgatctccgggaccttg
aggtcacatgcgtgggtgggacgtgagccacgaagacctgaggtcaagtccaactggtagctggacggcgtggaggtgcataatgcc
aagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggctgaatggca
aggagtacaagtgaagggtccaacaaagccctcccagccccatcgagaaaacaatctcaaagccaaagggcagccccgagaacc
acaggtgtacacctgccccatcccgggatgagctgaccaagaaccagggtcagcctgacctgcctggtcaaaggcttctatcccagcga
30 catcgccgtggagtgaggagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctccttctcc
tctacagcaagctcaccgtggacaagagcaggtggcagcagggaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccact
acacgcagaagagcctctccctgtctccgggtaaatga

WO 2005/037989

PCT/US2003/024918

CTLA-4 IgG WTH WTCH2CH3 Protein sequence:

mgvlltqrllslvlallfpmsasmamhvaqpavvlassrgiasfvceyaspgkatevrvtlrqadsqvtevaa
tymmgneftlddsictgtssgnqvnltiqglramdtglyickvelmypppyylgigngtqiyvidpepcpsdqpkscdkthtppc
papellggpsvflfppkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvsvltvlhqdwl
5 gkeykckvsnkalpapietiskakgqprepvytlppsrdeitknqvslclvkgfypsdiavewesngqpennyktpvldsdgs
fflyskltvdkrwwqgnvfscsvmhcalhnhytqkslspsgk

Human OncoM leader Peptide+CTLA4 EC (Bcll)

Atgggggtactgctcacacagaggacgtgctcagctgtgctccttgactcctgtttccaagcatggcgagcatggc
0 aatgcacgtggcccagcctgctgtggtactggccagcagccgagcatcgccagcttgtgtgtgagtatgcattccaggcaaagccact
gaggtccgggtgacagtgcctcggcaggctgacagccaggtgactgaagtctgtcggcaacctacatgatggggaatgattgacctc
ctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctaca
tctgcaagggtggagctcatgtaccaccgccatactacctgggcataggcaacggaacccagatttatgtaattgatccagaaccgtgcc
agattctgatcaa
5

Human OncoM leader Peptide+CTLA4 EC Peptide sequence:

mgvlltqrllslvlallfpmsasmamhvaqpavvlassrgiasfvceyaspgkatevrvtlrqadsqvtevaa
tymmgneftlddsictgtssgnqvnltiqglramdtglyickvelmypppyylgigngtqiyvidpepcpsdq

20 Human OncoM leader peptide nucleotide

atgggggtactgctcacacagaggacgtgctcagctgtgctccttgactcctgtttccaagcatggcgagcatg

Human OncoM leader peptide sequence:

25 Mgvlitqrllslvlallfpms

NT

Human CTLA4 EC (no LP)

Gcaatgcacgtggcccagcctgctgtggtactggccagcagccgagcatcgccagcttgtgtgtgagtatgcatt
ctccaggcaaagccactgaggtccgggtgacagtgcctcggcaggctgacagccaggtgactgaagtctgtcggcaacctacatgacg
30 gggaatgagttgaccttctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccat
ggacacgggactctacatctgcaagggtggagctcatgtaccaccgccatactacctgggcataggcaacggaacccagatttatgtaatt
gatccagaaccgtgccagattct

WO 2005/037989

PCT/US2003/024918

AA

Human CTLA4 EC (no LP)

Amhvaqpavvlassrgiasfvceyaspkgatevrvtrqadsqvtevcaatymtgneltfddsictgtssgnq
vnltiqglramdtglyickvelmypppyylgigngtqiyyidpepcpds

5

NT

Human CTLA4 IgG MTH (SSS) MTCH2CH3

Atgggggtactgctcacacagaggacgtgctcagtcgtgctccttgcactcctgtttccaagcatggcgagcatggc
aatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatgccagctttgtgtgtgagatgcatctccaggcaagccact
10 gaggtccgggtgacagtgttcggcaggctgacagccagggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgacctt
ctagatgattccatctgcacgggcacctccagtggaaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctaca
tctgcaagggtggagctcatgtaccaccgccatactacctgggcataggcaacggaaccagatttatgtaattgatccagaaccgtgccc
agattctgatcaacccaaatctctgacaaaactcacatccccaccgtccccagcacctgaactcctgggggagtcgtcagttctctctt
ccccccaaaaccaaggacaccctcatgatctccggaccctgaggtcacatgcgtggtgggtgacgtgagccacgaagaccctgag
15 gtcaagttcaactggtacgtggacggcgtggaggtgcataatgcaagacaaagccgaggaggagcagtacaacagcacgtaccgtg
tggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtcctcaacaagccctcccagcccc
atcgagaaaacaatctcaaaagccaaaggcagccccgagaaccacaggtgtacaccctgccccatccgggatgagctgaccaaga
accaggtcagcctgacctgcctgggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaa
ctacaagaccacgcctcccgctggacitccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggg
20 gaacgtctctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatga

AA

Human CTLA4 IgG MTH (SSS) MTCH2CH3

Mgvlltqrllslvlallfpsmasmamhvaqpavvlassrgiasfvceyaspkgatevrvtrqadsqvtevca
25 atymmgneftfddsictgtssgnqvnltiqglramdtglyickvelmypppyylgigngtqiyyidpepcpdsdpkssdkthtsp
spapellggssvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgvevhnaktkpreeqynstyrvsvltvlhqdwn
gkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsitclvkgfypsdiavewesngqpennykttpvldsdgs
fflyskltvdksrwqqgnvfscsvmhcalnhhytqkslspsgk

30

CTLA-4 IgAH IgACH2CH3 (Human-oncoMLP-CTLA4EC-IgA)

Nucleotide sequence:

WO 2005/037989

PCT/US2003/024918

atgggggtactgctcacacagaggacgctgctcagctggtccttgactcctgtttccaagcatggcgagcatggc
aatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatgccagctttgtgtgtgagtatgcatctccaggcaaagccact
gaggtccgggtgacagtgttcggcaggctgacagccagggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgaccttc
ctagatgattccatctgcacgggcacctccagtggaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctaca
5 tctgcaaggtggagctcatgtacccaccgccatactacctgggcataaggcaacggaacccagatttatgtaattgatccagaaccgtgcc
agattctgatcagccagttccctcaactccactacccatctccctcaactccactacccatctccctcatgctgccacccccgactgtca
ctgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtc
accttcacctggacgccctcaagtgggaagagcgctgttaaggaccacctgaccgtgacctctgtggctgtacagcgtgtccagtgtcc
tgccgggctgtgccgagccatggaacctgggaagaccttactgactgctgcctacccgagccaagaccccgtaaccgccacc
0 ctctcaaaatccggaacacattccggcccagggtccacctgctgcggccgccgtcggaggagctggccctgaacgagctggtgacgct
gacgtgcctggcacgtggtcctcagccccaaagatgtgctgttcgctgctgcagggggtcacaggagctgccccgcgagaagtacctga
cttgggcatccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcactatgcgcgtggcagccgaggactggaagaa
gggggacaccttctcctgcatgtgtggccacgagccctgccgtggccttcacacagaagaccatgaccgcttggcgggtaaaccca
cccattgtcaatgtgtctgtgtcatggcggagggtggacggcacctgctactgataatctaga

5

CTLA-4 IgAH IgACH2CH3 Protein sequence:

mgvlltqrllslvlallfpsmasmamhvaqpavvlassrgiasfvcyaspkgatevrvtvlrqadsqvteveaa
tymmgneftlfdstictgssgnqvnltiqglramdtglyickvelmypppylgigngtqiyvidpepcpsdqpvpstptpspst
pptpspcchprlslhrpaedlllgseailctltglrdasgvltfwtppssgksavqgppdrldgcysvssvlpgcaepwnhgtftcta
20 aypesktpltatlsksgntfrpevhllpppseelalnelvtltclargfspkdvlvrlwlgsgqlprekyltwasrqepsqgtttfavtsilrva
aedwkkgdtdfscmvghcalplftqktidrlagkpthvvnsvvmaevdgtcy

CTLA-4 IgAH IgA-T4 (Human-oncoMLP-CTLA4EC-IgA3T1)

Nucleotide sequence:

atgggggtactgctcacacagaggacgctgctcagctggtccttgactcctgtttccaagcatggcgagcatggc
aatgcacgtggcccagcctgctgtggtactggccagcagccgaggcatgccagctttgtgtgtgagtatgcatctccaggcaaagccact
gaagggtccgggtgacagtgttcggcaggctgacagccagggtgactgaagtctgtgcggcaacctacatgatggggaatgagttgaccttc
ctagatgattccatctgcacgggcacctccagtggaatcaagtgaacctcactatccaaggactgagggccatggacacgggactctaca
tctgcaaggtggagctcatgtacccaccgccatactacctgggcataaggcaacggaacccagatttatgtaattgatccagaaccgtgcc
30 agattctgatcagccagttccctcaactccactacccatctccctcaactccactacccatctccctcatgctgccacccccgactgtca
ctgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtc
accttcacctggacgccctcaagtgggaagagcgctgttcaaggaccacctgaccgtgacctctgtggctgtacagcgtgtccagtgtcc
tgccgggctgtgccgagccatggaacctgggaagaccttactgactgctgcctacccgagccaagaccccgtaaccgccacc

WO 2005/037989

PCT/US2003/024918

ctctcaaaatccggaaacacattccggcccagggtccacctgctgccgccgctcggaggagctggccctgaacgagctggtgacgct
gacgtgcctggcacgtggcttcagccccaaaggatgtgctggctcgtggctgcagggggtcacaggagctgccccgcgagaagtacctga
cttgggcatcccgccaggagcccagccagggcaccaccaccttcgtgtgaccagcatactgcgcgtggcagccgaggactggaagaa
ggggggacacctctcctgcatggtggggccacgaggccctgccgtggccttcacacagaagaccatcgaccgcttggcgggtaaaccca
5 cccatgtcaatgtgtgtgtcatggcggagggtggactgataatctaga

CTLA-4 IgAH IgA-T4 Protein sequence:

Mgvlltqrllslvlallfpsmasmamhvaqpavvlassrgiasfvceyaspgkatevrvtlvrqadsqytevca
atymmgneltfddsictgtssgnqvnltiqglramdtglyickvelmypppyylgigngtqiyvidpepcpdsdqvpstptpsps
10 tpptpspscchprlslhrpaledlllgseailtctltlrdasgvtftwtpssgksavqppdrdlcgysvssvlpgaepwnhgtftcta
aypesktpiltatlsksgntfrpevhllpppseelalnelvtltclargfspkdvlvrlwlgsgqlprekyltwasrqepsqgtttfavtsilrva
aedwkkgdtfscmvghealplafqtidrlagkpthvnvsvvmaevd

NT

15 human IgG1 CH2 with 238 mutation pro→ser

cctgaactcctggggggatcgtcagttcttcttcccccaaaacccaaggacacctcatgatctcccgaccct
gaggtcacatgcgtggtggtggacgtgagccacgaagacctgaggtcaagttcaactggtacgtggacggcgtggaggtgcataatgc
caagacaaagccgaggagagcagtagaacagcacgtaccgtgtggtcagcgtcctcacgtcctgcaccaggactggtgtaatggc
aaggagtacaagtgcaaggtctccaacaaagccctccagccccatcgagaaaaccatctccaaagccaaag

20

AA

human IgG1 CH2 with 238 mutation pro→ser

pellggssvflfpkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgvevlnaktkpreeqynstyrvvs
vltvlhqdwlngkeykckvsnkalpapiektiskak

25

Amino acids surrounding Pro to Ser in CH2

PAPELLGGPS

Amino acids surrounding Pro to Ser in CH2

30

PAPELLGGSS

HIgE5Bcl

gtt gtt gat cac gtc tgc tcc agg gac ttc acc cc

WO 2005/037989

PCT/US2003/024918

hIgE3stop

ggt ggt tct aga tta act ttt acc ggg att tac aga cac cgc tcg ctg g

5 hIgE3BB (leaves an open reading frame at end of gene to read into
transmembrane and cytoplasmic tail domain attached at either the BamHI or SfuI sites)

gtt gtt ttc gaa gga tcc gct tta ccg gga ttt aca gac acc gct cgc tgg

10

NT

human IgE Fc (CH2-CH3-CH4) ORF:

15 tgcacacgtctgctccagggaacttcacccgccaccgtgaagatcttacagtcgtcctgcgacggcggcggggcac
 tccccccgaccatccagctcctgtgcctcgtctctgggtacccccagggaactatcaacatcacctggctggaggacgggcaggtcatgg
 acgtggacttgtccaccgcctctaccacgcaggagggtgagctggcctccacacaanagcgagctcacctcagccagaagcactggctg
 tcagaccgcacctacacctgccaggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggg
 gtgagcgcctacctaagccggccagcccgttcgacctgttcacccgcaagtcgccacgatcacctgtctgggtggacctggcacc
 agcaagggggacctgaacctgacctgggtccgggccagtgggaagcctgtgaacctccaccagaaggaggagaagcagcgcgaat
 ggca cgttaaccgtcacgtccacctgccggtgggcacccgagactggatcaggggggagacctaccagtgcagggtgaccaccccc
 20 acctgccaggggccctcatcggtccacgaccaagaccagcggcccgctgctgccccgggaagtctatcgctttgcgacgccggagt
 gcgggggagccgggacaagcgcacccctgcctgcctgatccagaacttcacgtcctgaggacatctcgtgcagtggtgcacaacgag
 gtgcagctccggagcggcgacagcagcagcagccccgcaagaccaagggtcggcttcttctgtcttcagccgctggaggtga
 ccagggccgaatgggagcagaagatgagttcatctgccgtgcagtcctatgaggcagcagccccctcacagaccgtccagcgagcgggt
 gtctgtaaatcccggtaagcggatccttcgaa

25

AA

human IgE Fc (CH2-CH3-CH4) ORF:

dhvcsrdfpptvkilqsscdggghfpptiqllclvsytpgtinitwledgqvmvdvlstasttqegelastqselt
30 sqkhwlsdrtytcqvyqghtfedstklccadsnprgsayslrpspfdlfrksptitclvvdlapskgtnlwsrasgkpvnhstrkee
kqrngltltvtstlpvgtrdwiegetyqcrvthphlpralmrsttktsgraaapevyafatpewpgsrdkrtlacliqnfmpedisvqwllh
nevqlpdarhsttqprktkgsgffvfrlevtraeweqkdeficravhcaaspsqtvqravsvnpgkadps

WO 2005/037989

PCT/US2003/024918

IFhIgGwtBcl5

gtt gtt tga tca gga gcc caa atc ttg tga caa aac tca cac atg ccc acc gtg ccc agc acc

(63 mer)

5

hIgGWT3xba

gtt gtt tct aga tca ttt acc cgg aga cag gga gag gct ctt ctg cgt gta g

HuIgGMHWC (sense, 5' primer for mutating wild type hinge CCC to mutant

10 ***SSS'***

gtt gtt gat cag gag ccc aaa tct tct gac aaa act cac aca tct cca ccg tcc cca gca cct gaa

ctc ctg ggt gga ccg tca gtc ttc c

NT

15

1D8 VH

cagggtgcagctgaaggaggcaggacctggcctggtgcaaccgacacagaccctgtccctcacatgcactgtctctg

gggtctcattaaccagcgatgggtgacactggattcgacagcctccaggaaagggtctggaatggatgggaataatattatgatggaggc

acagattataattcagcaattaaatccagactgagcatcagcaggacacctccaagagccaagttttcttaaaatcaacagctgcaaaact

gatgacacagccatgtattactgtgccagaatccactttgattactggggccaaggagtcacagtcctcctct

20

AA

1D8 VH (no leader)

qvqlkeagpglvqptqtlsctvsgfsldgvhwirppgkglewmgiyydggtdynsaiksrlsrdtsks

qvflkinslqtdtdamyycarihfdywgqgvmvtvss

25

NT

1D8 VL (no leader)

gacattgtgctcactcagtcctcaacaaccatagctgcatctccaggggagaaggtcacatcacctgccgtgccag

ctccagtgtaagttacatgtactgggtaccagcagaagtcaggcgccctcccctaaactctggatttatgacacatccaagctgcttctggagtt

30

cca aatcgctcagtgaggctgggtctgggacctcttattctctgcaatcaacaccatggagactgaagatgctgccacttattactgtcagc

agtggagtagtactccgctcacgttcgggtctgggaccaagctggagatcaaacgg

WO 2005/037989

PCT/US2003/024918

AA

1D8 VL

divltqspttiaaspgekvtitcrasssvsymywyqqksgasplkiwydtsklasgvpnrfsgsgsgtsyslaint
metedaatyycqqwsstpltfsgsgtleikr

5

NT

1D8 scFv

aagcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
10 gtgctcactcagtcaccaacaacatagctgcatctccaggggagaaggtcacatcacctgccgtgccagctccagtgtaagttacatgta
ctggtagcagcagaagtcaggcgctccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtgga
gtgggtctgggacctcttattctctgcaatcaacacatggagactgaagatgctgccacttattactgtcagcagtgtagtagtactccgct
cacgttcgggtctgggaccaagctggagatcaaacgggtggcgggtggctcggcggtgggtcgggtggcgccgagatcaggtg
cagctgaaggaggcaggacctggcctggtgcaaccgacacagacctgtccctcacatgcactgtctctgggttctcattaaccagcgatg
15 gtgtacactggattcgacagcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatta
aatccagactgagcatcagcagggacacctccaagagccaagttttcttaaaatcaacagctctgcaaactgatgacacagccatgtattac
tgtgccagaatccactttgattactggggccaaggagtcagtggtcacagtcctctgatca

AA

20

1D8 scFv

mdfqvqifsfllisasvimsrgvdivltqspttiaaspgekvtitcrasssvsymywyqqksgasplkiwydtskl
asgvpnrfsgsgsgtsyslaintmetedaatyycqqwsstpltfsgsgtleikrgggsgggsgggsgqvqlkeagpglvqptqlsl
ctvsgfsltsdgvhwirppgkglewmgiyydgtdynsaiksrlsirdtsksqvflkinslqtdtdamyycaarihfdywgqgv
vtvss

25

NT

1D8 scFv IgG WTH WTCH2CH3

aagcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
30 gtgctcactcagtcaccaacaacatagctgcatctccaggggagaaggtcacatcacctgccgtgccagctccagtgtaagttacatgta
ctggtagcagcagaagtcaggcgctccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtgga
gtgggtctgggacctcttattctctgcaatcaacacatggagactgaagatgctgccacttattactgtcagcagtgtagtagtactccgct
cacgttcgggtctgggaccaagctggagatcaaacgggtggcgggtggctcggcggtgggtcgggtggcgccgagatcaggtg

WO 2005/037989

PCT/US2003/024918

cagctgaa ggaggcaggacctggcctgggtgcaaccgacacagacctgtccctacatgcactgtctctgggttcattaaccagcgatg
gtgtacactggattcgacagcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatta
aatccaga.ctgagcatcagcaggacacctccaagagccaagtttttaaaaaatcaacagtctgcaaactgatgacacagccatgtattac
tgtgccagaatccactttgattactggggccaaggagtcattgtcacagtctcctctgatcaggagcccaaatcttgacaaaactcacaca
5 tggccaccgtggccagcacctgaactcctggggggaccgtcagtcttctcttccccccaaaacccaaggacacctcatgatctcccga
cccctgaggtcacatgcgtgggtggacgtgagccaggaagacctgaggtcaagttcaactgggtacgtggacggcgtggaggtgcat
aatccaa.gacaaagccgaggaggagcagtagacaacagcacgtaccgtgtgtgcagcgtctcaccgtcctgcaccaggactggctga
atggcaaggagtacaagtgaaggtctccaacaagccctcccagccccatcgagaaaacaatctccaaagccaaagggcagccccg
agaaccacaggtgtacacctgccccatccgggatgagctgaccaagaaccaggtcagcctgacctggtcaaaggcttctatcc
10 cagcgacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctc
cttctctcttacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggctctgcac
aaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

15

AA

1D8 scFv IgG WTH WTCH2CH3

mdfvqifsfllisasvimsrgvdivltqspptiaaspgekvtitcrasssvsymywyqqksgaspklwiydtskl
asgvpnrfsgsgsgtsyslaintmetedaatyycqqwssptlftgsgtkleikrgggsgggsgggsgsqvqlkeagpglvqptqlsl
ctvsgfsltsdgvhwirpppgkglewmgiiyydggtdynsaiksrslsrdtsksqvflkinslqtdtdamyyarihfdywgqgvm
20 vtvssdqepkscldkthtccppcapellggpsvflfppkpkdltlmsrtpetvvcvvdvshedpevkfnwyvdgvevhnaktkpree
qynstyrvvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeftknqvsltelvkgfypsdiavewe
sngqpenryktpvldsdgsfflyskltvdksrwqqgnvfscsvmhleahnhytqkslsispkg

25

NT

1D8 scFv IgG MTH MTCH2CH3-CD80

aagcttatggatttcaagtgcagattttcagcttctcgtaatcagtgcttcagtcataatgtccagaggagtcgacatt
gtgtcactcagtcaccaacaaccatagctgcacatccaggggagaaggtcaccatcacctgccgtgccagctccagtgaagtacatgta
ctgtgtaccagcagaagtcaggcgcctccctaactctggatttatgacacatccaagctggcttctggaggtccaaatcgttcagtgga
gtgggtctgggacctcttattctctgcaatcaacacatggagactgaagatgctgccacttattactgtcagcagtgagtagtactccgct
30 cacgttcgggtctgggaccaagctggagatcaaacgggggtggcgtgctcggcggtgggtgggtcgggtggcgggcgatctcaggtg
cagctgaa ggaggcaggacctggcctgggtgcaaccgacacagacctgtccctacatgcactgtctctgggttcattaaccagcgatg
gtgtacactggattcgacagcctccaggaaagggtctggaatggatgggaataatatattatgatggaggcacagattataattcagcaatta
aatccaga.ctgagcatcagcaggacacctccaagagccaagtttttaaaaaatcaacagtctgcaaactgatgacacagccatgtattac

WO 2005/037989

PCT/US2003/024918

tgtgccagaatccactttgattactggggccaaggagtcaggtcacagtctcctctgatctggagcccaatcttctgacaaaactcacaca
agcccaccgagcccagcacctgaactcctggggggatcgtcagttctcttccccccaaaaccaaggacaccctcatgatctccggg
accctgaggtcacatgcgtgggtgggacgtgagccacgaagaccctgaggtcaagttcaactggtagcggcgtggaggtgca
taatgccaagacaaagccgaggagagcagtacaacagcacgtaccgtgtggtcagcgtctcaccgtcctgcaccaggactggctga
5 atggcaaggagtacaagtgaaggtctcaacaaagccctccagccccatcgagaaaaccatctccaagccaaagggcagccccg
agaaccacaggtgtacaccctgccccatccgggatgagctgaccaagaaccaggtcagcctgacctgctggtaaggctctatcc
cagcgacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaagaccacgcctcccgctggactccgacggctc
cttcttctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgaggtctgcac
aacactacacgcagaagagcctctccctgtctcgggtaagcggatccttgaacctgtcccatcctgggccattaccttaattcagta
10 aatggaattttgtgatagctgctgacctaactgcttgcctcccaagatgcagagagagaaggaggaatgagagattgagaagggaaagtgt
acgcctgtataaatcgata

AA

1D8 scFv IgG MTH MTCH2CH3-CD80

15 mdfqvqifsfllisasvimsrgvdivltqspttiaaspgekvtitrasssvsymywyqqksgasplkiwydtskl
asgvpnrfsgsgsytyslaintmetedaatyycqqwsstpltfsgtkleikrgggsgggsgggsgvqlkeagplvqptqtlst
ctvsgfsltsdgvhwirpppgklewmgiiyydggtdynsaiksrlsirdtsksqvflkinslqtdtdamyycaarihfdywgqgvm
vtvssdlepkssdkthtspsspapellggssvflfppkpkdtlmsirtpevtcvvdvshedpevkfnwyvdgvevhnaktkpreeq
ynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsitclvkgfypsdiavewes
20 ngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispgakdpsnllpswaitlisvngifvicc
ltycfaprerrrrnerlrresvrpv

NT

1D8 scFv IgG WTH WTCH2CH3-CD80

25 aagcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgctcactcagtcctcaacaaccatagctgcacatccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagtacatgta
ctgggtaccagcagaagtcaggcgccctccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgttcagtgga
gtgggtctgggacctcttattctctgcaatcaacaccatggagactgaagatgctgccacttattactgtcagcagtgagtagtactccgct
cacgttcgggtctgggaccaagctggagatcaaacgggggtggcgggtggctcggcggtggtgggtcgggtggcggggatctcaggtg
30 cagctgaaggaggcaggacctggcctgtgcaaccgacacagacctgtccctcacatgcactgtctctgggttctcattaaccagcgatg
gtgtacactggattcgacagcctccaggaaagggtctggaatggatgggaataatattatgatggaggcacagattataattcagcaatta
aatccagactgagcatcagcaggacacctccaagccaaagtttcttaaaaatcaacagctctgcaaactgatgacacagccatgtattac
tgtgccagaatccactttgattactggggccaaggagtcaggtcacagtctcctctgatctggagcccaatcttctgacaaaactcacaca

WO 2005/037989

PCT/US2003/024918

tgcccaccgtgccagcacctgaactcctggggggaccgtcagttctctctcccccaaaaccaaggacaccctcatgatctcccgga
cccctgaggtcacatgcgtggtggtggacgtgagccagaagaccctgaggtcaagtcaactggtacgtggacggcgtggaggtgcat
aatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagcgtcctcaccgtcctgcaccaggactggtgta
atggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccatcgagaaaaccatctccaaagccaaagggcagccccg
5 agaaccacaggtgtacaccctgccccatcccgggatgagctgaccaagaaccaggtcagcctgacctgctggtcaaggcttctatcc
cagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaagaccacgcctcccgtgctggactccgacggctc
cttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctcatgctccgtgatgcatgaggtctgcac
aaccactacacgcagaagagcctctccctgtctccgggtaaagcggatccttgaacctgctccatcctgggccattaccttaatctcagta
aatggaattttgtgatatgctgacctactgctttgccccaaagatgcagagagagaaggagggaatgagagattgagaagggaagtgt
10 acgccctgtataaatcgata

AA

1D8 scFv IgG WTH WTCH2CH3-CD80

mdfqvqifsfllisasvimsrgvdivltqspttiaaspgekvitcrasssvsymywyqqksgasplkiwydtskl
15 asgvpnrfsgsgsgtsyslaintmetedaatyycqwsstpltfsgstkleikrgggsgggsgggsgvqlkeagpglvqptqtlst
ctvsgfsltsdgvhwirpppgkglewmgiyydgtdynsaiksrslisrdsksqvflkinslqtdtdamyycaarihfdywgqgvm
vtvssdlepkscdkthtppcpapellggpsvflfppkpkdtlmisrtpetcvvvdvshedpevkfnwyvdgvevhnaktkpre
qynstyrvsvltvlhqdwlngkeyckvsnkalpapiektiskakqprepvytlppsrdeitknqvsltelvkgyfypsdiavewe
sngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhleahnhytqkslslspgkadsnllpswaitlisvngifvic
20 cltycfaprcrerrrnerlrresvrpv

NT

Anti human CD3 scFv WTH WTCH2CH3

aagcttatggatttcaagtgcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatc
25 cagatgacacagactacatcctcctgtctgcctctotgggagacagagtcaccatcagttgcagggcaagtcaggacattcgcaattatta
aactggatcagcagaaccagatggaactgttaactcctgatctactacacatcaagattacactcaggagtcctcatcaaggttcagtgcc
agtgggtctggaacagattattctctcaccattgccaacctgcaaccagaagatattgccacttactttgccaacagggtatacgtctccgt
ggacgttcggtggaggcaccaaactggttaaccaaacgggagctcgggtggcgggtgctcgggcgggtggtgggtcgggtggcggcggt
ctatcatgaaggccagctgcaacagcttggaacctgaactggtgaagcctggagcttcaatgtcctgcaaggcctctggttactcattcactg
30 gctacatcgtgaactggctgaagcagagccatggaaagaaccttgagtggttggaacttattaatccatacaaaagtcttactacataacc
agaaattcaagggaaggccacattaactgtagacaagtcacccagcagacctacatggagctcctcagctcgacatctgaagactctgc
agtctattactgtgcaagatctgggtactatggtgactcggactggtacttogatgtctggggcgaggaccaggtcaccgtctctctga
tcaggagcccaaatcttgacaaaactcacacatgccaccgtgcccagcacctgaactcctggggggaccgtcagttctctctcccc

WO 2005/037989

PCT/US2003/024918

ccaaaacc caaggacaccctcatgatctccggacccctgaggtcacatgctggtggtggacgtgagccacgaagaccctgaggtcaa
gttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgaggaggagcagtagaacagcacgtaccgtgtggtc
agcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctccagccccatcga
gaaaacaatctccaaagccaaaggcagccccgagaaccacaggtgtacaccctgccccatccgggatgagctgaccaagaacca
5 ggtcagcctgacctgcctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactaca
agaccacgctcctccgtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaac
gttcttcatgctccgtgatgcatgaggtctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

10 Anti human CD3 scFv WTH WTCH2CH3
Mdfqvqifsflisavimsrgvdiqmtqtsslsaslgdrvtiscrasqdirnylnwyqqkpdgtvkllyytsrlh
sgvpsrfs gsgsgtdysltianlqpediatyfcqqntlpwtfgggklvltkrelgggsgggsgggsggsidevqlqqsgpelvkpgas
msckasgysftgyivnwlkqshgknlewiglinpykglttnqkfkkgkatltvdksstaymellsitsedsavyycarsgyygdscd
wyfdvwgagttvtvssdqepkscdkthtppcpapellggpsvflfppkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgv
15 evhnaktkpreeqynstyrvsvltvlhqdwlngkeyckcvnskalpapiektiskakgqprepvytlppsrdeltnqnvsitclvk
gfypsdia vewesngqpennykthppvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslspspgk

NT

20 *2H7-antiCD40 scFv MTH (SSS) MTCH2WTCH3*
2h7-40.2.220Ig + restriction sites
aagcttggcccatggatttcaagtgcagatttccagcttctgctaatacagtgcttcagtcataattgccagaggaca
aattgtctctccagctcagcaatcctgtctgcatactccaggggagaaggcacaatgacttcagggccagctcaagtgaagtacat
gcactggtaccagcagaagccaggatcctccccaaccctggatttatgccccatccaacctggcttctggagtcctgctcgttcagtg
25 gcagtgggtctgggaccttactctctcacaatcagcagagtgaggagctgaagatgctgccacttattactccagcagtgaggatttaacc
caccacgctcgtgctgggaccaagctggagctgaaagggtggcggctgggctgggctgggtggatctggaggaggtgggagctctca
ggcttatctacagcagctcgtgggctgagctgggtgaggcctgggctcagtgagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggttaaagcagacacctagacagggcctggatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
30 gtctatttctgtgcaagagtggtgactatagtaacttctactggtacttcgatgtctggggcacagggaccacggtcaccgtctctctgatca
atccaactctgaagaagcaaaagaggaggccaaaaaggaggaagcaaaatctaacagcgtogacattgttctgactcagctctcc
agccacctgtctgtgactccaggagatagagctctcttctctgcagggccagccagagtattagcgactacttacactggtatcaaaaa
atcacatgagctccaaggcttctcatcaaatatgcttccattccatctctgggatccctccaggttcagtggcagtgatcagggtcagatt

WO 2005/037989

PCT/US2003/024918

tcactctcagtatcaacagtgtggaacctgaagatgttgaatttactgtcaacatggtcacagcttccgtggacgttcggaggagcac
caagctggaaatcaaacggggtggcgggtggctcggcgagggtgggtcgggtggcgcggtatcagatccagttggtgcaatctgga
cctgagctgaagaagcctggagagacagtcaggatctctgcaaggctctgggtatgccttcacaactactggaatgcagtggtgcaag
agatgccaggaaagggttgaaagtggattggctggataaacaccccactctggagtgccaaaatagtgaagactcaaggacgggttgc
5 cttctcttggaaacctctgccaacactgcataattacagataagcaacctcaaagatgaggacacggctacgtattctgtgagatccggg
aatgtaactatgacctggcctactttgcttactggggccaagggacactggcactgtctctgatcaggagcccaatcttgacaaaact
cacacatccccacgtccccagcacctgaactcctgggggagtcgtcagttctctctcccccaaaacccaaggacacctcatgatctc
ccggacccctgaggtcacatgctggtgggtggacgtgagccacgaagacctgaggtcaagttcaactggtacgtggacggcgtggag
gtgcataatgccaaagacaagccgcgaggagcagtagacaacgacgtaccgtgtggtcagcgtctcaccgtcctgcaccaggactg
10 gctgaatgcaaggagtacaagtgaaggtctcaacaagccctcccagccccatcgagaaaacaatctcaaaagccaaagggcag
ccccgagaaccacaggtgtacacctgccccatccccggatgagctgaccaagaaccaggtcagcctgacctgctgtgtaaaaggctt
ctatcccagcgacatcgccgtggagtgaggagcaatgggcagccggagagaacaactacaagaccacgctcccgtgtgactccgac
ggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtctctcatgctccgtgatgcatgaggctct
gcacaaccactacacgcagaagacccctctcctgtctccgggtaaatgatctaga

15

AA

2H7-antiCD40 scFv MTH (SSS) MTCH2WTCH3

2H7-40.2.220Ig

mdfvqifsfllisasviiargqivlsqpailsaspekvmtcrassvsymhwyqqkpgsspkpwiapsn
20 lasgvparfsgsgsgtsysltisrveadaatyycqwsfnpptfagtklelkgggsgggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsnyhmhwkqtrqglewigaiypngndtsynqkfkgtatltvdkssstaymqlsltsedsavyfcarvvyysns
ywyfdvwtgtvtvssdqsnseeakkeeakkeeakksnsdivltqspatlsvtpgdrvslsrasqsisdylhwyqqkshesprlli
kyashsisgipsrfsfgsgsgdftlsinsvepedvgiyyqhgshfptfgggtkleikrgggsgggsgggsggiqlvqsgpelkk
pgetvriscasgyafttgmqwvqempgkglkwigwintplwsakicrrlqgrfafsletsantaylqisnlkdedtatyfcvrsng
25 nydlayfaywgqgtlvtvsdqepkssdkthtspppapellggssvflfppkpkdtlmisrtpevtcvvdvshedpevkfnwyvdg
vevhnaktkpreeqynstyrvsvltvlhqdwlngkeyckvsnkalpapietkiskakgqprepvytlppsrdeltknqvsitclv
kgfypsdiavewesngqpennyktppvldsdsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispkg

NT

30 5B9 VH (includes the VH leader peptide)

atggctgtcttggggtgctcttctgcctgtgacattccaagctgtgtcctatcccaggtgcagctgaagcagtcag
gacctggcctagtcagtcctcacagagcctgacctacactgcacagtcctgtgttctcattactacatgtgtacactgggttcgcca
gtctccaggaaagggtctggagtggctgggagtgataggagtggtggaatcacagactataatgcagctttcatatccagactgagcatca

WO 2005/037989

PCT/US2003/024918

ccaaggacgattccaagagccaagtttctttaaataaacagctgtcaacctaatacacagccatttactgtgccagaaatgggggtg
ataactacccttattactatgtatggactactgggtcaaggaacctcagtcaccgtctcctca

5B9 VH missing the leader:

5 caggtgcagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctg
gtttctcattaaactaccatgtgtgtacactgggttcgccagctcctcaggaagggtctggagtggctgggagtgtatggagtggatgaatca
cagactataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagtttctttaaataaacagctgtcaaccta
tgacacagccatttactgtgtccagaaatgggggtgataactacccttattactatgtatggactactgggtcaaggaacctcagtcacc
gtctcctca

10

AA

5B9 VH (includes leader peptide)

MAVLGLLFLVTFPSCVLSQVQLKQSGPGLVQSSQSLITCTVSGFSLTTY
AVHWVRQSPGKGLEWLGVIWSSGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPN
15 AIYYCARNGGDNYPPYYAMDYWGQGTSTVTVSS

5B9 VH no leader peptide

QVQLKQSGPGLVQSSQSLITCTVSGFSLTTYAVHWVRQSPGKGLEWLG
VIWSSGITDYNAAFISRLSITKDDSKSQVFFKMNSLQPNDAIYYCARNGGDNYPPYYA
20 MDYWGQGTSTVTVSS

NT

5B9 VL

atgaggttctctgtcagcttctggggctgctgtgtcttgatccctggatccactgcagatattgtgatgcgcagg
25 ctgcattctccaatcagtcactcttgaacatcagcttccatctcctgcaggtctagtaagagtctctacatagtaatggcatcacttattgta
ttggatctgcagaaagccaggccagtcctcagctcctgattatcagatgtccaaccttgctcaggagtccagacaggttcagtagcag
tgggtcaggaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgtttactgtgtctaaaatctagaactccgct
cacgttcggtgctgggaccaagctggagctgaaacgg

30

AA

5B9 VL

PCT/US2003/024918

30 aagcttgcgcgcacgaggttctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcagatattgt
gatgacgcagggctgcatttccaatccagtcactcttgaacatcagcttccatctctgcaggctagtaagatctctacatagtaattggc
atcacttatttgattggatctgcagaagccaggccagtcctcfcagctcctgatttatcagaigtccaacctggcctcaggagtgccagacag
gttcagtagcagtgggtcaggaaactgatttcacactgagaatcagcagagtggaggctgaggatgtgggtgttttactgtgtctaaaatct
agaaattccgctcacgttcgggtgctggggaccaagctggagctgaaacgggggtggcgggtggctcgggcggtgtgtgggtcgggtggcgcc

WO 2005/037989

PCT/US2003/024918

ggatcgtcacaggtgcagctgaagcagtcaggacctggcctagtcagtcctcacagagcctgtccatcacctgcacagtctctggtttctc
attaactacatgctgtacactgggttcgccagctccaggaaagggtctggagtggtgggagtgtatggagtggtggaatcacagact
ataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagttttttaaataaacagtctgcaacctaatacacac
agccatttattactgtgccagaaatgggggtgataactaccttattactatgctatggactactgggggtcaaggaaacctcagtcaccgtctcc
5 tctgactcggagcccaaattcttgacaaaactcacacaagcccaccgagcccagcacctgaactcctggggggatcgtcagttctctctt
ccccccaaaacccaaggacacctcatgatctccggaccttgaggtcacatgcgtggtgggtggacgtgagccacgaagacctgag
gtcaagtcaactggtcagtggtgacggcgtggaggtgcataatgccaagacaagccgcgggaggagcagtacaacagcagctaccgtg
tggtcagcgtctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccc
atcgagaaaacatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgcccccatccgggatgagctgaccaaga
10 accaggtcagcctgacctgcctggtcaaaggcttctatccagcgacatcgccgtggagtgaggagcaatgggcagccggagaacaa
ctacaagaccacgcctccgtgctggactccgacggtcctcttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggg
gaacgtcttctcatgctccgtgatgcatgaggtctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaagcggatcctt
cgaacctgtctccatcctgggccattaccttaatctcagtaaatggaattttgtgatgctgctgacctactgctttgcccccaagatgcaga
gagagaaggagggaatgagagattgagaagggaagtgtacgccctgtataaatgatactcgag
15

AA

5B9 scFv-hmIgG1-hCD80

MRFSAQLLGLLVLPWPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLH
SNGITYLYWYLQKPGQSPQLLIYQMSNLASGVDPDRFSSSSGSGTDFTLRISRVEAEDVGV
20 YYCAQNLELPLTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSI
TCTVSGFSLTTYAVHWVRQSPGKGLEWLGVIWWSGGITDYNAAFISRLSITKDDSKSQVF
FKMNSLQPNDTAIYYCARNGGDNYPYYAMDYWGQGTSVTVSSDLEPKSSDKTHTSP
PSPAPELLGGSSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
25 EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGS
FFLYSKLTVDKSRWQQGNVFSFSVMHEALHNHYTQKSLSLSPGKADPSNLLPSWAITLI
SVNGIFVICCLTYCFAPRCRERRRRNERLRRESVRPV

30

NT

2e12 scFv WITH CH2 CH3 (2e12 scFv-WithIgG-CD80)

aagcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgtcacccaatctccagcttcttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgttgatattatgtca

WO 2005/037989

PCT/US2003/024918

caagtttaatgcagtggtaccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc
caggtttagtggcagtggtgtgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagcaaa
taggaaggttccttgacgttcggtggaggcaccagctggaaatcaaacggggtggcgtggcctggcggagggtgggtcgggtggc
ggcggatctcagggtcagctgaaggagtcaggacctggcctgggtggcgcctcacagagcctgtccatcacatgcaccgtctcagggttc
5 tcattaaccggctatggtgtaaactgggtcggcagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcaca
gactataattcagctctcaatccagactgagcatcaccaaggacaactccaagagccaagttttctaaaaatgaacagtctgcaactgat
gacacagccaataactgtgacagagatggtatagtaactttactactatgttatggactactggggtcaaggaacctcagtcaccgtct
cctcagatctggagcccaaatcttgacaaaaactcacatgcccaccgtgccagcacctgaactcctggggggaccgtcagtttct
ctccccccaaacccaaggacacctcatgatctccggaccctgaggtcacatgcgtggtgggtggacgtgagccacgaagacctg
10 aggtcaagttcaactgtacgtggacggcgtggaggtgcataatgccaagacaaagccgaggaggagcagtacaacagcacgtaccg
tgtgtcagcgtctcaccgtcctgcaccaggactggtgaatggcaaggagtacaagtgaaggtctcaacaaagccctcccagcccc
catcgagaaaaccatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgcccccatccgggatgagctgaccaag
aaccaggtcagcctgacctgcctggtcaaaggcttctatccagcgacatgccgtggagtgggagagcaatgggcagccggagaaca
actacaagaccacgcctcccgtctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcagg
15 ggaacgtctctcatgctcctggtgatgcatgaggtctgcacaaccactacacgcagaagagcctctcctgtctccgggtaaagcggatcct
tcgaacctgctcccatcctgggccattaccttaatctcagtaaatggaatgttgatgctgcctgacctactgctttgccccaaagatgcaga
gagagaaggagggaatgagagattgagaagggaagtgtacgccctgtataaatcgat

20 2e12 scFv WTH CH2 CH3 2e12 scFv-WthIgG-CD80
mdfqvqifslisasvimsrgvdivltqspaslavslgqratiscrasesveyyvtlsmqwyyqqkpgppklilis
aasnvesgvparfsgsgsgtdfslnihpveediamyfcqqsrkvpwtfgggtkleikrgggsgggsgggsgsqvqlkesgpglva
psqslsitcvsfgsltygvnwvrpppgkglewlgmiwgdgstdynsalksrslitkdnsksqvlkmnslqtdtdaryycardgys
nfhyvmdywgqgtsvtvssdlepkscdkthtppcpapellggpsvflfppkpkdtlmsrtpevtcvvvdvshedpevkfnwy
25 vdgevehnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepqvytlppsrdeitknqvsit
clvkgyfypsdiavewesngqpennykttppvldsdgsfflyskltvdkswqqgnvfscsvmhcalhnhytqkslspsgkadsnl
lpswaitlisvngifviccltycfaprerrrrrnlrresvrpv

NT

30 2H7-human IgE Fc (CH2-CH3-CH4)
aagcttgccgcatggattttcaagtgcagatttcagcttctcctaatacagtgcttcagtcataattgccagaggaca
aattgtctctccagctcagcaatcctgtctgcatctccaggggagaaggtcacaatgacttcagggccagctcaagtgttaagtacat
gcaactggtacagcagaagccaggtatcctccccaaacctggatttatccccatccaacctggcttctggagtcctctgctcgttcagt

WO 2005/037989

PCT/US2003/024918

gcagtgggtctgggacctctactctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtgagggtttaacc
caccacggttcggctgggaccaagctggagctgaaagggtggcggtggctcgggcgggtgggtggtatctggaggaggtgggagctctca
ggcttatctacagcagctctgggctgagctgggtgaggcctgggcctcagtgagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgactgggtaaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
5 aagltcaaggggcaaggccacactgactgtagacaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgggtactatagtaactcttactggacttcgatgtctggggcacagggaccacggtcaccgtctctgatcacgt
ctgtccaggggacttcaccccgccaccgtgaagatcttacagtcgtcctgcgacggcgccgggcaacttccccccgacctccagctcct
gtgcctcgtctctgggtacacccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggacttgcaccgcctct
accacgcaggagggtgagctggcctccacaaaagcagctcacctcagccagaagcactggctgtcagaccgacctacacctgcc
10 aggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctacctaaagccgg
cccagcccgttcgacctgttcacccgcaagtcgcccagatcacctgtctggtgggtgacctggcaccacgaaggggaccgtgaacctg
acctgtcccgggcccagtggaagcctgtgaaccactccaccagaaaggaggagaagcagcgaatggcacgttaaccgtcacgtcca
ccctgccgggtgggcacccgagactggatcagggggagacctaccagtgagggtgaccacccccacctgccaggccctcatgc
ggtcacgaccaagaccagcggcccgctgctgccccggaagtctatgcgtttgcgacgccggagtgccgggggagccgggacaagc
15 gcacctcgcctgcctgatccagaactcatgcctgaggacatctcgggtcagtggtgcacaacgaggtgcagctcccgacggcggg
cacagcacgacgcagccccgaagaccaagggtcgcggcttctctgtctcagccgcctggaggtgaccagggccgaatgggagcaga
aagatgagttcatctgccgtgcagtcctatgaggcagcgagccctcacagaccgtccagcgagcgggtgtctgtaaatcccggtaaatgata
atctaga

20 AA

2H7 scFv IgE (CH2-CH3-CH4)

mdfqvqifsfllisasviiargqivlsqpailsaspgekvtmtcrassvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyycqqsfnpptfagtklelkgggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsymhvwkqtrpqglewigaiypngdtsynqkfkkgkatltvdkssstaymqlssltedsavyfcarvvysns
25 ywyfdvwgtgtvtvsdhvcsrdftptvkilqsscdggghfpptiqlclvsytpgtinitwledqvmddvldstastqegelastqs
eltlsqkhwlslrtytcqvtqgthfedstkkcadsnprgvsaylsrspfdlfrksptitclvvdlapskgtvnlwsrasgkpvnhstr
keekqrngltltvtstlpvgtrdwiegetyqcrvthphlpralmrsttktsppraapevyafatpewpgsrdrkrtlacliqnfmpeidsvq
wlhnevqlpdarhsttpqrktkgsgffvfrlevtraeweqkdeficravheaaspsqtvqravsvnpgk

30 NT

2H7 scFv MH (SSS) MCH2WTCH3

aagcttgcgcccatggattttcaagtgcagattttcagcttcctgctaatactgcttcagtcataattgccagaggaca
aatgttctctccagctctccagcaatcctgtctgcacatccaggggagaaaggtcacatgacttcagggccagctcaagtgttaagtacat

WO 2005/037989

PCT/US2003/024918

gcactgggtaccagcagaagccaggatcctccccaaccctggatttatgccccatccaacctggcttctggagtcctgctgctcagtg
gcagtgggtctgggacCtcttactctctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtgaggatttaacc
caccacagcttcggtgctgggaccaagctggagctgaagatggcggtggctcggcggtgggtgatctggaggagtgaggagctctca
ggcttatctacagcagtctggggctgagctggtgaggcctggggcctcagtgaagatgctcctgcaaggcttctggctacacatttaccagt
5 acaatatgcactgggtaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctcacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaaga gtggtgtactatagtaactcttactgggtactctgatgtctggggcacaggaccacgggtcaccgtctctctgatca
ggagcccaaatcttctgacaaaactcacatccccaccgtccccagcacctgaactcctggggggatgctcagcttctcttccccca
aaccgaaggacacctcatgatctccggaccctgaggtcacatgcgtggtgggtgagcgtgagccacgaagacctgaggtcaagttc
10 aactggtacgtggagcgcggtggaggtgcataatccaagacaaagccggggaggagcagtacaacagcacgtaccgtgtggtcagc
gtctcaccgtcctgcaCaggactggctgaatggcaaggagtacaagtgaaggcttccaacaaagccctccagccccatcgagaa
aacaatctcaaaagccaaggggcagccccgagaaccacaggtgtacacctgccccatcccgggatgagctgaccaagaaccaggtc
agcctgacctgctggtcaaaggcttctatccagcgcacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaaga
ccacgcctcccgctgctgactccgacggctcctctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
15 tctcatgctccgtgatgc atgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

2H7 scFv MH (SSS) MCH2WTCH3

mDfqvqifsflisaviiargqivlsqpailsaspgekvmtcrasssvsymhwyqqkpgsspkpwiayapsn
20 lasgvparfsgsgsgtsysltisrveadaatyycqwsfnppftfagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytfsynmhwwkqtrqglewigaiypngndtsynqkfkkatltvdksstaymqlssltedsavyfcarvvyysns
ywyfdvwtgtvtvssdqepkssdkthtspspapellggssvflfppkpkdtlmisrtpevtcvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeltknqvsltclvk
gfypsdiafewesngqpennyktpvpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk
25

NT

5B9 scFv MTHWTCH2CH3

aa gcttggcccatgagggtctctgctcagcttctggggctgcttctgctctggatccctggatccactgcagatattgt
gatgacgcaggtgcattctcaatccagtcactcttgaacatcagcttccatctctgcaggtctagtaagagtctctacatagtaatggc
30 atcacttatttgattggtatctgcagaagccaggccagctcctcagctcctgattatcagatgccaacctgctcaggagctccagacag
gttcagtagcagtggtcaggaaactgattcacactgagaatcagcagagtggaggctgaggatgtgggtgttattactgtgctcaaatct
agaactccgctcagcttcggtgctgggaccaagctggagctgaaacgggggtggcggtggctcgggcgggtgggtgggtcgggtggcggc
ggatcgtcacaggtgcagctgaagcagtcaggacctggcctagtcagtcctcacagagcctgtccatcacctgcacagtctctggttctc

WO 2005/037989

PCT/US2003/024918

attaactacctatgctgtacactgggttcgccagtctccaggaaagggctgaggaggctgggagtgatatggagtgggtggaatcacagact
ataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagttttcttaaaatgaacagctcgcaacctaatacacac
agccatttattactgtgccagaaatgggggtgataactacccttattactatgctatggactactgggggtcaaggaaacctcagtcaccgtctcc
tctgalcaggagcccaaatcttctgacaaaactcacacatccccaccgtcccagcacctgaactcctggggggaccgtcagcttctctott
5 cccccaaaacccaaggacacctcatgatctccggaccctgaggtcacatgcgtggtgggtggagctgagccacgaagacctgag
gtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtg
tggtcagcgtcctcaccgtctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaagccctcccagccccc
atcgagaaaacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgcccccatccgggatgagctgaccaaga
accaggtcagcctgacctgctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaa
10 ctacaagaccacgcctcccggtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggg
gaacgtcttctcatgctccgtgatgcatgaggtctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

15

5B9 scFv MTHWTCH2CH3

MRFSAQLLGLLVLPWPGSTADIVMTQAAFSNPVTLGTSASISCRSSKSLHH
SNGITYLYWYLQKPGQSPQLLIYQMSNLASGVPDRFSSSGSGTDFTLRISRVEAEDVGV
YYCAQNLELPLTFGAGTKLELKRGGGGSGGGGSGGGGSSQVQLKQSGPGLVQSSQSLSI
TCTVSGFSLTTYAVHWVRQSPGKGLEWLGVIWSGGITDYNAAFISRLSITKDDSKSQVF
20 FKMNSLQPNDAIYYCARNGGDNYPIYYYAMDYWGQTSVTVSSDQEPKSSDKTHTSP
PSPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPR
EPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGS
FFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

25

Human IgG1 hinge mutations

30

2H7 scFv- MTH (CSS) WTCH2CH3

Nucleotide:

aagcttgcgccatggattttcaagtcagattttcagcttctgctaatcagtgcttcagtcataattgccagaggaca
aattgttctctccagctcagcaatcctgtctgcatctccagggagagaaggtcacatgacttcagggccagctcaagtgttaagtacat

WO 2005/037989

PCT/US2003/024918

gca.ctgg.taccag.caga.agccaggat.cctccccaaacctggatttatgcccacccaacctggcttctggagtcctgctcgttcagtg
gca.gtg.ggtctgggaccttactctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtgaggatttaacc
cac.ccacgttcggtgctgggaccaagctggagctgaaagatggcgggtgctcgggcgggtgggagatctggaggagtgaggagctctca
ggcttatctacagcagctctggggctgagctggtagggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacattaccagt
5 aca.atatgcactgggtaaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtc.tatttctgtcaagagtgggtgactatagtaactcttactggtacttcgatgtctggggcacagggaccacggtcaccgtctctctgatca
ggagcccaaatcttgtgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagttctcttccccca
aaa.cccaaggacacctcatgatctccggaccctgaggtcacatgctggtggtggagctgagccacgaagacctgaggtcaagtt
10 caa.ctggtacgtggacggcgtggagggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
gtc.ctcaccgtctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctccagccccatcgagaa
aac.aatctccaaagccaaaggcagccccgagaaccacaggtgtacacctgccccatcccggtgatgctgaccaagaaccaggtc
agc.ctgacctgctggtcaaaggcttctatcccagcgacatgccgtggagtgggagagcaatgggcagccggagaaacaactacaaga
cca.cgcctccgtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacctct
15 tctcatgctccgtgatgatgaggctctgcacaaccactacgcagaagagcctctccctgtctccgggtaaatgatctaga

2H7 scFv- MTH (CSS) WTCH2CH3 protein:

mdfqvqifsfllisasviiarqgqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypsn
las.gvparfsgsgsgtsysltisrveadaatyycqqsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
20 msckasgytftsymbhvwkqtrqglewigaiypngdtsynqkfkglkatltvdkssstaymqlsstsedsavyfcarvvyysns
ywyfdvwgtgtvtvssdqepkscdkhtspspapellggpsvflfppkpkdtlmsrtpevtcvvvdvshedpevkfnwyvdgv
evh.naktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepqvytlppsrdeitknqvsitclvk
gfy.psdiafewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslslspgk

25 2H7 scFv- MTH (SCS) WTCH2CH3:

Nucleotide:

aagcttgccgcatggattttcaagtgcagattttcagcttctgtaatacagtgcttcagtcataattgccagaggaca
aat.tgttctctccagctccagcaatcctgtctgcatctccagggagaaaggtcacaatgacttcagggccagctcaagtgtgaattacat
gca.ctggtaccagcaga.agccaggat.cctccccaaacctggatttatgcccacccaacctggcttctggagtcctgctcgttcagtg
30 gca.gtg.ggtctgggaccttactctcacaatcagcagagtggaggctgaagatgctgccacttattactgccagcagtgaggatttaacc
cac.ccacgttcggtgctgggaccaagctggagctgaaagatggcgggtgctcgggcgggtgggagatctggaggagtgaggagctctca
ggcttatctacagcagctctggggctgagctggtagggcctggggcctcagtgaagatgtcctgcaaggcttctggctacacattaccagt
aca.atatgcactgggtaaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag

WO 2005/037989

PCT/US2003/024918

aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgggtgactatagtaactcttactgttacttcgatgtctggggcacaggggaccacggtcaccgtctcttctgatca
ggagcccaaatcttctgacaaaactcacatgccaccgtccccagcacctgaactcctggggggaccgtcagttctctcttccccca
aaaccaaggacaccctcatgatctccggaccctgaggtcacatgcgtggtgggtggacgtgagccacgaagaccctgaggtcaagtt
5 caactggtagctggacggcgtggaggtgcataatgccaagacaaagccgaggaggagcagtagacaacagcacgtaccgtgtggtcagc
gtctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtcaaggtctccaacaaagccctccagccccatcgagaa
aacaatctccaaagccaaaggcgagccccgagaaccacaggtgtacacctgccccatccgggatgagctgaccaagaaccaggtc
agcctgacctgcctggtcaaaggcttctatccagcgacatcgccgtggagtgggagagcaatggcgagccggagaacaactacaaga
ccacgcctcccgctggtgactccgacggctcttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
10 tctcatgctccgtgatgcatgaggtctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

2H7 scFv- MTH (SCS) WTCH2CH3 Protein:

mdfqvqifsfllisasviiargqivlsqpailsaspgkvtmtcrasssvsymhwyqqkpgsspkpwiypasn
lasgvparfsgsgsgtsysltisrveadaatyycqwsfnptfagtklelkdggsgsgggsgggssqaylqqsgaelvrpgasvk
15 msckasgytftsynmhvwkqtpqrqglewigaiypngndtsynqkfkgtatltvdksstaymqlssltedsavfyfcarvvyysns
ywyfdvwgtgtvtvssdqepkssdkthtccppspapellggpsvflfpkpkdltlmisrtpevtcvvvdvshdepvkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsitclvk
gfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispk

20

2H7 scFv- MTH (SSC) WTCH2CH3:

Nucleotide:

aagcttgccgcatggattttcaagtgcagattttcagcttctgctaatacagtcctcagtcataattgccagaggaca
aattgttctctccagctcctcagcaatcctgtctgcacatccaggggagaaaggtcacaatgacttcaggggccagctcaagtgttaagttacat
25 gcactggtagcagcagaagccaggatcctccccaaccctggatttatcccatccaacctggcttctggagtcctctgctcgttcagtg
gcagtggtgtgggaccttctactcttcacaatcagcagagtgagggtgaagatgctgccacttattactccagcagtgagggtttaacc
caccacgttcggtgctgggaccaagctggagctgaaagatggcgggtggctcgggcgggtggatctggaggaggtgggagctctca
ggcttatctacagcagctctggggctgagctggtagggcctggggcctcagtgaaagatgctcgaaggcttctggctacacatttaccagtt
acaatatgcactgggtaaagcagacacctagacagggcctggaatggattggagctatltatccaggaatgggtgatacttctacaatcag
30 aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgggtgactatagtaactcttactgttacttcgatgtctggggcacaggggaccacggtcaccgtctcttctgatca
ggagcccaaatcttctgacaaaactcacatccccaccgtgccagcacctgaactcctggggggaccgtcagttctctcttccccca
aaaccaaggacaccctcatgatctccggaccctgaggtcacatgcgtggtgggtggacgtgagccacgaagaccctgaggtcaagtt

WO 2005/037989

PCT/US2003/024918

caactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtcaagggtcctcaacaaagccctcccagccccatcgagaa
aacaatctccaaagccaaaggcgagccccgagaaccacaggtgtacacctgccccatcccgggatgagctgaccaagaaccaggct
agcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccgggagaacaactacaaga
5 ccacgcctcccgtgtgactccgacggctccttctctctacagcaagtcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtctccgggtaaagtatctaga

2H7 scFv- MTH (SSC) WTCH2CH3 Protein:

10 mdfqvqifsflisasviiargqivlsqspailsaspgekvtmterasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsytstisrveadaatyccqwsfnptfgagtklelkdgsgsgsgsgsgssqaylqqsgaelvrpgasvk
msckasgytftsynmhwwkqtrqglewigaiypngdtsynqkfkkgkatltvdksstaymqlssltedsavyfcarvvyysns
ywyfdvwgtgtvtvssdqepkssdkthtspcpapellggpsvflfppkpkdtlmisrtpetvcvvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsltlvk
15 gfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhleahnhytqkslsispk

HIgGMHcys1

ggt ggt gat cag gag ccc aaa tct tct gac aaa act cac aca tg

20

HIgGMHcys2

ggt ggt gat cag gag ccc aaa tct tgt gac aaa act cac aca tct cca ccg tgc

HIgGMHcys3

25 ggt ggt gat cag gag ccc aaa tct tgt gac aaa act cac aca tgt cca ccg tcc cca gca cct

NT

HuIgG1 MTCH3Y405

30 gggcagccccgagaaccacaggtgtacacctgccccatcccgggaggagatgaccaagaaccaggtcagcc
tgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccgggagaacaactacaagaccac
gcctcccgtgctggactccgacggctccttctacatctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctca
tgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtccccgggtaaata

WO 2005/037989

PCT/US2003/024918

AA

HuIgG1 MTCH3Y405

GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

5 YKTTTPVLDSDGSFYLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

NT

HuIgG1 MTCH3A405

gggcagccccgagaaccacaggtgtacaccctgcccccatccgggaggagatgaccaagaaccaggtcagcc

10 tgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaagaccac
gcctcccgtgctggactccgacggctccttcgccctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga

AA

15 HuIgG1 MTCH3A405

GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

YKTTTPVLDSDGSFALYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

NT

20 HuIgG1 MTCH3A407

Gggcagccccgagaaccacaggtgtacaccctgcccccatccgggaggagatgaccaagaaccaggtcagcc

tgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaagaccac
gcctcccgtgctggactccgacggctccttctcctcgcagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga

25

AA

HuIgG1 MTCH3A407

GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN

YKTTTPVLDSDGSFFLASKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

30

NT

HuIgG1 MTCH3Y405A407

WO 2005/037989

PCT/US2003/024918

gggcagccccgagaaccacaggtgtacaccctgccccatccgggaggagatgaccaagaaccaggtcagcc
tgacctgcctggtaaaggcttctatcccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaagaccac
gcctcccgtgctggactccgacggctccttctacctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctc
atgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga

5

AA

HuIgG1 MTCH3Y405A407

GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN
YKTTTPVLDSGFSYLASKLTVDKSRWQQGNVFCSSVMHEALHNHYTQKSLSLSPGK

10

NT

HuIgG1 MTCH3A405A407

gggcagccccgagaaccacaggtgtacaccctgccccatccgggaggagatgaccaagaaccaggtcagcc
tgacctgcctggtaaaggcttctatcccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaactacaagaccac
gcctcccgtgctggactccgacggctccttctacctcgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtcttctc
catgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatga

15

AA

HuIgG1 MTCH3A405A407

gqprepqvylppsreemtknqvslclvkgfypsdiavewesngqpennykttppvlldsgsfalaskltvdk
srwqqgnvfscsvmhealhnhytqkslspsgk

20

NT

2H7 scFv MTH (SSS) WTCH2MTCH3Y405

aagcttgccgccatggatttcaagtgcagatttcagcttctgctaatacagtgcttcagtcataattgccagaggaca
aattgttcttcccagtcctcagcaatcctgtctgcactctccaggggagaaggtcacaatgacttgaggggccagctcaagtgttaagtacat
gcactgggtaccagcagaagccaggatcctccccaaacctggatttatgccccatccaacctggcttctggagtcctgctcgttcagtg
gcagtggggtctgggacctcttactcttcacaatcagcagagtggaaggctgaagatgctgccacttattactgccagcagtgagggttgaacc
caccacgttcgggtgctgggaccaagctggagctgaaagatggcgggtggctcggcggtgggtgatctggaggaggtgggagctctca
ggcttatctacagcagtgctgggggtgagctgggtgagggcctcagtggaagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggttaaagcagacacctagacagggcctggaatggattggagctatttatccaggaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgggtgactatagtaactcttactggtaactctgatgtctggggcacagggaccacgggtcaccgtctcttctgaica

25

30

WO 2005/037989

PCT/US2003/024918

ggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagttcttcttccccca
aaaccaaggacaccctcatgatctcccggaccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagtt
caactggtacgtggacggcgtggaggtgcataatgccaagacaaagccggggaggagcagtacaacagcacgtaccgtgtggtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagccccatcgagaa
5 aacaatctccaaagccaaaggcagccccgagaaccacaggtgtacacccctgccccatccggggaggagatgaccaagaaccaggt
cagcctgacctgcctggtcaaaggcttctatcccagcgacatcgccgtggagtgaggagcaatgggcagccggagaacaactacaag
accacgcctcccgctgctgactccgacggctccttctacctctatagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt
cttctcatgctcgtgatgcatgaggtctgcacaaccactacacgcagaagagcctctccctgtccccgggtaaatgatctaga

10

AA

2H7 scFv MTH (SSS) WTCH2MTCH3Y405

mdfqvqifslisaviiargqivlsqspailsaspgekvmtcrasssvsymhwyqqkpgsspkpwiapsn
lasgvparfsgsgsgtsysltisrveadaatyycqqwsfnppftgagtklelkdggsgggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsnnmhvkwqtrpqglewigaiypngdtsynqkfkgtatltvdksstaymqllslltsedsavyfcarvvyysns
15 ywyfdvwtggtvtvssdqepkssdkthtspspapellggpsvflfpkpkdtlmisrtpvctvvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsreemtknqvsltelv
kgfypsdiavewesngqpennyktpvldsdgsfylvskltvdksrwqqgnvfscsvmhealhnhytqkslsispkg

20

NT

2H7 scFv MTH (SSS) WTCH2MTCH3A405

aagcttgcgccatggattttcaagtgcagattttcagcttctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctctccagtcctcagcaatcctgtctgcacatccaggggagaaggtcaccaatgacttgaggccagctcaagttaagtacat
gcactggtaccagcagaagccaggatcctccccaaccctggatttatgccccatccaacctggcttctggagtcctgctcgttcagtg
25 gcagtgggtctgggaccttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgagggtttaacc
caccacgttcgggtctgggaccaagctggagctgaaagatggcgggtggctcgggcgggtggtgagatctggaggaggtgggagctotca
ggcttatctacagcagctcgggctgagctggtgagccctggggcctcagtgagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcactgggtaaagcagacacctagacaggcctggaatggattggagctatttatccaggaaatggtgatacttctcacaatcag
aagttcaagggcaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctcg
30 gtctatttctgtgcaagagtggtgtactatagtaactcttactgtgacttcgatgtctggggcacaggaccaggtcaccgtctctctgatca
ggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagttcttcttccccca
aaaccaaggacaccctcatgatctcccggaccctgaggtcacatgcgtggtggtggacgtgagccacgaagaccctgaggtcaagtt
caactggtacgtggacggcgtggaggtgcataatgccaagacaaagccggggaggagcagtacaacagcacgtaccgtgtggtcagc

WO 2005/037989

PCT/US2003/024918

gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccatcgagaa
aacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgccccatcccgggaggagatgaccaagaaccaggt
cagcctgacctgcctgtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaag
accacgcctcccgtgctggactccgacggctccttgcctctatagaagctcaccgtggacaagagcaggtggcagcaggggaacgt
5 cttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtccccgggtaaatga

AA

2H7 scFv MTH (SSS) WTCH2MTCH3A405

mdfqvqifsfllisasviiargqivlsqpailsaspgkvtmtcrassvsymhwyqqkpgsspkpwiapsn
10 lasgvparfsgsgsgtsysltisrveadaatyycqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsymbhvwkqtpqglewigaiypngndtsynqkfkkgkatltvdksstaymqlssltedsavfyfcarvvyysns
ywyfdvwtgtttvtvssdqepkssdkthtspspapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvvsvltvlhqdwlngkeyckcvsnkalpapiektiskakgqprepvytlppsreemtknqvsltlv
kgfypsdiavewesngqpennykthppvldsdsfalyskltdksrwqqgnvfscsvmhealhnhytqkslslspgk

15

NT

2H7 scFv MTH (SSS) WTCH2MTCH3A407

aagcttgccgccatggattttcaagtgcagattttcagcttctgctaatacagtgcttcagtcataattgccagaggaca
20 aattgttctctcccagctctccagcaatcctgtctgcactctccaggggagaaggtcacaatgacttgaggccagctcaagtgaagtacat
gcactggtaccagcagaagccaggatctccccaaacctggattatgccccatccaacctggcttctggagtcctgtcgttcagtg
gcagtgggtctgggacctcttactctctcacaatcagcagagtgagggtgaagatgctgccactattactgccagcagtgaggatttaacc
caccacgttcggtgctgggaccaagctggagctgaaagatggcgggtgctcggcggtggtggtatctggaggaggtgggagctctca
ggcttactacagcagctctggggctgagctggtagggcctgggagcctcagtgagatgtcctgcaaggcttctggctacacattaccagtt
25 acaatatgcactgggtaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaagggcacactgactgtagacaaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctcg
gtctatttctgtgaagagtggtgtactatagtaactcttactgttacttcgatgtctggggcacagggaccacggtcaccgtctcttgatca
ggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagttctcttccccca
aaaccaaggacacctcatgatctcccggaccctgaggtcacatgcgtggtggtggacgtgagccacgaagacctgaggtcaagtt
30 caactggtacgtggacggcgtggaggtgcataatgcaagacaaagccgaggagagcagtagaacagcacgtaccgtgtgtgcag
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccatcgagaa
aacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgccccatcccgggaggagatgaccaagaaccaggt
cagcctgacctgcctgtcaaaggcttctatcccagcgacatcgccgtggagtgggagagcaatgggcagccggagaacaactacaag

WO 2005/037989

PCT/US2003/024918

accacgcctcccgtgctggactccgacggctccttctcctgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt
cttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtccccgggtaaatga

AA

5 2H7 scFv MTH (SSS) WTCH2MTCH3A407
mdfqvqifsflisaviiargqivlsqpailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiapsn
lasgvparfsgsgsgtsysltisrveadaatyycqqsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftslnmhwwkqtrqglewigaiypngndtsynqkfkkgkatltvdkssstaymqlssltedsavyfcarvvyysns
ywyfdvwtgtttvssdqepkssdkthtspspapellggpsvflfppkpkdtlmisrtpvtecvvvdvshdepvkfnwyvdgv
10 evhnaktkpreeqynstyrvsvltvlhqdwlngkeyckvsnkalpapiektiskakgqprepvytlppsreemtknqvsltelv
kgfypsdiavewesngqpennykttppvldsdsfflaskltvdksrwqqgnvfscsvmhlealnhhtytkslslspgk

NT

2H7 scFv MTH (SSS) WTCH2MTCH3Y405A407
15 aagcttgcgccatggattttcaagtgcagattttcagcttctcgtctaatcagtgcttcagtcataattgccagaggaca
aattgttcttcccagcttccagcaatcctgtctgcatctccaggggagaaggtcacatgacttgaggccagctcaagtgttaagtacat
gcactggtagcagcagaagccaggatcctccccaaacctggatttatgccccatcaacctggcttctggagtcctctgcttcagt
gcagtggtgctgggaccttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgagtttaacc
caccacgcttgggtgctgggaccaagctggagctgaaagatggcgggtggctcgggcgggtggtgatctggaggagtgaggctctca
20 ggcttatctacagcagcttggggctgagctggtagggcctggggcctcagtgagatgtcctgcaaggcttctgggtacacattaccagtt
acaatatgcactgggtaagcagacacccagagggcctggatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtggtgtactatagtaactcttactgtgacttcgatgtctggggcacagggaccacggtcaccgtctcttgatca
ggagccc aaatcttctgacaaaactcacatccccaccgtccccagcacctgaactcctggggggaccgtcagttctcttccccca
25 aaacccaaggacacctcatgatctccggaccctgaggtcacatgcgtggtggtggacgtgagccacgaagacctgaggtcaagtt
caactggtacgtggagcggcgtggaggtgcataatgccaaagacaagccgggaggagcagtagaacagcacgtaccgtgtggtcagc
gtctcaccgtctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaagccctcccagccccatcgagaa
aacaatctccaagccaaaggcagccccgagaaccacaggtgtacacctgccccatccgggaggagatgaccaagaaccaggt
cagcctgacctgcctgtgtaaggcttatcccagcgacatcgccgtggagtgaggagagcaatgggcagccgggagaaactacaag
30 accacgcctcccgtgctggactccgacggctccttctacctgccagcaagctcaccgtggacaagagcaggtggcagcaggggaacgt
cttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtccccgggtaaatga

WO 2005/037989

PCT/US2003/024918

AA

2H7 scFv MTH (SSS) WTCH2MTCH3Y405A407

mdfqvqifsfllisasviiargqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypasn
lasgvparfsgsgsgtsysltisrveaadaatyycqqsfnpptfgagtkleldggsgggsgggssqaylqqsgaelvrpgasvk
5 msckasgytfts ynmhwwkqtpqrqglewigaiypngdtsynqkfkkgkatltvdksstaymqlssltedsavvyfcarvvyysns
ywyfdvwgtgtttvtvssdqepkssdkthtspspapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgv
evhnaktpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepvytlppsreemtknqvsltlv
kgfypsdiavewesngqpennykttppvldsdgsfylaskltvdksrwqqgnvfscsvmhealhnhytqkslsispkg

10

NT

2H7 scFv MTH (SSS) WTCH2MTCH3A405A407

aagcttgccgcatggatttcaagtgagatttcagcttcctgctaagtcagtgcttcagtcataattgccagaggaca
aattgttctctcccagctctccagcaatcctgtctgcactctccaggggagaaaggtcacaatgacttcagggccagctcaagtgttaagttacat
15 gcactgggtacca gcagaagccaggatcctccccaaaccctggatttatgccccatccaacctggcttctggagtcctgtctgccttcagtg
gcagtggtgtcgggaccttactctctcacaatcagcagagtgaggctgaagatgctgccacttattactgccagcagtgagggttgaacc
caccacgttcgggtctgggaccaagctggagctgaagatggcgggtggctcgggagggtggatctggaggagggtggagctctca
ggcttactacagcagctctggggtgagctgggtgagcctggggcctcagtgaaagatgctctgcaaggcttctggctacacattaccagtt
acaatatgcactgggtaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacacatcag
20 aagttcaagggc aaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtc aagagtgtgtactatagtaactcttactgttacttcgatgtctggggcacagggaccacggtcaccgtctctctgatca
ggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcacctgaactcctggggggaccgtcagttctctcttccccca
aaaccaaggacacacctcatgatctccggaccctgaggtcacatgcgtgggtggacgtgagccacgaagacctgaggtcaagtt
caactggtacgtggacggcgtggagggtgcataatgccaaagccgaggaggagcagtagaacagcacgtaccgtgtgtgtcagc
25 gtctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggctcacaacaaagccctccagccccatcagagaa
aacaatctccaaagccaaaggcgagccccgagaaccacaggtgtacacctgccccatccgggaggagatgaccaagaaccaggt
cagcctgacctgcctgtgcaaggcttctatccagcagacatgcctggagtgaggagcaatgggcagccggagaacaactacaag
accacgcctcccgtgtgactccgacggctccttcgcctgccagcaagctcaccgtggacaagagcaggtggcagcagggggaacg
tcttctcatgctcctgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctcctgtccccgggtaaatga

30

AA

2H7 scFv MTH (SSS) WTCH2MTCH3A405A407

WO 2005/037989

PCT/US2003/024918

mdfqvqifsfllisasviiargqivlsqpailsaspgkevmtcrassvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyycqqsfnpptfagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsnyhmhwkqprqglewigaiypngdtsynqkfkkgkatltvdksstaymqllsstdsavyfcarvvyysns
ywyfdvwtgtttvssdqepkssdkthtspspapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgv
5 evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepvytlppsreemtknqvslclv
kgfypsdiavewesngqpennykthppvldsdgsfalaskltvdksrwqqgnvfscsvmhcalhnhytqkslsispkg

NT

2H7 scFv MTH (SCC) WTCH2CH3

10 aagcttgccgcatggattttcaagtgagattttcagcttctgctaatcagtgcttcagtcataattgccagaggaca
aattgttctctcccagtcctcagcaatcctgtctgcatctccagggagaaagtcacaatgacttgaggccagctcaagtgttaattacat
gcactgggtaccagcagaagccaggtatctccccaaacctggattatgccccatccaacctggcttctggagtcctgctgcttcagtg
gcagtggtctgggaccttactctctcacaatcagcagagtgaggctgaagatgctgccacttattactgccagcagtgaggatttaacc
caccacgcttcggtgctgggaccaagctggagctgaaagatggcggtggctcggcggtggtgagctggaggagggtgggagctctca
15 ggcttatctacagcagtcctgggctgagctggtagggcctggggcctcagtgaaagatgctcgaaggcttctggctacacattaccagtt
acaatatgcactgggtaaagcagacacctagacagggcctggatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaagagtgggtgactatagtaactcttactgtgacttctgatgctggtgggcacagggaccacggcaccgtctctctgatca
ggagcccaaatcttctgacaaaactcacacatgccaccgtgccagcacctgaactcctggggggaccgtcagcttctcttccccca
20 aaacccaaggacacctcatgatctccggaccctgaggtcacatgcgtgggtggagctgagccacgaagacctgaggtcaagtt
caactgggtacgtggagggcgtggaggtgcataatgccaagacaaagccgaggaggagcagtagaacagcacgtaccgtgtggtcagc
gtctcaccgtcctgcaccagactgggtgaatggcaaggagtacaagtgaaggtctccaacaagccctccagcccccatcgagaa
aacaatctccaaagccaaaggcagccccgagaaccacaggtgtacacctgccccatcccgggatgagctgaccaagaaccaggtc
agcctgacctgcctgggtcaaaaggcttctatcccagcagatcgccgtggagtgaggagcaatgggcagccggagacaactacaaga
25 ccacgcctccgtgctggactccgacggctcttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

2H7 scFv MTH (SCC) WTCH2CH3

30 mdfqvqifsfllisasviiargqivlsqpailsaspgkevmtcrassvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyycqqsfnpptfagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsnyhmhwkqprqglewigaiypngdtsynqkfkkgkatltvdksstaymqllsstdsavyfcarvvyysns
ywyfdvwtgtttvssdqepkssdkthtppcpapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgv

WO 2005/037989

PCT/US2003/024918

evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsltelvk
gfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispgk

NT

5

2H7 scFv MTH (CSC) WTCH2CH3

aagcttgccgcatggattttcaagtgagattttcagcttcctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctctccagctctccagcaatcctgtctgcatctccaggggagaaggtcacatgacttgaggccagctcaagtgaagtacat
gcactgggtaccagcagaagccaggatcctccccaacccctggatttatccccatccaacctggcttctggagtcctgctcgttcagtg
gcagtggtgtgggacctcttactcttcacaatcagcagagtgaggagctgaagatgctgccacttattactgccagcagtgaggatttaacc
10 caccacgttcgtgctgggaccaagctggagctgaaagatggcgggtgctcgggctgggtggtggtatctggaggagtggtgagctctca
ggcttatctacagcagtctggggctgagctggtgaggcctggggcctcagtgaaagatgctcgaaggcttctggctacacattaccagtt
acaatatgcactgggttaaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacacatcag
aagttcaagggcaaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtgcaaagtggtgtactatagtaacttactgttacttcgatgtctggggcacagggaccacggtcaccgtctctctgatca
15 ggagcccaaatctgtgacaaaactcacacatctccaccgtgccagcacctgaactcctggggggaccgtcagctctctcttcccccaaa
aaccaaggacaccctcatgatctcccgacccctgaggtcacatgcgtggtggtgacgtgagccacgaagaccctgaggtcaagttc
aactggtacgtggacggcgtggaggtgcataatgccaaagacaaagccgcgggaggagcagtagaacagcacgtaccgtgtggtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaagccctcccagccccatcgagaa
aacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacccctgccccatcccgggatgagctgaccaagaaccaggtc
20 agcctgacctgctgtgcaaaaggtcttatccagcagacatgccgtggagtgaggagcaatgggcagccggagacaactacaaga
ccacgctcccgctgtggactccgacggctcttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccgtgatgcatgaggtctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

25

2H7 scFv MTH (CSC) WTCH2CH3

mndfvqifsfllisasviiargqivlsqpailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgtsysltisrveadaatyycqwsfnpptfgagtkleldggsgggsgggssqaylqqsgaelvrpgasvk
msckasgyftsynmhvkwqtpqrglewigaiypngdtsynqkfkgtatltvdkssstaymqlssltedsavfearvvyysns
ywyfdvwtgttvtvssdqepkscdkthtppcpapellggpsvflfppkpkdtlmisrtpetvvdvshdepvkfnwyvdgv
30 evhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapiektiskakgqprepvytlppsrdeitknqvsltelvk
gfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhealhnhytqkslsispgk

NT

WO 2005/037989

PCT/US2003/024918

2H7 scFv MTH (CCS) WTCH2CH3

aagcttgccgccatggatttcaagtcgagatttcagcttctgctaatactgcttcagtcataattgccagaggaca
aattgtctctcccagctctccagcaatcctgtctgcatctccaggggagaaggtcacaatgactgcagggccagctcaagtgaagttacat
gcactggtaccagcagaagccaggatcctcccccaccctggatttatgcccacccaacctggcttctggagtcctgctcgttcagt
5 gcagtggtctgggaccttactctctcacaatcagcagagtgagggtgaagatgtgccacttattactgccagcagtgaggtttaacc
caccacgttcggtgctgggaccaagctggagctgaaagatggcgggtgctgggcgggtggtgatctggaggagtgaggagctctca
ggcttatctacagcagctctggggctgagctggtagggcctggggcctcagtgaaagatgtcctgcaaggcttctggctacacattaccagtt
acaatatgcaactgggtaaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaatctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
10 gtctatttctgtgcaagagtggtgtactatagtaactcttactgtactctgatgtctggggcacagggaccaggtcacctgtctctctgatca
ggagcccaaatcttgtgacaaaactcacatgtccaccgtccccagcacctgaactctggggggaccgtcagttctcttccccccaa
aaccaaggaacacctcatgatctccggaccttgaggcacatgcgtggtggtgagctgagccacgaagacctgaggtcaagttc
aactggtacgtggagcggctggaggtgcataatgccaaagacccgcgggaggagcagtacaacagcacgtaccgtgtggtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgaaggtctccaacaaagccctcccagccccatcgagaa
15 aacaatctccaaagccaaagggcagccccgagaaccacaggtgtacacctgcccccatcccgggatgagctgaccaagaaccaggtc
agcctgacctgcctggtcaaaaggcttctatccagcgacatcgccgtggagtgaggagagcaatgggcagccggagacaactacaaga
ccacgcctcccgctgctggactccgacggctcttcttctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgtctccgtgatgcagtaggctctgcacaaccactacacgcagaagagcctctccctgtctcgggtaaatgatctaga

20 AA

2H7 scFv MTH (CCS) WTCH2CH3

mdfqvqifsfllisasviiargqivlsqpailsaspgkvtmtcrassvsymhwyqqkpgsspkpwiapsn
lasgvparfsgsgsgtsysltisrveadaatyycqwsfnpptfagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsymbhvwkqtpqglewigaiypngdtsynqkfkgtkatltvdksstaymqllsstedsavycarvvyysns
25 ywyfdvwtgtttvtvssdqepkscdkthtppspapellggpsvflfppkpkdtlmisrtpevtcvvvdvshedpevkfnwyvdgv
evhnaktkpreeqynstyrvsvltvlhqdwlngkeyckvsnkalpapietiskakgqprepvytlppsrldtlnqvsltclvk
gfypsdiavewesngqpennykitppvldsdgsfflyskltvdksrwqqgnvfscsvmhleahnhytqkslsispk

30 NT

HuIgAHIgA-T4-ORF

tgatcagccagttccctcaactccacetaacccatctccctcaactccacetaacccatctccctcatgtgccacccc
cgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcc

WO 2005/037989

PCT/US2003/024918

tcagggtgcaccttcacctggacgccctcaagtgggaagagcgctgttcaaggaccacctgacctgacacctctgtggctgctacagcgtgt
ccagtgtcctgccgggctgtgccgagccatggaacctgggaagaccttcacttgactgctgcctaccccgagccaagaccccgctaa
ccgccaccctctcaaaatccggaacacattccggcccgagggtccacctgctgcccgcccgctcgaggagctggccctgaacgagct
gggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggctgctgaggggtcacaggagctccccgcgaga
5 agtacctgacttgggcacccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgagga
ctggaagaagggggacaccttctcctgcatgtggggccacgagggcctgccgctggccttcacacagaagaccatcgaccgcttggcgg
gtaaaccaccatgtcaatgtgtctgtgtcatggcgagggtggacgcggatccttgaac

AA

10 HuIgAHlgA-T4-ORF

Dqpvpstptpsptptpspschprlsihrpaledlllgseailtctltglrdasgvtftwtpssgksavqgppdr
dlcgysvssvlpgaepwnhgktftctaaypeskptlatlsksntfrpevhllpppseelalnelvtltclargfspkdvlvrlwqsg
elprekyltwasrqepsqgtttfavtsilrvaaedwkkgdtfscmvghcalplafktidrlagkpthvnsvvmaevdadpsn

NT

15 HuIgAHlgA-T4-ORF

tgatcagccagttccctcaactccacctacccatctccctcaactccacctacccatctccctcatgctgccacccc
cgactgtcactgcaccgaccggccctcgaggacctgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcc
tcagggtgcaccttcacctggacgccctcaagtgggaagagcgctgttcaaggaccacctgacctgacacctctgtggctgctacagcgtgt
ccagtgtcctgccgggctgtgccgagccatggaacctgggaagaccttcacttgactgctgcctaccccgagccaagaccccgctaa
20 ccgccaccctctcaaaatccggaacacattccggcccgagggtccacctgctgcccgcccgctcgaggagctggccctgaacgagct
gggtgacgctgacgtgcctggcacgtggcttcagccccaaggatgtgctggctgctgaggggtcacaggagctccccgcgaga
agtacctgacttgggcacccggcaggagcccagccagggcaccaccaccttcgctgtgaccagcatactgcgcgtggcagccgagga
ctggaagaagggggacaccttctcctgcatgtggggccacgagggcctgccgctggccttcacacagaagaccatcgaccgcttggcgg
gtaaaccaccatgtcaatgtgtctgtgtcatggcgagggtggacgcggatccttgaac

25

AA

HuIgAHlgA-T4-ORF

dqpvpstptpsptptpspschprlsihrpaledlllgseailtctltglrdasgvtftwtpssgksavqgppdrd
lccgysvssvlpgaepwnhgktftctaaypeskptlatlsksntfrpevhllpppseelalnelvtltclargfspkdvlvrlwqsgq
30 lprekyltwasrqepsqgtttfavtsilrvaaedwkkgdtfscmvghcalplafktidrlagkpthvnsvvmaevdadpsn

NT

1D8-IgAH IgA-T4-CD80

WO 2005/037989

PCT/US2003/024918

aa gcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgctcactcagctcc aacaaccatagctgcatctccaggggagaaggtcaccatcacctgccgtgccagctccagtgtaagttacatgta
ctggtagcagcagaagtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaaatcgcttcagtgga
gtgggtctgggacctcttattctctcgaatcaacacatggagactgaagatgctgccacttattactgtcagcagtgaggtagtactccgct
5 cagcttcgggtctgggaccaagctggagatcaaacgggggtggcgggtgctcggcggtggtgggtcgggtggcgggatctcagtg
cagctgaaggaggcaggacctggcctggtgcaaccgacacagacctgtccctcatatgactgtctctgggttctcattaaccagcgatg
gtgtactggtgattcga cagcctccaggaaagggtctggaatggatgggaataatattatgatggaggcacagattataattcagcaatta
aatccagactgagcatcagcaggacacctccaagagccaagttttctaaaaatcaacagtctgcaaacatgatgacacagccatgtattac
tgtgccagaatccactttgattactggggccaaggagtcaggtcacagctcctctgatcagccagttccctcaactccacctacccatctc
10 cctcaactccacctacc ccatctccctcatgctgccacccccactgtcactgcacggaccggccctcgaggacctgctcttaggttcagaa
gggactctcactgca cactgaccggcctgagagatgcctcaggtgtcaccttcacctggacgccctcaagtgggaagagcgtgttcaa
ggaccacctgaccgtgacctctgtggtgctacagcgtgtccagtgctcctgccgggctgtgccgagccatggaaccatgggaagaccttc
acttgactgctgcctaccccaggtccaagaccccgtaacggccacctctcaaatccggaaacacattccggcccaggtccacctg
ctgccgccgctcgaggagctggccctgaacgagctggtagcgtgacgtgcctggcacgtggcttcagcccaaggatgtgctggt
15 tcgctggctgcaggggtcacaggagctgcccgcgagaagtacgtgacttgggcatccggcaggagcccagccaggggcaccaccac
cttcgctgtgaccagcaatactgcgcgtggcagccgaggactggaagaagggggacaccttctcctcatggtgggccacgagggccctgc
cgctggccttcacaca gaagaccatcgaccgcttggcgggtaaacccaccatgtcaatgtgtctgttgcagcggaggtggacgcgg
atccttgaacaacctgctcccatcctgggccattaccttaatctcagtaaatggaattttgtgatgtgctgcctgacctactgctttgccccaa
gatgcagagagagaa ggagggaatgagagattgagaagggaagtgtacgcctgtataaatcgatac

20

AA

1D8 scFv IgAH IgA-T4-CD80

m d f q v q i f s f l l i s a s v i m s r g v d i v l t q s p t t i a a s p g e k v t i t c r a s s s v s y m y w y q q k s g a s p k l w i y d t s k l
25 a s g v p n r f s g s g t s y s l a i n t m e t e d a a t y y c q q w s s t p l t f g s g t k l e i k r g g g s g g g s g g g s q v q l k e a g p g l v q p t q t l s t
c t v s g f s l t s d g v h w i r q p p g k g l e w m g i i y d g g t d y n s a i k s r l s i s r d t s k s q v f l k i n s l q t d d t a m y c a r i h f d y w g q g v m
v t v s s d q p v p s t p t p s p s t p t p s p s c h p r l s h r p a l e d l l l g s e a i l t c t l t g l r d a s g v t f t w p s s g k s a v q g p p d r d l c g c y s v s s
v l p g c a e p w n h g k t f t c t a a y p e s k t p l t a t l s k s g n t f r p e v h l p p p s e l a l n e l v t l t c l a r g f s p k d v l v r w l q g s q e l p r e k y l t w
a s r q e p s q g t t t f a v t s i l r v a e d w k k g d t f s c m v g h e a l p l a f t q k t i d r l a g k p t h v n v s v m a e v d a d p s n n l p s w a i t l i s v n
30 g i f v i c l t y c f a p r c r r r n e r l r r e s v r p v

NT

WO 2005/037989

PCT/US2003/024918

human IgE Fc (CH2-CH3-CH4) ORF:

tgatcacgtctgctccagggaacttcacccgccaccgtgaagatcttacagtcgtcctgcgacggcgggggcacc
tccccccgaccatccagtcctgtgcctcgtctctgggtacacccagggaactcaacatcacctggctggaggacgggcaggtcatgg
acgtggacttgccaccgcctctaccacgcaggaggggtgagctggcctccacacaaagcgagctcacctcagccagaagcactggctg
5 tcagaccgcacctacacctgccaggtcacctatcaaggtcacacctttgaggacagcaccagaagtgtgcagattccaacccgagaggg
gtgagcgcctacctaagccggcccagcccgttcacctgttcatccgcaagtcgccacgatcacctgtctggtgggtggacctggcacc
agcaaggggaccgtgaacctgacctgtcccggggcagtggaagcctgtgaacctccaccagaagaggagagaagcagcgcgaat
ggcacgttaacctgacgtccacctgcccgtgggcacccgagactggatcgagggggagacctaccagtgcagggtgaccaccccc
acctgccaggggccctcatgcggtccacgaccaagaccagcggcccgctgctgcccggaagtctatcggttgcgacgccggagtg
10 gccggggagccgggacaaagcgcacctcgcctgcctgatccagaactcatgctgaggacatctcggtcagtggtgcacaacgag
gtgcagctcccgacgccgggcacagcacgacgcagccccgaagaccaagggtccggcttcttcagccgcctggaggtga
ccaggggcgaatgggagcagaaagatgagttcatctgccgtgcagtcctatgaggcagcgagccccctcacagaccgtccagcgagcgg
gtctgtaaatcccgtaaagcggatcctcgaa

15

AA

human IgE Fc (CH2-CH3-CH4) ORF:

dhvcsrdftptvkilqsscdggghfpptiqlclvsgytpgtinitwledgqvmdvdlstastqegelastqseltl
sqkhwlslrtytcqvttyqghtfedstkkcadnsnprgvsaylsrpspfdlfrksptitclvdlapskgvnltsrasgkpvnhstrikee
20 kqrngtltvtstlpvgtrdwiegetyqcrvthphlpralmrsttktsgraaapevyafatpewpgsrdrktlacliqnfmnpedisvqwlh
nevqlpdrhsttqprktksgffvfrlevtraewekdeficravheaaspsqtvqravsvnpgkadps

NT

25 1D8 scFv-human IgE Fc (CH2-CH3-CH4)-CD80

aagcttatggattttcaagtcagattttcagcttcctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgctcactcagtcctcaacaaccatagctgcattcctcaggggagaaaggtcacatcacctgccgtgccagctccagtgttaagtacatgta
ctggtaccagcagaagtcaggcgcctcccctaaactctggatttatgacacatccaagctggcttctggagttccaatcgcttcagtgga
gtgggtctgggaccttattctctgcaatcaacacctggagactgaagatgctgccacttattactgtcagcagtgaggtagtactccgct
30 cacgttcgggtctgggaccaagctggagatcaaacgggggtggcggtggctcggcggtggtgggtcgggtggcgcggtatctcaggtg
cagctgaaggagcagcagacctggcctggtgcaaccgacacagacctgtccctcacatgcactgtctctgggttctcattaaccagcagtg
gtgtacactggattcgacgcctccaggaaagggtctggaatggatgggaataatattatgatggaggcacagattataattcagcaatta
aatccagactgagcatcagcaggacacctccaagagccaagttttcttaaaaatcaacagctctgcaactgatgacacagccatgtattac

WO 2005/037989

PCT/US2003/024918

tgtgccagaatccactttgattac tggggccaaggagtcaggtcacagtctcctctgatcacgtctgtccagggacttcaccccgccacc
gtgaagatcttacagtcgtcctg c gacggcgggcggcacttcccccgaccatccagctcctgtgcctcgtctctgggtacaccccaggga
ctatcaacatcacctggctgga g gacggcgaggtcatggacgtggacttgcaccgcctctaccacgcaggagggtgagctggcctcc
acacaaagcgagctcacctca gccagaagcactggctgtcagaccgcacctacacctgccagggtcacctatcaaggtcacaccttgag
5 gacagaccaagaagtgtgca gattccaacccgagaggggtgagcgctacctaagccggcccagccgttcgacctgttcacccgaa
gtcggccacgatcacctgtctg gtgtggacctggcaccagcaaggggaccgtgaacctgacctgggtccggggccagtgggaagcct
gtgaaccactccaccagaaag gaggagaagcagcgcaatggcagcttaaccgtcacgtccacctgccgggtgggcacccgagactgg
atcgagggggagacctaccagtgcagggtgacccacccccacctgccaggccctcatgcggtccacgaccaagaccagcgggccg
cgtgctgccccggaagtctatg cgtttgcgacggcgagtgccggggagccgggacaagcgacccctcgctgctgatccagaactt
10 catgctgaggacatctcgggtg cagtggtgcacaacgaggtgcagctcccgacgcccggcacagcacgacgagccccgcaagac
caagggtccggcttctctctctcagccgcctggaggtgaccagggccgaatgggagcagaagatgagttcatctgccgtgcagtcca
tgaggcagcgagccccctaca gaccgtccagcgagcggtgtctgtaaatccggtaaaaggatccttcgaagctcccatcctgggccat
tacctaatctcagtaaatggaa ttttgtgatatgctgcctgacctactgctttgcccccaagatgcagagagagaaggagggaatgagagattg
agaaggggaaagtgtacgcct g tataaatcgata

15

AA 1D8-scFv-human IgE Fc (CH2-CH3-CH4)-CD80

mfdqvqi fsflilisavimsrgvdivltqspttiaaspgekvtitrasssvsymywyqksgasplkiwydtskl
asgvpnrfsgsgsgtsyslain tmetedaatyycqqwsstpltfsggtkleikrgggsgggsgggsgggsgvqlkeagpglvqptqlsl
ctvsgfsltsdgvhwirppgk glewmgiyydgtdynsaiksrlsisrdtsksqvlkinslqtdtdamyycarihfdywgqgvm
20 vtvssdhvcsrdftppvkilq sscdggghfpptiqlclvsgytpgtinitwledgqvm dvlstattqegelaastqseltslqkhwlsd
rtytcqvyqghtfedstkkca dsnprgvsaylsrspfdl firkspitclvvdlapskgtnltwsrasgkpvnhstrkeekqrngltvt
stlpvgrtdwiegetyqcrvth phlpralmrsttktsgraaapevyafatpewpgsrdrklaciqnfmpeidsvqwlhnevqlpdar
hsttprktkgsgffvfrlevtra eweqkdeficravheaaspsqtvqravsvnpgkadpsklpswaitlisvngifviccltycfapr
errrnerlrresvrpv

25

NT

5B9-IgA H IgA-T4-CD80

aagcttgc c gccatgagggtctctgctcagcttctggggctgcttgtgctctggatccctggatccactgcagatattgt
30 gatgacgcaggtgcattctccaatccagtcactcttgaacatcagcttccatctcctcaggtctagtaagagtctcctacatagtaatggc
atcacttatttattgtatctgc agaagccaggccagctctcctcagctcctgattatcagatgtccaaccttgcctcaggagtccagacag
gttcagtagcagtggttcagga actgatttcacactgagaatcagcagagtgaggctgaggatgtgggtgtttatfactgtgctcaaatct
agaactccgctcacggttcggt gctgggaccaagctggagctgaaacggggtggcggtggctcgggcgggtgggtgggtggcggc

WO 2005/037989

PCT/US2003/024918

ggatcgtcacaggtgcagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtcctctggtttctc
 attaacctacatgtgtacactgggttcgccagtcctcaggaaagggtctggagtggtggagtgatatggagtggtggaatcacagact
 ataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagttttttaaataaacagctgcaacctaatgacac
 agccatttattactgtgccagaaatgggggtgataactaccttattactatgctatggactactggggtaaggaacctcagtcaccgtctcc
 5 tctgatcagccagttccctcaactccacctaccccatctccctcaactccacctaccccatctccctcatgctgccacccccactgtcactgc
 accgaccggccctcaggacactgctcttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcacctt
 cacctggacgcccctcaagtgggaagagcgtgttcaaggaccactgaccgtgacctctgtggctgctacagcgtgtccagtgtcctgcc
 gggtgtgccgagccatggaacctgggaagaccttcaactgcaactgctgctaccccgagtcgaagaccccgttaaccgccacctctc
 aaaatccggaaacacattccggcccagggtccacctgctgccgccgctcgaggagctggccctgaacgagctggtgacgctgacg
 10 tgcctggcacgtggcttcagccccaggatgtgctggtcgtggtgcaggggtcacaggagctgccccgcgagaagtacgtgacttgg
 gcatcccgaggagagccagccagggcaccaccaccttctgctgtgaccagcatactgcgctggcagccaggactggagaagggg
 gacaccttctctgcatggtgggcccagaggccctgccgctggccttcacacagaagacctgaccgcttggcgggtaaacccacctat
 gtcaatgtgtctgttgcattggcgagggtggacgggaccttcgaacaacctgctcccatctgggccattaccttaattctcagtaaatgga
 attttctgatatgctgacctactgcttggcccaagatgcagagagagaaggagggaatgagagattgagaagggaagtgtacgcc
 15 ctgtataaatcgatac

AA

5B9-IgAH IgA-T4-CD80

mrfsaqlglvliwipgstadivmtqaafsnvptlgtasiscrskslhsngitylywylqkpgqspqlliyqms
 20 nlasgvprdfsssgsgtdflrisrveadvgyvyaqnlelpltfagtklelkrggggsgggsgggssqvqlkqsgpglvqssqsl
 sitctvsgfsltyavhwvrqspgkglewlgviwsggitynaafsrslsitkddsksqvffkmnslqpnndaiyyarnngdnpyyy
 amdywgqgtsvtvssdqvpstptpsptpspschprlslhrraledlllgseailtctltglrdasgvtftwtpssgksavqgpp
 drdlcgcyssvslpgcaepwnhgktftctaaypesktpatlsksngntfrpevhllpppseelalnelvtltclargfspkdvlvrlqg
 sqelprekyltwasrqepsqgtttfavtsilrvaaedwkkgdftscmvghaelplafktidrlagkpthvnsvmaevdadpsnnl
 25 lpswaitlisvngifvicltycfaprerrrrerlrrsvrpv

NT

5B9-scFv-human IgE Fc (CH2-CH3-CH4)-CD80

aagcttgccgccatgaggttctctgctcagcttctgggctgctgtgctctggatccctggatccactgcagatattgt
 30 gatgacgcaggctgcattctccaatccagtcactcttggaacatcagcttccatctcctgcaggctagtaagagtctcctacatagtaatggc
 atcacttatttattgtatctgcagaagccaggccagctcctcagctcctgattatcagatgtccaaccttgcctcaggagtccagacag
 gttcagtagcagtggtcaggaactgatttcacactgagaatcagcagagtgagggtgaggatgtgggtgtttattactgtctcaaatct

WO 2005/037989

PCT/US2003/024918

agaactccgctcacgttcggtgctgggaccaagctggagctgaaacggggtggcgggtggctcgggcgggtgggtgggtcgggtggcggc
ggatcgtcacaggtgcagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggtttctc
attaactacatgtgtacactgggttcgccagctcaggaaggggtctggagtggctgggagtatatggagtgggtggaatcacagact
ataatgcagctttcatatccagactgagcatcaccaaggacgattccaagagccaagttttcttaaaatgaacagtctgcaacctaataacac
5 agccatttattactgtgccagaatgggggtgataactacccttattactatgctatggactactggggtcaaggaaacctcagtcaccgtctcc
tctgatcacgtctgtccagggaacttccccgccaccgtgaagatcttacagtcgtcctgcgacggcggcgggcacttcccccgacca
tccagctcctgtgctcgtctctgggtacacccagggactatcaacatcacctggctggaggacgggcaggtcatggacgtggactgtc
cacgcctctaccacgcaggagggtgagctggcctccacacaaagcgagctcacctcagccagaagcactggctgtcagaccgcacc
tacacctgccaggtcacctatcaaggtcacacctttgaggacagcaccaagaagtgtgcagattccaacccgagaggggtgagcgcctac
ctaagccggcccagcccgttcgacctgttcatccgaagtcgcccacgatcacctgtctggtggtggacctggcaccagcaaggggac
10 cgtgaacctgacctggtcccggccagtggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaacc
gtcacgtccacctgccgggtggcaccgagactggatcgaggggagacctaccagtgacgggtgaccacccccacctgccagg
gccctcatgcggtccacgaccaagaccagcggcccgcgtgctgccccggaagtctatgcgttgcgacgccgagtgccggggagcc
gggacaagcgacacctgcctgcctgatccagaatctatgcctgaggacatctcgggtcagtggtgcacaacgaggtgcagctcccg
15 gacgcccggcacagcacgacgcagccccgaagaccaagggtccggcttctctctcagccgcctggaggtgaccagggccgaat
gggagcagaaagatgagttc atctgccgtgcagtcctatgaggcagcgagccctcacagacctccagcgagcgggtgtctgtaaatccc
ggtaaagcggatccttgaaactccatcctgggccattacctaatactcagtaaatggaattttgtgatgtctgcctgacctactgctttgcc
ccaagatgcagagagagaaaggaggaatgagagattgagaagggaagtgtacgcctgtataaatcgata

20

AA

5B9-scFv-human IgE Fc (CH2-CH3-CH4)-CD80

mrfsaqlllglvlwipgstadivmtqaafsnptlgtasiscrskslhsngitylywylqkpgqspqlliyqms
nlasgvprdfsssgsgtdflr isrveadvgvycaqnlepltfagtklelkrggggsgggsgggssqvqlkqsgpglvqssqsl
25 sitctvsgfsltyavhwvrqspgkglewlgviwsggitynaafisrlsitkddsksqvffkmnslqpnndtaiyyarnngdnpyyy
amdywgqgtsvtvssdhvc srdftpptvkilqsscdggghfpptiqlclvsgytpgtinitwledgqvm dvlstasttqegelastqs
eltlsqkhwl sdrtytcqvtyc ghtfedstkkcadsnprgvsaylsrspfdl firkspitclvdlapskgtvnlwsrasgkpvnhstr
keekqrmgtltvtstlpgvtrd wiegetyqervthphlpralmrstktsgpraapevyafatpewpgsrdkrtlaclinqfmpedisvq
wlhnevqlpdarhsttprkctkgsgffvfrlevtraeweqkdeficravheaaspsqtvqravsvnpgkadpsklpswaitlisvngif
30 vicltycfaprrerrrrerlrresvrpv

NT

2e12-scFv-IgAH IgA-T4-CD80

WO 2005/037989

PCT/US2003/024918

aagcttaaggatttcaagtcagatcttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgctcaccgaatctccagcttcttggctgtgtcttaggtcagagagccaccatctcctgcagagccagtgaaagtggaatattatgtca
caagtttaagcagtggtaccaacagaaaccaggacagccacccaaactcctcatctctgctgcatccaacgtagaatctggggtccctgc
caggtttagtgagtggtgctgggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtattctgtcagcaaaag
5 taggaaggttccttgagctcgggtggaggcaccagctggaaatcaaacgggggtggcgtggctgggaggagtggtgggtggc
ggcggatctcaggtgcagctgaaggagtcaggacctggcctgggtggcggcctcacagagcctgtccatcacatgcaccgtctcagggttc
tcaftaaccggctatggtgtaaactgggttcgccagcctccaggaaagggtctggagtggtgggaatgatatggggtgatgaagcaca
gactataattcagctctcaatccagactgagcatcaccaaggacaactccaagagccaagtttcttaaaaatgaacagctctgcaaaactgat
gacacagccagatactactgtgccagagatggtatagtaactttcattactatgtatggactactggggtcaaggaacctcagtcaccgtct
10 cctcagatcagccagttccctcaactccacctaccatctccctcaactccacctaccatctccctcatgctgccacccccgactgtcact
gcaccgaccggccctcagggacctgctttaggttcagaagcgatcctcacgtgcacactgaccggcctgagagatgcctcaggtgtcac
cttcacctggagccctcaagtgggaagagcgcgttcaaggaccacctgacctgtggtgctacagcgtgtccagtgctcctg
ccgggctgtgccgagccatggaacctgggaagaccttcacttgcactgtgcctaccccgagtccaagaccccgctaaccgccacctc
tcaaatccggaaacacattcaggcccgaggtccacctgtgcggccggcgtggaggagctggccctgaacgagctggtgacgtga
15 cgtgcctggcacgtggcttcaagcccaaggtgtgctggttcgctggctgcaggggtcacaggagctgccccgcgagaagtagctgactt
gggcatcccgagcagcagccagccagggcaccaccaccttcgctgtgaccagcactatgcgcgtggcagccgagagctggaagaagg
gggacaccttctctgcatggtggggccagagccctgccgtggccttcacacagaagaccatcgaccgttggcgggtaaacccacc
catgtcaatgtgtctgtgtcatggcgagggtggagcgggatccttcgaacaacctgtcccatcctgggccattacctaattcagtaaatg
gaattttgtgatgtgctgcctgacctactgctttgccccagatgcagagagagaaggagggaatgagagattgagaagggaagtgtacg
20 ccctgtataaatcgatac

AA

2e12-scFv-IgAH IgA-T4-CD80

25 mdfqvqifsfllisasvimsrgvdivltqspaslavslgqratisrasesveyyvtslmqwyqqkpgqppkllis
aasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikrgggsgggsgggsgvqlkesgpglva
psqslsitctvsgfsltygvnwwrpppgkglewlgmiwgdgstdynsalksrsltkdnskqvflkmnslqtdtdaryycardgys
nfhyvymdywgqgtsvtvssdqvpstptpsptpspcchprlsihrpaledlllgseailtctlgldasgvtftwtpssgksa
vqppdrdlcgcysvssvlpgaepwnhgktftctaaypeskptlatlsksngtfrpevhllpppseelalnelvtlclargfspkdvlv
30 rwlqgsqelprekyltwasrcqpsqgtttfavtsilrvaedwkkgdftscmvghalplafktidrlaglkpthvnsvvmaevda
dpsnnllpswaitlisvngifviccltycfaprcrrrrnerlrresvrpv

NT

WO 2005/037989

PCT/US2003/024918

2e12-scFv-human IgE Fc (CH2-CH3-CH4)-CD80

aagcttatggattttcaagtcagattttcagcttctgctaatacagtgcttcagtcataatgtccagaggagtcgacatt
gtgtcaccacaatccagcttctttggctgtgtctctaggtcagagagccaccatctcctgcagagccagtgaaagtgtgaatattatgtca
caagtttaatgcagtggtac caacagaaaccaggacagccacccaaactcctcatctctgtgcacccaacgtagaatctggggtccctgc
5 caggtttagtggcagtggtgtctggacagacttcagcctcaacatccatcctgtggaggaggatgatattgcaatgtatttctgtcagaaa
taggaaggttccttgacgttcggtggaggcaccaagctggaaatcaaacggggtggcgtggctcgggcggaggtgggtcgggtggc
ggcggatctcaggtgcagctgaaggagtcaggacctggcctgggtggcgcctcacagagcctgtccatcacatgcaccgtctcagggttc
tcattaaccggctatgtgtaaactgggttcgccagcctccaggaaagggtctggagtggctgggaatgatatggggtgatggaagcaca
gactataattcagctctcaaattccagactgagcatcaccaaggacaactccaagagccaagttttctaaaaatgaacagctctgcaaaactgat
10 gacacagccagatactactgtgccagagatggttatagtaactttcattactatgttatggactactgggtcaaggaacctcagtcaccgtct
cctcagatcacgtctgtccagggacttcaccccgccaccgtgaagatctfacagtcgtcctgcgacggcgccgggacttcccccca
ccatccagctcctgtgcctcgtctctgggtacacccagggactatcaacatcacctggctggaggacgggcagggtcatggacgtggactt
gtccaccgcctctaccacgcaggagggtgagctggcctccacacaaagcagctcacctcagccagaagcactggctgtcagaccgc
acctacacctgccagggtcacctatcaagggtcacacctttgaggacagcaccaagaagtgtgcagattccaaccggagagggtgagcgc
15 ctacctaaagccggccagcccggttcgacctgttcacccgaagtcgccacgatcacctgtctggtggtggacctggcaccagcaagggt
gacctgaacctgacctggtcccgggccagtggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgtta
accgtcacgtccacctgc cgggtgggcacccgagactggatcgagggggagacctaccagtgcagggtgacccacccccacctgccc
agggccctcatcggtccacgaccaagaccagcggcccgctgctgccccggaagtctatgcgtttgcgacgccggagtggtggccgggg
agccgggacaagcgcacctcgcctgcctgatccagaacttcacctgaggacatctcgggtcagtggtgcacaacagggtgcagct
20 cccggagcggcgacagacgacgagccccgaagaccaagggtcggcttctctgtcttcagccgcctggaggtgaccagggc
cgaatgggagcagaaagatgagttcatctgccgtgcagtcctatgaggcagcgagccctcacagaccgtccagcgagcgggtgtctgtaa
atccggtaaaagcggtatcttcgaagctccatctcgggccattacctaatactcagtaaatggaattttgtgatatgctgcctgacctactgc
tttccccaagatgcagagagagaaggagggaatgagagattgagaagggaagtgtacgccctgtataaatcagata

25

AA

2e12-scFv-human IgE Fc (CH2-CH3-CH4)-CD80

mfdqvvqifsfllisasvmsrgvdivltqspaslavslgqratiscrasesveyyvtslmqwyqqkpgqppkllis
aasnvesgvparfsgsgsgtdfslnihpveeddiamyfcqqsrkvpwtfgggtkleikrgggsgggsgggsgvqlkespglva
30 psqslsitctvsgfsltygvnwvrrppgkglewlgmiwgdstdynsalksrslsitkdnsksqvfllkmnslqtdtdaryycardgys
nfhyvmdywgqgtsvtvssdhvcsrdftppvtkilqsscdggghfpptiqlclvsgytpgtinitwledgqvmvdldstasttqege
lastqseltlsqkhwlsdrtytcqvtyqghtfedstkkcadnprgvsaylsrpspfdlfrksptitclvvdlapskgtnlwtwsrasgkpv
nhstrkeekqrngtltvtstlpvgtrdwegetyqcrvthphlpralmrsttktsgpaaapevyafatpewpgsrdkrtlaclqnfmpep

WO 2005/037989

PCT/US2003/024918

isvqwlhnevqlpdarhsttqprktkgsgrffvfrlevtraeweqkdeficravheaaspsqtvqravsvnpkgadpsklpswaitlisv
ngifviccltycfaprerrmerlrresvrpv

NT

5 500A2 scFv

atgtgtatacatctcagctcctgggcttttactcttctggatttcagcctccagaagtgacatagtgctgactcagactc
cagccactctgtctataattcttggagaaagagtcacaaatgacgtgaagaccagtcagaatattggcacaattcttacttggtatcaccaaa
aaccaaaggaggtccaagggtctcatcaagtatgcttcgagtcattctcgggatccctccagattcagtggcagtggttcggaaaca
gatttcactctcagcatcaataacctggagcctgatgatcggaaatttactgtcaacaaagtagaagctggcctgtcacgttcggtcctg
10 gcaccaagctggagataaaacggggtggtgggtggtcggggcggaggtgggtcgggtggcggcgatctcaggtcaagctgcagcagt
ccgggtctgaactagggaacctggggcctcagtgaaactgtcctgcaagacttcaggctacatattcacagatcactatattcttgggtgaa
acagaagcctggagaaaagcctgcaagtggataggaaatgttatgggtggaaatgggtgtacaagctacaatcaaaaattccagggcaaggc
cacactgactgtagataaaatctctacacagcctacatggaactcagcagcctgacatctgaggattctgccatctattactgtgcaagaag
gccggtagcgacgggcatgctatggactactggggtcaggggatccaagttaccgtctcctctgac

15

AA

500A2 scFv

mlytsqllglllfwisarsdivltqtpatlslipgervtmtcktsqniqtilhwyhqpkeapralikyasqsipgip
srfsgsgsetdftlsinnlepddigiyyccqsrswpvtfpgptkleikrgggsgggsgggsgqvkllqsgselgkpgasvklckts
20 gyiftdhyiswvkqkpgeslqwi gnvygnggtsynqkfqgkatltvdkisstaymelsltsedsaiyyccarrpvatghamdywg
qgiqvtvssd

5' oligo:

25

Name : hIgAbcl5

Sequence : GTTGTTGATCAGCCAGTTCCTCAACTCCACCTACC

3' oligo:

30

Name : IgA3BB

GTTGTTTTTCGAAGGATCCGCGTCCACCTCCGCCATGACAACAGA

5' oligo:

Name : IgGWT3

WO 2005/037989

PCT/US2003/024918

GTTGTTTTTCGAAGGATCCGCTTTACCCGGAGACAGGGAGAGGCTCTT

3' oligo:

Name : hIgGWT5

5

GTTGTTAGATCTGGAGCCCAAATCTTGTGACAAAACACACATG

WO 2005/037989

PCT/US2003/024918

5' oligo:

Name : FADD5

Sequence :

5 GTTGTGGATCCTTCGAACCCGTTCTGGTGCTGCTGCACTCGGTGTCG

3' oligo:

Name : FADD3

Sequence :

10 GTTGTTCATCGATCTCGAGTTATCAGGACGCTTCGGAGGTAGATGCGTC

FADD-CSSCFV:

Gtggatccttcgaacccgttcctggtgctgctgcactcggtgtcgtccagcctgtcagcagcgagctgaccgagct
caagttcctatgcctcgggcgcgtggcgaagcgcaagctggagcgcgtgcagagcggcctagacctcttccatgctgctggagcaga
15 acgacctggagcccgggcacaccgagctcctgcgcgagctgctgcctccctgcggcgccacgacctgctgcggcgctcgcagactt
cgaggcggggcgggcgccggggccgcgcctggggaagaagacctgtgtgcagcatttaacgtcatatgtgataatgtgggaaagat
tggagaaggctggctcgtcagctcaaagtctcagacaccaagatcgacagcatcgaggacagatacccccgcaacctgacagagcgtgt
gcgggagtcactgagaatctggaagaacacagagaaggagaacgcaacagtgggccacctggtgggggctctcaggtcctgccagatg
aacctggtggctgacctggtacaagagggtcagcagggccgtgacctccagaacaggagtggggccatgtccccgatgtcatggaactc
20 agacgcacatctacctccgaagcgtcctgataactcgagatcgataacaac

Peptide sequence:

vdpsnpflvllhsvssslsssttelkfclgrvgrklervqsgldlfsmllleqndlepghtellrellaslrhdllrrv
ddfeagaaagaapgeedlcaafnvi cdnvgkdwrrlarqlkvsdtkidsiedryprnltervreslriwkntekenatvahlvgalrscq
25 mnlvadlvqevqqardlqnrsgamspmswnsdastseas

Name : HCD28tm5B

GTTGTGGATCCTCCCTTTTGGGTGCTGGTGGTGGTGGTGGTGGTGGCTT
30 GCTATAGCTTG

Name : HCD28tm3S

WO 2005/037989

PCT/US2003/024918

GTTGTTTCGAACCCAGAAAATAATAAAGGCCACTGTTACTAGCAAGCT
ATAGCAAGCCAG

5 HCD28tm5'
GTTGTGGATCCTCCCTTTTGGGTGCTGGTGGT
HCD28tm3'
GTTGTTTCGAACCCAGAAAATAATAAAGGCCAC

10 HCD80tm5'
GTTGTGGATCCTCCTGCTCCCATCCTGG
HCD80tm3'
GTTGTTTCGAACGGCAAAGCAGTAGGTCAGGC

15 Name : MFADD5BB
Sequence :
GTTGTGGATCCTTCGAACCCATTCCTGGTGCTGCTGCACTCGCTG

20 Name : MFADD3XC
Sequence :
GTTGTTATCGATCTCGAGTCAGGGTGTTTCTGAGGAAGACAC

25 Murine FADD Nucleotide sequence (full length, but without flanking -Ig or
transmembrane sequences):

Gtggatccttgaacatggaccattcctggtgctgctgcactcgctgccggcagcctgtcgggcaacgatctgat
ggagctcaagttctgtgccgcgagcgcgtgagcaaacgaaagctggagcgcgtgcagagtgccctggacctgtcacggtgctgctgg
agcagaacgacctggagcgcgggcacaccgggctgctgcgcgagttgctggcctcgctgcgccgacacgatctactgcagcgcctgga
cgacttcgaggcggggacggcgaccgctgcgccccggggaggcagatctgcaggtggcatttgacattgtgtgtgacaatgtgggg
30 agagactggaaaagactgcccgcgagctgaaggtgtctgaggccaagatggatgggattgaggagaagtacccccgaagtctgagtg
agcgggtaaggagagcttgaaagtctggaagaatgctgagaagaagaacgcctcggtggccggactggtcaaggcgtgcggacct
gcaggctgaatctgtggctgacctggtggaagaagcccaggaatctgtgagcaagagtgagaatatgtccccagtactaagggaattcaa
ctgtgtcttctcagaaacacccctgactcgagatcgat

WO 2005/037989

PCT/US2003/024918

Murine FADD

vdpsnmdpflvllhslsgslsgndlmelkflcrervskrklerqvsgldlftvlleqndlerghtglrellaslrhdll
qrlddfeagtataappgeadlqvafdivcdnvgrdwkrlarelkvseakmdgieekyprlservreslkvwknaekknasvaglvk
5 alrtcrlnlvadlveeaqesvsksenmbspvlrdstvsstetp

Name : MCASP3-5
10 Sequence :

GTTGTGGATCCTTCGAACATGGAGAACAACAAAACCTCAGTGGATTCA

Name : MCASP3-3
Sequence :

GTTGTTATCGATCTCGAGCTAGTGATAAAAGTACAGTTCTTTCGT

15

Name : mcasp8-5
Sequence :

20 GTTGTTTCGAACATGGATTTCCAGAGTTGTCTTTATGCTATTGCTG

Name : mcasp8-3
Sequence :

GTTGTTATCGATCTCGAGTCATTAGGGAGGGAAGAAGAGCTTCTTCCG

25

Name : hcasp3-5
Sequence :

GTTGTGGATCCTTCGAACATGGAGAACAACACTGAAAACCTCAGTGGAT

Name : hcasp3-3
30 Sequence :

GTTGTTATCGATCTCGAGTTAGTGATAAAAATAGAGTTCTTTGTGAG

WO 2005/037989

PCT/US2003/024918

Name : hcas8-5

Sequence :

GTTGTGGATCCTTCGAACATGGACTTCAGCAGAAATCTTTATGAT

Name : hcas8-3

5 Sequence :

GTTGTTATCGATGCATGCTCAATCAGAAGGGAAGACAAGTTTTTTTCT

HuIgGMHWC

10 gtt gtt gat cag gag ccc aaa tct tct gac aaa act cac aca tct cca ccg tcc cca gca cct gaa
ctc ctg ggt gga ccg tca gtc ttc c

NT

15 2H7-human IgE (CH2-CH3-CH4)

aagcttgccgcatggattttcaagtgagattttcagcttcctgctaatacagtgcttcagtcataattgccagaggaca
aattgttctctccagtcctcagcaatcctgtctgcatctccaggggagaaggtcacaatgacttcagggccagctcaagttaagttacat
gcactggtagcagagaagccaggtatcctcccaaacctggatttatgccccatccaacctggcttctggagtcctgctcgttcagtg
gcagtggtgtgggacctcttactctctcacaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgaggtttaacc
20 caccacgttcgtgtgctgggaccaagctggagctgaaaggtggcgggtgctcgggcgggtgggtgagatctggaggaggtgggagctctca
ggcttatctacagcagtcctggggtgagctgggtgagggcctggggcctcagtgaaagatgctcgaaggcttctggctacacattaccagtt
acaatatgcactgggtaaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggcaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctgcg
gtctatttctgtcgaagagtgggtactatagtaactcttactggtacttcgatgtctggggcacagggaccaggtcaccgtctctgacacgt
25 ctgctccagggaacttcaccccgccaccgtgaagatcttacagtcgtcctgcgacggcgggcggcacttcccccgaccatccagctcct
gtgcctcgtctctgggtacacccagggactatcaaatcacctggctggaggacgggcaggtcatggagctggactgtccaccgcctct
accacgcaggaagggtgagctggcctccacacaaagcgagctcacctcagccagaagcactggctgtcagaccgcacctacacctgcc
aggtcacctatcaaggtcacaccttgaggacagcacaagaagtgtgcagattccaacccgagaggggtgagcgcctacctaaagccgg
cccagcccgttcgacctgttcatccgaagtgcgccacgatcacctgtctggtggtggacctggcaccagcaaggggaccgtgaacctg
30 acctggtcccggccagtggaagcctgtgaaccactccaccagaaaggaggagaagcagcgcaatggcacgttaaacgtcacgtcca
ccctgccgggtggcaccggagactggatcgagggggagacctaccagtgaggggtgaccacccccacctgccagggcctcatgc
gggtccacgaccagaccagcggcccgctgctgccccggaagtctatgcgtttgcgacggcgagtgccgggggagccgggacaaagc
gcacctcgctgctgatccagaacttcagctgaggacatctcgggtgagtggtgcacaacgaggtgcagctcccgacgcccgg

WO 2005/037989

PCT/US2003/024918

cacagcacgacgcagccccgaagaccaagggtccggcttcttcttctcagccgcctggaggtgaccagggccgaatgggagcaga
aagatgagttcatctgccgtgcagtcctatgaggcagcgagccctcacagaccgtccagcgagcgggtgtctgtaaatcccggtaatgata
atctaga

5

AA

2H7 scFv IgE (CH2-CH3-CH4)

mdfqvqifsflisasviiargqivlsqspailsaspgekvtmtcrasssvsymhwyqqkpgsspkpwiypsn
lasgvparfsgsgsgtsysltisrveadaatyycqawsfnpptfgagtklelkgggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsymbhvwkqtrpqglewigaiypngdtsynqkfkkgkatltvdkssstaymqllsstsedsavycarvvyysns
10 ywyfdvwgtgtvtvsdhvcsrdftptvkilqsscdggghfpptiqlclvsytpgtinitwledgqvmdvdlstastqegelastqs
eltlsqkhwlsdrtytcqvytqghfedstkkcadsnprgvsaylsrspfdlfrksptitclvdlapskgtvnltsrasgkpvnhstr
keekqrngltvtstlpvgtrdwiegetyqcrvthphlpralmrsttktsgpaaapevyafatpewpgsrdkrtlacliqnfmpeidivq
wlhnevqlpdarhsttqprtkgsgffvfrlevtraeweakdeficravheaaspsqtvqravsvnpqk

15

NT

2H7 scFv MH (SSS) MCH2WTCH3

aagcttgccgccatggatttcaagtgcagatttgcagcttctgctaatcagtgcttcagtcataattgccagaggaca
20 aattgttcttcccagtcctccagcaatcctgtctgcattcctcaggggagaaggtcacatgacttcagggccagctcaagtgaattacat
gcactgggtaccagcagaagccaggtcctccccaaacctggattatgccccatccaacctggcttctggagtcctgctcgttcagtg
gcagtggtgtgggacctcttactcttcacaaatcagcagagtgagggtgaagatgctgccacttattactgccagcagtgaggatttaacc
caccacgttcgggtctgggaccaagctggagctgaagatggcgggtggctcggcggtgggtgatctggaggagtggtggagctctca
ggcttatctacagcagtcctgggctgagctggtgagcctgggacctcagtgagatgctcctgaaggcttctggctacacattaccagtt
25 acaatatgcactgggttaaagcagacacctagacagggcctggaatggattggagctatttatccaggaaatggtgatacttctacaatcag
aagttcaagggaaggccacactgactgtagacaaatcctccagcacagcctacatgcagctcagcagcctgacatctgaagactctcgg
gtctatttctgtgcaagagtggtgtactatagtaactcttactggacttctgatgtctggggcacaggaccacggtcaccgtctcttctgatca
ggagcccaaatcttctgacaaaactcacacatccccaccgtccccagcactgaactcctggggggatcgtcagttctcttctcccccaa
aaccgaaggacacctcatgatctccggaccttgaggatcatgcgtggtgtggagctgagccacgaagacctgaggtcaagttc
30 aactggtacgtggagcggcgtggaggtgcataatccaagacaagccgcgggaggagcagtlacaacagcacgtaccgtgtgtcagc
gtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtcaaggtctccaacaaagccctcccagccccatcgagaa
aacaatctccaaagccaaaggcagccccgagaaccacaggtgtacacctgccccatccgggatgagctgaccaagaaccaggtc
agcctgacctgcctggtaaggcttctatccagcgacatgcctggagtgaggagagcaatgggcagccggagaaactacaaga

WO 2005/037989

PCT/US2003/024918

ccacgcctcccgctgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggggaacgtct
tctcatgctccgctgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

5

2H7 scFv MH (SSS) MCH2WTH3

mdfqvqifsflisaviiargqivlsqpailsaspgkvtmtcrasssvsymhwyqqkpgsspkpwiapsn
lasgvparfsgsgtsysltisrveadaatyccqwsfnpptfgagtklelkdggsgggsgggssqaylqqsgaelvrpgasvk
msckasgytftsynmhwwkqtrqglewigaiypngdtsynqkfkkgkatltvdkssstaymqlssltedsavycarvvyysns
ywyfdvwtgtttvssdqepkssdkthtspspapellggssvflfppkpkdtlmisrtpetvctvvdvshedpevkfnwyvdgv
10 evhnaktkpreeqynstyrvsvltvlhqdwlngkeyckvsnkalpapietiskakgqprepvytlppsrdeltknqvsltclvk
gfypsdiavewesngqpennyktpvldsdgsfflyskltvdksrwqqgnvfscsvmhcalhnhytqkslspsgk

NT

5B9 scFv MTHWTH2CH3

15

aagcttgccgccatgaggttctctgctcagcttctggggctgctgtgctctggatccctggatccactgcagatattgt
gatgacgcaggctgcatttccaatccagtcactcttggaaacatcagcttccatctctgcaggctctagtaagagtctcctacatagtaattggc
atcacttatttgattggatctgcagaagccaggccagctctcctcagctcctgatttatcagatgtccaaccttgcctcaggagtccagacag
gttcagtagcagtggtgaggaactgatttcacactgagaatcagcagagtgaggctgaggatgtgggtgtttactgtgctcaaatct
agaactccgctcacgttcggtgctgggaccaagctggagctgaacggggtggcgggtggctcggcggtggtgggtgggtggcgcc
20 ggatcgtcacagggtgcagctgaagcagtcaggacctggcctagtgcagtcctcacagagcctgtccatcacctgcacagtctctggttctc
attaactacctatgctgtacactgggtcggcagctcctcaggaaagggtctggagtggtggagtgatatggagtgggtgaatcacagact
ataatgcagcttcatatccagactgagcatcaccaaggacgattccaagagccaagtttctttaaataaacagcttgaacctaataacac
agccatttattactgtgccagaaatgggggtgataactacccttattactatgctatggactactggggtcaaggaaacctcagtcaccgtctcc
tctgatcaggagcccaaatctctgacaaaactcacatccccaccgtcccagcactgaactcctggggggaccgtcagcttctctt
25 ccccccaaaacccaaggacacctcatgatctccggaccttgaggtcacatgcgtggtgggtgagcgtgagccacgaagacctgag
gtcaagttcaactggtacgtggacggcgtggaggtgcataatgccaagacaaagccgcgggaggagcagtacaacagcacgtaccgtg
tggtcagcgtcctcaccgtcctgcaccaggactggctgaatggcaaggagtacaagtgcaaggtctccaacaaagccctcccagcccc
atcgagaaaacaatctccaaagccaaaggcgagccccgagaaccacaggtgtacacctgcccccatccgggatgagctgaccaaga
accaggtcagcctgacctgcctgggtcaaaaggcttctatcccagcgacatcgccgtggagtgaggagagcaatgggcagccggagaacaa
30 ctaacagaccacgcctccgtgctggactccgacggctccttctctctacagcaagctcaccgtggacaagagcaggtggcagcaggg
gaacgtcttctcatgctccgtgatgcatgaggctctgcacaaccactacacgcagaagagcctctccctgtctccgggtaaatgatctaga

AA

WO 2005/037989

PCT/US2003/024918

5B9 scFv MTHWTCH2CH3

mrfsaqllgllvlwipgstadivmtqaafsnptlgtasiscrskslhsngitylywylqkpgqspqlliyqms
nlasgvpdrfsssgsgtdflrisrveadvgvyycanlelpltfagtklelkrgggsgggsgggssqvqlkqsgpglvqssqsl
sitctvsgfslttyavhwvrqspgkglewlgviwsggitdynaafisrlsitkddsksqvffkmnslqpndtaiyycarnggdnyppyy
5 amdywgqgtsvtvssdqepkssdkthtsppspapellggpsvflfppkpkdtlmisrtpetcvvvdvshedpevkfnwyvdgve
vhnaktkpreeqynstyrvsvltvlhqdwlngkeykckvsnkalpapietiskakgqprepvytlppsrdeitknqvsltelvkgf
ypsdiafewesngqpennykttppvldsdgsfflyskltvdksrwqqgnvfscsvmhcalnhhytqkslsispk

10

From the foregoing, it will be appreciated that, although specific embodiments of
the invention have been described herein for the purpose of illustration, various modifications
may be made without deviating from the spirit and scope of the invention. Accordingly, the
15 present invention is not limited except as by the appended claims.

WO 2005/037989

PCT/US2003/024918

CLAIMS

1. A binding domain-immunoglobulin fusion protein, comprising:
 - 5 (a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein said hinge region polypeptide is selected from the group consisting of (i) a wild-type human IgG1 immunoglobulin hinge region polypeptide, (ii) a mutated human IgG1 immunoglobulin hinge region polypeptide that is derived from a wild-type immunoglobulin hinge region polypeptide having three or more cysteine residues, wherein said mutated human
10 IgG1 immunoglobulin hinge region polypeptide contains two cysteine residues and wherein a first cysteine of the wild-type hinge region is not mutated, (iii) a mutated human IgG1 immunoglobulin hinge region polypeptide that is derived from a wild-type immunoglobulin hinge region polypeptide having three or more cysteine residues, wherein said mutated human IgG1 immunoglobulin hinge region polypeptide contains no more than one cysteine residue, and
15 (iv) a mutated human IgG1 immunoglobulin hinge region polypeptide that is derived from a wild-type immunoglobulin hinge region polypeptide having three or more cysteine residues, wherein said mutated human IgG1 immunoglobulin hinge region polypeptide contains no cysteine residues;
 - (b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to
20 the hinge region polypeptide; and
 - (c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide,
wherein:
 - (1) the binding domain-immunoglobulin fusion protein is capable of at least
25 one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation, and
 - (2) the binding domain polypeptide is capable of specifically binding to an antigen.
- 30 2. An isolated binding domain-immunoglobulin fusion protein comprising: a) a binding domain polypeptide capable of specifically binding to an antigen; b) an immunoglobulin hinge region polypeptide fused to said binding domain polypeptide, said immunoglobulin hinge region polypeptide comprising first, second, and third cysteine residues, where said first cysteine reside

WO 2005/037989

PCT/US2003/024918

is N-terminal to said second cysteine and said second cysteine is N-terminal to said third cysteine, wherein said first cysteine residue is not mutated and one or both of said second and third cysteine residues is substituted or deleted; and c) an N-terminally truncated immunoglobulin heavy chain constant region polypeptide fused to said immunoglobulin hinge
5 region polypeptide, wherein the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation.

3. The binding domain-immunoglobulin fusion protein of claim 1 or 2 wherein the binding
10 domain polypeptide comprises at least one immunoglobulin variable region polypeptide that is selected from the group consisting of an immunoglobulin light chain variable region polypeptide and an immunoglobulin heavy chain variable region polypeptide.

4. A binding domain-immunoglobulin fusion protein according to claim 3 which comprises
15 an immunoglobulin heavy chain variable region polypeptide, wherein said heavy chain variable region polypeptide is a human immunoglobulin heavy chain variable region polypeptide comprising a mutation at an amino acid at a location corresponding to amino acid position 11 in the first framework region of the heavy chain variable region.

20 5. A binding domain-immunoglobulin fusion protein according to claim 3 which comprises a polypeptide having a sequence selected from the group consisting of SEQ ID NO:___ and SEQ ID NO:___.

6. The binding domain -immunoglobulin fusion protein of claim 3 wherein the
25 immunoglobulin variable region polypeptide is derived from a human immunoglobulin.

7. The binding domain -immunoglobulin fusion protein of claim 3 wherein the immunoglobulin variable region polypeptide comprises a humanized immunoglobulin polypeptide sequence.

30

8. The binding domain-immunoglobulin fusion protein of claim 3 wherein the immunoglobulin variable region polypeptide is derived from a murine immunoglobulin.

WO 2005/037989

PCT/US2003/024918

9. The binding domain-immunoglobulin fusion protein of claim 1 or 2 wherein the binding domain polypeptide comprises:
 - (a) at least one immunoglobulin light chain variable region polypeptide;
 - (b) at least one immunoglobulin heavy chain variable region polypeptide; and
 - 5 (c) at least one linker polypeptide that is fused to the polypeptide of (a) and to the polypeptide of (b).
10. The binding domain-immunoglobulin fusion protein of claim 9 wherein the immunoglobulin light chain variable region and heavy chain variable region polypeptides are
10 derived from human immunoglobulins.
11. The binding domain-immunoglobulin fusion protein of claim 9 wherein the linker polypeptide comprises at least one polypeptide having as an amino acid sequence Gly-Gly-Gly-Gly-Ser [SEQ ID NO:___].
15
12. The binding domain-immunoglobulin fusion protein of claim 9 wherein the linker polypeptide comprises at least three repeats of a polypeptide having as an amino acid sequence Gly-Gly-Gly-Gly-Ser [SEQ ID NO:___].
- 20 13. A binding domain-immunoglobulin fusion protein according to claim 9 wherein the linker comprises a glycosylation site.
14. The fusion protein of claim 13 wherein the glycosylation site is selected from the group consisting of an asparagine-linked glycosylation site, an O-linked glycosylation site, a C-
25 mannosylation site, a glypiation site and a phosphoglycation site.
15. The binding domain-immunoglobulin fusion protein of claim 1 wherein at least one of the immunoglobulin heavy chain CH2 constant region polypeptide and the immunoglobulin heavy chain CH3 constant region polypeptide is derived from a human immunoglobulin heavy
30 chain.

WO 2005/037989

PCT/US2003/024918

16. The binding domain-immunoglobulin fusion protein of claim 1 wherein the immunoglobulin heavy chain constant region CH2 and CH3 polypeptides are of an isotype selected from the group consisting of human IgG and human IgA.
- 5 17. The binding domain-immunoglobulin fusion protein of claim 1, 2 or 73 wherein the antigen is selected from the group consisting of CD19, CD20, CD22, CD37, CD40, L6, CD2, CD28, CD30, CD40, CD50 (ICAM3), CD54 (ICAM1), CD80, CD86, B7-H1, CD134 (OX40), CD137 (41BB), CD152 (CTLA-4), CD153 (CD30 ligand), CD154 (CD40 ligand), ICOS, CD19, CD3, CD4, CD25, CD8, CD11b, CD14, CD25, CD56 and CD69.
- 10 18. The binding domain-immunoglobulin fusion protein of claim 1 or 2 wherein the binding domain polypeptide comprises a CD154 extracellular domain.
- 15 19. The binding domain-immunoglobulin fusion protein of claim 1 or 2 wherein the binding domain polypeptide comprises a CD154 extracellular domain and at least one immunoglobulin variable region polypeptide.
- 20 20. The binding domain-immunoglobulin fusion protein of claim 1 or 2 wherein the binding domain polypeptide comprises a CTLA-4 extracellular domain.
- 25 21. The binding domain-immunoglobulin fusion protein of claim 2 or 20 wherein at least one of the immunoglobulin heavy chain constant region polypeptides selected from the group consisting of a CH2 constant region polypeptide and a CH3 constant region polypeptide is a human IgG1 constant region polypeptide.
- 30 22. The binding domain-immunoglobulin fusion protein of claim 20 wherein at least one of the immunoglobulin heavy chain constant region polypeptides selected from the group consisting of a CH2 constant region polypeptide and a CH3 constant region polypeptide is a human IgA constant region polypeptide.
23. A binding domain-immunoglobulin fusion protein, comprising:
 - (a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide;

WO 2005/037989

PCT/US2003/024918

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide; and

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide,

5 wherein:

(1) the binding domain polypeptide comprises a CTLA-4 extracellular domain that is capable of specifically binding to at least one CTLA-4 ligand selected from the group consisting of CD80 and CD86,

(2) the immunoglobulin hinge region polypeptide comprises a polypeptide
10 that is selected from the group consisting of a human IgA hinge region polypeptide and a human IgG1 hinge region polypeptide,

(3) the immunoglobulin heavy chain CH2 constant region polypeptide comprises a polypeptide that is selected from the group consisting of a human IgA heavy chain CH2 constant region polypeptide and a human IgG1 heavy chain CH2 constant region
15 polypeptide,

(4) the immunoglobulin heavy chain CH3 constant region polypeptide comprises a polypeptide that is selected from the group consisting of a human IgA heavy chain CH3 constant region polypeptide and a human IgG1 heavy chain CH3 constant region polypeptide, and

(5) the binding domain-immunoglobulin fusion protein is capable of at least
20 one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation.

24. A binding domain-immunoglobulin fusion protein, comprising:

(a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein said hinge region polypeptide comprises a human IgE hinge region polypeptide;

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a human
30 IgE CH2 constant region polypeptide; and

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a human IgE CH3 constant region polypeptide

WO 2005/037989

PCT/US2003/024918

wherein:

- (1) the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and induction of an allergic response mechanism, and
- 5 (2) the binding domain polypeptide is capable of specifically binding to an antigen.

25. A binding domain-immunoglobulin fusion protein according to claim 24 that comprises a human IgE CH4 constant region polypeptide.

10

26. The binding domain-immunoglobulin fusion protein of claim 24 wherein the antigen is a tumor antigen.

27. A binding domain-immunoglobulin fusion protein, comprising:

15 (a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein the binding domain polypeptide is capable of specifically binding to at least one antigen that is present on an immune effector cell and wherein the hinge region polypeptide comprises a polypeptide selected from the group consisting of a human IgA hinge region polypeptide, a human IgG hinge region polypeptide, and a human IgE hinge region polypeptide;

20

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH2 constant region polypeptide, a human IgG CH2 constant region polypeptide, and a human IgE CH2 constant region polypeptide;

25

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH3 constant region polypeptide, a human IgG CH3 constant region polypeptide, and a human IgE CH3 constant region polypeptide; and

30

(d) a plasma membrane anchor domain polypeptide.

WO 2005/037989

PCT/US2003/024918

28. The binding domain-immunoglobulin fusion protein of claim 27 wherein the membrane anchor domain polypeptide comprises a transmembrane domain polypeptide.
29. The binding domain-immunoglobulin fusion protein of claim 27 wherein the membrane anchor domain polypeptide comprises a transmembrane domain polypeptide and a cytoplasmic tail polypeptide.
30. The binding domain-immunoglobulin fusion protein of claim 29 wherein the cytoplasmic tail polypeptide comprises an apoptosis signaling polypeptide sequence.
31. The binding domain-immunoglobulin fusion protein of claim 30 wherein the apoptosis signaling polypeptide sequence is derived from a receptor death domain polypeptide.
32. The binding domain-immunoglobulin fusion protein of claim 31 wherein the death domain polypeptide comprises a polypeptide selected from the group consisting of an ITIM domain, an ITAM domain, FADD, TRADD, RAIDD, CD95 (FAS/ Apo-1), TNFR1 and DR5.
33. The binding domain-immunoglobulin fusion protein of claim 30 wherein the apoptosis signaling polypeptide sequence comprises a polypeptide sequence derived from a caspase polypeptide that is selected from the group consisting of caspase-3 and caspase-8.
34. The binding domain-immunoglobulin fusion protein of claim 27 wherein the plasma membrane anchor domain polypeptide comprises a glycosyl-phosphatidylinositol-linkage polypeptide sequence.
35. The binding domain-immunoglobulin fusion protein of claim 27 wherein the antigen that is present on an immune effector cell is selected from the group consisting of CD2, CD28, CD30, CD40, CD50 (ICAM3), CD54 (ICAM1), CD80, CD86, B7-H1, CD134 (OX40), CD137 (41BB), CD152 (CTLA-4), CD153 (CD30 ligand), CD154 (CD40 ligand), ICOS, CD19, CD20, CD22, CD37, L6, CD3, CD4, CD25, CD8, CD11b, CD14, CD25, CD56 and CD69.
36. The binding domain-immunoglobulin fusion protein of claim 27 wherein the human IgG is human IgG1.

WO 2005/037989

PCT/US2003/024918

37. A binding domain-immunoglobulin fusion protein, comprising:

(a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein the binding domain polypeptide is capable of specifically binding to at least one antigen that is present on a cancer cell surface and wherein the hinge region polypeptide comprises a polypeptide selected from the group consisting of a human IgA hinge region polypeptide, a human IgG hinge region polypeptide, and a human IgE hinge region polypeptide;

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH2 constant region polypeptide, a human IgG CH2 constant region polypeptide, and a human IgE CH2 constant region polypeptide;

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH3 constant region polypeptide, a human IgG CH3 constant region polypeptide, and a human IgE CH3 constant region polypeptide; and

(d) a plasma membrane anchor domain polypeptide.

38. The binding domain-immunoglobulin fusion protein of claim 37 wherein the membrane anchor domain polypeptide comprises a transmembrane domain polypeptide.

39. The binding domain-immunoglobulin fusion protein of claim 37 wherein the membrane anchor domain polypeptide comprises a transmembrane domain polypeptide and a cytoplasmic tail polypeptide.

40. The binding domain-immunoglobulin fusion protein of claim 37 wherein the membrane anchor domain polypeptide comprises a glycosyl-phosphatidylinositol-linkage polypeptide sequence.

30

41. The binding domain-immunoglobulin fusion protein of claim 37 wherein the human IgG is human IgG1.

WO 2005/037989

PCT/US2003/024918

42. A binding domain-immunoglobulin fusion protein, comprising:

- (a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein said hinge region polypeptide comprises a wild-type human IgA hinge region polypeptide;
- 5 (b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a human IgA CH2 constant region polypeptide; and
- (c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a polypeptide selected from the group consisting of (i) a wild-type human IgA CH3 constant region polypeptide and (ii) a mutated human IgA CH3 constant region polypeptide that is incapable of associating with a J chain,

wherein:

- (1) the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation, and
- (2) the binding domain polypeptide is capable of specifically binding to an antigen.

43. The binding domain-immunoglobulin fusion protein of claim 42 wherein the mutated human IgA CH3 constant region polypeptide that is incapable of associating with a J chain is selected from the group consisting of (i) a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:___ and (ii) a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:___.

25

44. A binding domain-immunoglobulin fusion protein, comprising:

- (a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide;
- (b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a llama CH2 constant region polypeptide that is selected from the group consisting of a llama IgG1 CH2 constant region polypeptide, a llama IgG2 CH2 constant region polypeptide and a llama IgG3 CH2 constant region polypeptide; and

WO 2005/037989

PCT/US2003/024918

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a llama CH3 constant region polypeptide that is selected from the group consisting of a llama IgG1 CH3 constant region polypeptide, a llama IgG2 CH3 constant region polypeptide and a llama IgG3 CH3 constant region polypeptide

wherein:

- (1) the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and induction fixation of complement, and
- (2) the binding domain polypeptide is capable of specifically binding to an antigen.

45. A binding domain-immunoglobulin fusion protein according to claim 44 wherein the immunoglobulin hinge region polypeptide, the llama CH2 constant region polypeptide and the llama CH3 constant region polypeptide comprise sequences derived from a llama IgG1 polypeptide and wherein the fusion protein does not include a llama IgG1 CH1 domain.

46. A binding domain-immunoglobulin fusion protein according to any one of claims 1, 2, 23, 24, 27, 37, 42 or 44 wherein the hinge region polypeptide is mutated to contain a glycosylation site.

47. The fusion protein of claim 46 wherein the glycosylation site is selected from the group consisting of an asparagine-linked glycosylation site, an O-linked glycosylation site, a C-mannosylation site, a glypiation site and a phosphoglycation site.

48. A binding domain-immunoglobulin fusion protein according to any one of claims 1, 2, 23, 24, 27, 37, 42 or 44 wherein the binding domain polypeptide comprises two or more binding domain polypeptide sequences wherein each of said binding domain polypeptide sequences is capable of specifically binding to an antigen.

49. A binding domain-immunoglobulin fusion protein, comprising:

WO 2005/037989

PCT/US2003/024918

(a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein the hinge region polypeptide comprises an alternative hinge region polypeptide sequence;

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide; and

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide,

wherein:

(1) the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation, and

(2) the binding domain polypeptide is capable of specifically binding to an antigen.

50. A binding domain-immunoglobulin fusion protein, comprising:

(a) a binding domain polypeptide that is fused to an immunoglobulin hinge region polypeptide, wherein the binding domain polypeptide is capable of specifically binding to at least one antigen that is present on a cancer cell surface and wherein the hinge region polypeptide comprises an alternative hinge region polypeptide sequence;

(b) an immunoglobulin heavy chain CH2 constant region polypeptide that is fused to the hinge region polypeptide, wherein said CH2 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH2 constant region polypeptide, a human IgG CH2 constant region polypeptide, and a human IgE CH2 constant region polypeptide;

(c) an immunoglobulin heavy chain CH3 constant region polypeptide that is fused to the CH2 constant region polypeptide, wherein said CH3 constant region polypeptide comprises a polypeptide selected from the group consisting of a human IgA CH3 constant region polypeptide, a human IgG CH3 constant region polypeptide, and a human IgE CH3 constant region polypeptide; and

(d) a plasma membrane anchor domain polypeptide.

51. A binding domain-immunoglobulin fusion protein according to either claim 49 or claim 50 wherein the alternative hinge region polypeptide sequence comprises a polypeptide sequence

WO 2005/037989

PCT/US2003/024918

of at least ten continuous amino acids that are present in a sequence selected from the group consisting of SEQ ID NOS: __ - __.

52. An isolated polynucleotide encoding a binding domain-immunoglobulin fusion protein
5 according to any one of claims 1, 2, 23, 24, 27, 37, 42, 44, 49 and 50.

53. A recombinant expression construct comprising a polynucleotide according to claim 52 that is operably linked to a promoter.

10 54. A host cell transformed or transfected with a recombinant expression construct according to claim 53.

55. A method of producing a binding domain-immunoglobulin fusion protein, comprising the steps of:

- 15 (a) culturing a host cell according to claim 54 under conditions that permit expression of the binding domain-immunoglobulin fusion protein; and
- (b) isolating the binding domain-immunoglobulin fusion protein from the host cell culture.

56. A pharmaceutical composition comprising a binding domain-immunoglobulin fusion
20 protein according to any one of claims 1, 2, 23, 24, 42, 44, 49 or 50 in combination with a physiologically acceptable carrier.

57. A pharmaceutical composition comprising an isolated polynucleotide encoding a binding
25 domain-immunoglobulin fusion protein according to any one of claims 1, 2, 23, 24, 27, 37, 42, 44, 49 and 50 in combination with a physiologically acceptable carrier.

58. The use of a compound according to claim 1 in the preparation of a medicament for the treatment of a subject having or suspected of having a malignant condition or a B-cell disorder, comprising administering to a patient a therapeutically effective amount of a pharmaceutical
30 composition selected from the group consisting of the pharmaceutical composition of claim 56 and the pharmaceutical composition of claim 57.

WO 2005/037989

PCT/US2003/024918

59. The use of claim 58 wherein the malignant condition or B-cell disorder is selected from the group consisting of a B-cell lymphoma and a disease characterized by autoantibody production.

5 60. The use of claim 58 wherein the malignant condition or B-cell disorder is selected from the group consisting of rheumatoid arthritis, myasthenia gravis, Grave's disease, type I diabetes mellitus, multiple sclerosis and an autoimmune disease.

61. The use of claim 58 wherein the malignant condition is selected from the group
10 consisting of melanoma, carcinoma and sarcoma.

62. A binding domain-immunoglobulin fusion protein according to claim 2 wherein said second cysteine residue is substituted or deleted and said third cysteine residue is not substituted or deleted.

15

63. A binding domain-immunoglobulin fusion protein according to claim 62 wherein said second cysteine residue is substituted and not deleted.

64. A binding domain-immunoglobulin fusion protein according to claim 63 wherein said
20 second cysteine is replaced with serine.

65. A binding domain-immunoglobulin fusion protein according to claim 2 wherein said third cysteine residue is substituted or deleted and said second cysteine residue is not substituted or deleted.

25

66. A binding domain-immunoglobulin fusion protein according to claim 65 wherein said third cysteine residue is substituted and not deleted.

67. A binding domain-immunoglobulin fusion protein according to claim 66 wherein said
30 third cysteine is replaced with serine.

68. A binding domain-immunoglobulin fusion protein according to claim 2 wherein said second cysteine and said third cysteine residues are both substituted or deleted.

WO 2005/037989

PCT/US2003/024918

69. A binding domain-immunoglobulin fusion protein according to claim 68 wherein said second cysteine and said third cysteine are substituted.

5 70. A binding domain-immunoglobulin fusion protein according to claim 68 wherein said second cysteine and said third cysteine are replaced with serine.

71. A binding domain-immunoglobulin fusion protein according to any one of claims 2, 62, 63, 64, 65, 66, 67, 68, 69, or 70 wherein said N-terminally truncated immunoglobulin heavy
10 chain constant region polypeptide comprises an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

72. A binding domain-immunoglobulin fusion protein according to any one of claims 2, 62, 63, 64, 65, 66, 67, 68, 69, or 70 wherein said N-terminally truncated immunoglobulin heavy
15 chain constant region polypeptide consist essentially of an IgG CH2 constant region polypeptide attached to an immunoglobulin heavy chain IgG CH3 constant region polypeptide.

73. An isolated binding domain-immunoglobulin fusion protein comprising: a) a binding domain polypeptide capable of specifically binding to an antigen, said binding domain
20 polypeptide comprising an immunoglobulin light chain variable region polypeptide and an immunoglobulin heavy chain variable region polypeptide, wherein the leucine at position 11 in the first framework region of said heavy chain variable region polypeptide is substituted or deleted; b) an immunoglobulin hinge region polypeptide fused to said binding domain polypeptide; and c) an N-terminally truncated immunoglobulin heavy chain constant region
25 polypeptide fused to said immunoglobulin hinge region polypeptide, wherein the binding domain-immunoglobulin fusion protein is capable of at least one immunological activity selected from the group consisting of antibody dependent cell-mediated cytotoxicity and complement fixation.

30

WO 2005/037989

PCT/US2003/024918

FIG. 1A

1/53

2H7scFv-Ig cDNA and predicted amino acid sequence:

HindIII NcoI 2H7 V_L Leader Peptide→
 ~~~~~  
 M D F Q V Q I F S F L L I S A S  
 1 AAGCTTGCCG CC ATGGATTT TCAAGTGCAG ATTTTCAGCT TCCTGCTAAT CAGTGCTTCA

2H7 V<sub>L</sub>→  
 V I I A R G Q I V L S Q S P A I L S A S  
 61 GTCATAATTG CCAGAGGACA AATTGTTCTC TCCCAGTCTC CAGCAATCCT GTCTGCATCT

P G E K V T M T C R A S S S V S Y M H W  
 121 CCAGGGGAGA AGGTCACAAT GACTTGCCAGG GCCAGCTCAA GTGTAAGTTA CATGCACTGG

BamHI  
 ~~~~~  
 Y Q Q K P G S S P K P W I Y A P S N L A
 181 TACCAGCAGA AGCCAGGATC CTCCCCCAA CCCTGGATTT ATGCCCCATC CAACCTGGCT

S G V P A R F S G S G S G T S Y S L T I
 241 TCTGGAGTCC CTGCTCGCTT CAGTGGCAGT GGGTCTGGGA CCTCTTACTC TCTCACAATC

S R V E A E D A A T Y Y C Q Q W S F N P
 301 AGCAGAGTGG AGGCTGAAGA TGCTGCCACT TATTACTGCC AGCAGTGGAG TTTTAACCCA

(Gly₄Ser)₃ Linker
 P T F G A G T K L E L K G G G G S G G G
 361 CCCACGTTCTG GTGCTGGGAC CAAGCTGGAG CTGAAAGGTG GCGGTGGCTC GGGCGGTGGT

2H7 V_H→
 G S G G G G S S Q A Y L Q Q S G A E L V
 421 GGATCTGGAG GAGGTGGGAG CTCTCAGGCT TATCTACAGC AGTCTGGGGC TGAGCTGGTG

R P G A S V K M S C K A S G Y T F T S Y
 481 AGGCCTGGGG CCTCAGTGAA GATGTCCTGC AAGGCTTCTG GCTACACATT TACCAGTTAC

N M H W V K Q T P R Q G L E W I G A I Y
 541 AATATGCACT GGGTAAAGCA GACACCTAGA CAGGGCCTGG AATGGATTGG AGCTATTATT

P G N G D T S Y N Q K F K G K A T L T V
 601 CCAGGAAATG GTGATACTTC CTACAATCAG AAGTTCAAGG GCAAGGCCAC ACTGACTGTA

D K S S S T A Y M Q L S S L T S E D S A
 661 GACAAATCCT CCAGCACAGC CTACATGCAG CTCAGCAGCC TGACATCTGA AGACTCTGCG

V Y F C A R V V Y Y S N S Y W Y F D V W
 721 GTCTATTCTT GTGCAAGAGT GGTGTACTAT AGTAACTCTT ACTGGTACTT CGATGTCTGG

WO 2005/037989

PCT/US2003/024918

2/53

FIG.1B

BclI

-----human IgG1 Fc domain →

```

781  G T G T T V T V S D Q E P K S C D K T H
    GGCACAGGGA CCACGGTCAC CGTCTCTGAT CAGGAGCCCA AATCTTGTGA CAAAACCTCAC

841  T C P P C P A P E L L G G P S V F L F P
    ACATGCCCAC CGTGCCCAGC ACCTGAACTC CTGGGGGGGAC CGTCAGTCTT CCTCTTCCCC

901  P K P K D T L M I S R T P E V T C V V V
    CCAAAACCCA AGGACACCCCT CATGATCTCC CGGACCCCTG AGGTCACATG CGTGGTGGTG

961  D V S H E D P E V K F N W Y V D G V E V
    GACGTGAGCC ACGAAGACCC TGAGGTCAAG TTCAACTGGT ACGTGGACGG CGTGGAGGTG

1021 H N A K T K P R E E Q Y N S T Y R V V S
    CATAATGCCA AGACAAAGCC GCGGGAGGAG CAGTACAACA GCACGTACCG TGTGGTCAGC

1081 V L T V L H Q D W L N G K E Y K C K V S
    GTCCTCACCG TCCTGCACCA GGACTGGCTG AATGGCAAGG AGTACAAGTG CAAGGTCTCC

1141 N K A L P A P I E K T I S K A K G Q P R
    AACAAAGCCC TCCCAGCCCC CATCGAGAAA ACAATCTCCA AAGCCAAAGG GCAGCCCCGA

1201 E P Q V Y T L P P S R D E L T K N Q V S
    GAACCACAGG TGTACACCCT GCCCCCATCC CGGGATGAGC TGACCAAGAA CCAGGTCAGC

1261 L T C L V K G F Y P S D I A V E W E S N
    CTGACCTGCC TGGTCAAAGG CTTCTATCCC AGCGACATCG CCGTGGAGTG GGAGAGCAAT

1321 G Q P E N N Y K T T P P V L D S D G S F
    GGGCAGCCGG AGAACAACTA CAAGACCACG CCTCCCCTGC TGGACTCCGA CGGCTCCTTC

1381 F L Y S K L T V D K S R W Q Q G N V F S
    TTCCTCTACA GCAAGTCAC CGTGGACAAG AGCAGGTGGC AGCAGGGGAA CGTCTTCTCA

1441 C S V M H E A L H N H Y T Q K S L S L S
    TGCTCCGTGA TGCATGAGGC TCTGCACAAC CACTACACGC AGAAGAGCCT CTCCTGTCT

```

XbaI

~~~~~

```

1501 P G K * S R
    CCGGGTAAAT GATCTAGA


```

WO 2005/037989

PCT/US2003/024918

3/53

# **FIG.2**




| Clone      | LFE @ 1:50 | Estimated Concentration<br>(µg/ml) |
|------------|------------|------------------------------------|
| D2         | 26.1       | 56                                 |
| IIIC6      | 25.7       | 55                                 |
| IVA3       | 28.6       | 61                                 |
| Spent bulk | 29.6       | 64                                 |

WO 2005/037989

PCT/US2003/024918

4/53

**FIG.3**



WO 2005/037989

PCT/US2003/024918

5/53

## FIG. 4A

**Complement Mediated B Cell Killing After Binding of CD20-targeted 2H7 Derivatives:**

| 2H7scFv-Ig Concentration | RAMOS | BJAB |
|--------------------------|-------|------|
| 20 µg/ml + complement    | 0.16  | 0.07 |
| 5 µg/ml + complement     | 0.2   | N.D. |
| 1.25 µg/ml + complement  | 0.32  | 0.1  |
| Complement alone         | 0.98  | 0.94 |


\*Viability was determined by trypan blue exclusion and is tabulated as the fraction of viable cells out of the total number of cells counted.

\*\*N.D. (not determined).

## FIG. 4B

**Antibody-dependent cellular cytotoxicity (ADCC) mediated by 2H7scFv-Ig:**

**ADCC Activity of 2H7scFv-Ig on Ramos Cells**




WO 2005/037989

PCT/US2003/024918

6/53

**FIG. 5**




WO 2005/037989


PCT/US2003/024918

7/53

**FIG.6A**



**FIG.6B**



WO 2005/037989

PCT/US2003/024918

8/53

**FIG. 7A**

2H7-CD154 L2 cDNA and predicted amino acid sequence:

HindIII      NcoI    2H7 V<sub>L</sub> Leader Peptide →  
 ~~~~~      ~~~~~  
 1 **AAGCTT**GCCG CC ATGGATT^T TCAAGTGCAG ATTTTCAGCT TCCTGCTAAT CAGTGCCTCA
 M D F Q V Q I F S F L L I S A S
 2H7 V_L →
 61 GTCA**TAAT**TG CCAGAGGACA AATGTTCTC TCCAGTCTC CAGCAATCCT GTCTGCATCT
 V I I A R G Q I V L S Q S P A I L S A S
 121 CCAGGGGAGA AGGTCA**CAAT** GACTTGCAGG GCCAGCTCAA GTGTAAGTTA CATGCACTGG
 P G E K V T M T C R A S S S V S Y M H W
 BamHI
                                          ~~~~~  
 181    TACCAGCAGA AGCCAGGATC CTCCCC**CAAA** CCCTGGATT<sup>T</sup> ATGCCCCATC CAACCTGGCT  
                                          Y Q Q K P G S   S P K   P W I Y A P S   N L A  
 241    TCTGGAGTCC CTGCTCGCTT CAGTGGCAGT GGGTCTGGGA CCTCTTACTC TCTCACAATC  
                                          S G V P A R F   S G S   G S G T S Y S   L T I  
 301    AGCAGAGTGG AGGCTGAAGA TGCTGCCACT TATTACTGCC AGCAGTGGAG TTTTAACCCA  
                                          S R V E A E D   A A T   Y Y C Q Q W S   F N P  
                                          (Gly<sub>4</sub>Ser)<sub>3</sub> Linker →  
 361    CCCACGTT**CG** GTGCTGGGAC CAAGCTGGAG CTGAAAGGTG GCGGTGGCTC GGGCGGTGGT  
                                          P T F G A G T   K L E   L K G G G G S   G G G  
                                          2H7 V<sub>H</sub> →  
 421    GGATCTGGAG GAGGTGGGAG CTCTCAGGCT TATCTACAGC AGTCTGGGGC TGAGCTGGTG  
                                          G S G G G G S   S Q A   Y L Q Q S G A   E L V  
 481    AGGCCTGGGG CCTCAGTGAA GATGTCCTGC AAGGCTTCTG GCTACACATT TACCAGTTAC  
                                          R P G A S V K   M S C   K A S G Y T F   T S Y  
 541    AATATGCACT GGGTAAAGCA GACACCTAGA CAGGGCCTGG AATGGATTGG AGCTATTTAT  
                                          N M H W V K Q   T P R   Q G L E W I G   A I Y  
 601    CCAGGAAATG GTGATACTC CTACAATCAG AAGTTCAAGG GCAAGGCCAC ACTGACTGTA  
                                          P G N G D T S   Y N Q   K F K G K A T   L T V  
 661    GACAAATCCT CCAGCACAGC CTACATGCAG CTCAGCAGCC TGACATCTGA AGACTCTGCG  
                                          D K S S S T A   Y M Q   L S S L T S E   D S A  
 721    GTCTATTTCT GTGCAAGAGT GGTGTACTAT AGTAACTCTT ACTGGTACTT CGATGTCTGG  
                                          V Y F C A R V   V Y Y   S N S Y W Y F   D V W

WO 2005/037989

PCT/US2003/024918

9/53

**FIG.7B**

human CD154/amino acid 48→

Bcl/Bam hybrid site

781 | G T G T T V T V S D P R R L D K I E D E  
GGCACAGGGA CCACGGTCAC CGTCTCTGAT CCAAGAAGGT TGGACAAGAT AGAAGATGAA

841 R N L H E D F V F M K T I Q R C N T G E  
AGGAATCTTC ATGAAGATTT TGTATTTCATG AAAACGATAC AGAGATGCAA CACAGGAGAA

901 R S L S L L N C E E I K S Q F E G F V K  
AGATCCTTAT CCTTACTGAA CTGTGAGGAG ATTAAAAGCC AGTTTGAAGG CTTTGTGAAG

BclI

961 D I M L N K E E T K K E N S F E M Q K G  
GATATAATGT TAAACAAAGA GGAGACGAAG AAAGAAAACA GCTTTGAAAT GCAAAAAGGT

BclI  
~~~~~

1021 D Q N P Q I A A H V I S E A S S K T T S
GATCAGAATC CTCAAATTGC GGCACATGTC ATAAGTGAGG CCAGCAGTAA AACAACTCT

1081 V L Q W A E K G Y Y T M S N N L V T L E
GTGTTACAGT GGGCTGAAAA AGGATACTAC ACCATGAGCA ACAACTTGGT AACCTCGGAA

1141 N G K Q L T V K R Q G L Y Y I Y A Q V T
AATGGGAAAC AGCTGACCGT TAAAAGACAA GGACTCTATT ATATCTATGC CCAAGTCACC

HindIII
~~~~~

1201 F C S N R E A S S Q A P F I A S L C L K  
TTCTGTTCCA ATCGGGAAGC TTCGAGTCAA GCTCCATTTA TAGCCAGCCT CTGCCTAAAG

1261 S P G R F E R I L L R A A N T H S S A K  
TCCCCCGGTA GATTCGAGAG AATCTTACTC AGAGCTGCAA ATACCCACAG TTCGCGCAA

1321 P C G Q Q S I H L G G V F E L Q P G A S  
CCTTGCGGGC AACAATCCAT TCACTTGGGA GGAGTATTTG AATTGCAACC AGGTGCTTCG

NcoI  
~~~~~

1381 V F V N V T D P S Q V S H G T G F T S F
GTGTTTGTCA ATGTGACTGA TCCAAGCCAA GTGAGCCATG GCACTGGCTT CACGTCCTTT

XhoI XbaI
~~~~~                      ~~~~~

1441 G L L K L E \* \* S R  
GGCTTACTCA AACTCGAGTG ATAATCTAGA



WO 2005/037989

PCT/US2003/024918

10/53

**FIG.7C****2H7scFv-CD154 S4 cDNA and predicted amino acid sequence:**

HindIII      NcoI  
 ~~~~~~  
 ~~~~~~2H7 V<sub>L</sub> Leader Peptide→  
                   M D F Q V Q I F S F L L I S A S  
 1 AAGCTTGCCG CC ATGGATT TCAAGTGCAG ATTTTCAGCT TCCTGCTAAT CAGTGCTTCA

                  2H7 V<sub>L</sub> →  
                   V I I A R G Q I V L S Q S P A I L S A S  
 61 GTCATAATTG CCAGAGGACA AATTGTTCTC TCCAGTCTC CAGCAATCCT GTCTGCATCT

                  P G E K V T M T C R A S S S V S Y M H W  
 121 CCAGGGGAGA AGGTCACAAT GACTGTCAGG GCCAGCTCAA GTGTAAGTTA CATGCACTGG

                  BamHI  
                   ~~~~~  
 Y Q Q K P G S S P K P W I Y A P S N L A
 181 TACCAGCAGA AGCCAGGATC CTCCCCAAA CCCTGGATT TATGCCCCATC CAACCTGGCT

 S G V P A R F S G S G S G T S Y S L T I
 241 TCTGGAGTCC CTGCTCGCTT CAGTGGCAGT GGGTCTGGGA CCTCTTACTC TCTCACAATC

 S R V E A E D A A T Y Y C Q Q W S F N P
 301 AGCAGAGTGG AGGCTGAAGA TGCTGCCACT TATTACTGCC AGCAGTGGAG TTTTAACCCA

 (Gly₄Ser)₃ Linker →
 P T F G A G T K L E L K G G G G S G G G
 361 CCCACGTTG GTGCTGGGAC CAAGCTGGAG CTGAAAGGTG GCGGTGGCTC GGGCGGTGGT

 2H7 V_H →
 G S G G G G S S Q A Y L Q Q S G A E L V
 421 GGATCTGGAG GAGGTGGGAG CTCTCAGGCT TATCTACAGC AGTCTGGGGC TGAGCTGGTG

 R P G A S V K M S C K A S G Y T F T S Y
 481 AGGCCTGGGG CCTCAGTGAA GATGTCCTGC AAGGCTTCTG GCTACACATT TACCAGTTAC

 N M H W V K Q T P R Q G L E W I G A I Y
 541 AATATGCACT GGGTAAAGCA GACACCTAGA CAGGGCCTGG AATGGATTGG AGCTATTTAT

 P G N G D T S Y N Q K F K G K A T L T V
 601 CCAGGAAATG GTGATACTTC CTACAATCAG AAGTTCAAGG GCAAGGCCAC ACTGACTGTA

 D K S S S T A Y M Q L S S L T S E D S A
 661 GACAAATCCT CCAGCACAGC CTACATGCAG CTCAGCAGCC TGACATCTGA AGACTCTGCG

 V Y F C A R V V Y Y S N S Y W Y F D V W
 721 GTCTATTTCT GTGCAAGAGT GGTGTACTAT AGTAACTCTT ACTGGTACTT CGATGTCTGG

WO 2005/037989

PCT/US2003/024918

11/53

FIG.7D

human CD154/amino acid 108 →

```

                                Bcl/Bam hybrid site          BclI
      G T G T T V T V S D P E N S F E M Q K G
781  GGCACAGGGA CCACGGTCAC CGTCTCTGAT CCAGAAAACA GCTTTGAAAT GCAAAAAGGT

      BclI
      -----
      D Q N P Q I A A H V I S E A S S K T T S
841  GATCAGAATC CTCAAATTGC GGCACATGTC ATAAGTGAGG CCAGCAGTAA AACAACATCT

      V L Q W A E K G Y Y T M S N N L V T L E
901  GTGTTACAGT GGGCTGAAAA AGGATACTAC ACCATGAGCA ACAACTTGGT AACCCCTGGAA

      N G K Q L T V K R Q G L Y Y I Y A Q V T
961  AATGGGAAAC AGCTGACCGT TAAAAGACAA GGACTCTATT ATATCTATGC CCAAGTCACC

                                HindIII
                                -----
      F C S N R E A S S Q A P F I A S L C L K
1021 TTCTGTTCCA ATCGGGAAGC TTCGAGTCAA GCTCCATTTA TAGCCAGCCT CTGCCTAAAG

      S P G R F E R I L L R A A N T H S S A K
1081 TCCCCCGGTA GATTGAGAG AATCTTACTC AGAGCTGCAA ATACCCACAG TTCCGCCAAA


      P C G Q Q S I H L G G V F E L Q P G A S
1141 CCTGCGGGC AACAATCCAT TCACTTGGGA GGAGTATTTG AATTGCAACC AGGTGCTTCG

                                NcoI
                                -----
      V F V N V T D P S Q V S H G T G F T S F
1201 GTGTTTGTCA ATGTGACTGA TCCAAGCCAA GTGAGCCATG GCACTGGCTT CACGTCCTTT

                                XhoI          XbaI
                                -----
      G L L K L E * * S R
1261 GGCTTACTCA AACTCGAGTG ATAATCTAGA
  
```

12/53

FIG. 8




CD20 CHO cell targets + (control or fusion protein)
+ Biotin-CD40Ig + PE-SA

WO 2005/037989

PCT/US2003/024918

13/53

FIG.9




.....control supernatant 2H7scFv-CD154 supernatant

WO 2005/037989

PCT/US2003/024918

14/53




WO 2005/037989

PCT/US2003/024918

15/53

FIG. 11




WO 2005/037989

PCT/US2003/024918


16/53

FIG. 12



17/53

FIG. 13




WO 2005/037989

PCT/US2003/024918

18/53

FIG. 14




WO 2005/037989

PCT/US2003/024918

19/53

FIG. 15




| Day | Monkey J99231 | | Monkey K99334 | |
|----------------------------|---------------|---------------------------------------|---------------|---------------------------------------|
| | LFE(1:40) | Concentration
($\mu\text{g/mL}$) | LFE(1:40) | Concentration
($\mu\text{g/mL}$) |
| Injection \rightarrow -7 | 2.41 | <0.6 $\mu\text{g/mL}$ | 1.51 | <0.4 $\mu\text{g/mL}$ |
| 0 | 2.22 | <0.6 $\mu\text{g/mL}$ | 1.63 | <0.4 $\mu\text{g/mL}$ |
| 1 | 73.8 | 220 $\mu\text{g/mL}$ | 44.4 | 100 $\mu\text{g/mL}$ |
| Injection \rightarrow 3 | 20.0 | 28 $\mu\text{g/mL}$ | 40.2 | 80 $\mu\text{g/mL}$ |
| 7 | 15.6 | 24 $\mu\text{g/mL}$ | 15.7 | 24 $\mu\text{g/mL}$ |
| 8 | 39.1 | 80 $\mu\text{g/mL}$ | 42.6 | 92 $\mu\text{g/mL}$ |
| 10 | 11.5 | 18 $\mu\text{g/mL}$ | 2.74 | 1.2 $\mu\text{g/mL}$ |
| 14 | 2.05 | 0.6 mg/mL | 1.96 | 0.6 $\mu\text{g/mL}$ |

WO 2005/037989


PCT/US2003/024918

FIG. 16



21/53

FIG.17




WO 2005/037989

PCT/US2003/024918

22/53

FIG. 18



WO 2005/037989

PCT/US2003/024918

FIG. 19A

23/53




FIG. 19B





FIG. 19C




WO 2005/037989

PCT/US2003/024918


24/53

FIG.20




25/53

FIG.21



26/53

FIG.22



WO 2005/037989

PCT/US2003/024918

27/53

FIG.23

| | Hinge | CH2 |
|--|---------------------------|--|
| Human IgG1: | DOEPKSCDKT-----HTCPPC | PAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDG |
| Llama IgG2: | DOEPKTPKQPQPQPNPTTESKCPKC | PAPELLGGPSVFLFPPKPKDVLISIGRPEVTCVVVDVGQEDPEVSFNWYIDG |
| Llama IgG1: | --EPHGG-----CTCPQC | PAPELLGGPSVFLFPPKPKDVLISIGRPEVTCVVVDVGKEDPEVNFNWIIDG |
| Llama IgG3: | --AHHSEDP-----SKCPKC | PGPELLGGPTVFLFPPKAKDVLISITRKPEVTCVWVTKTLRSSSSWSVDD |
| CH3 | | |
| VEVHNAKTPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIISKAKGQPREPQVYITLPPSRDELTKNQVSLT | | |
| TAEVRASTRPKEEQFNSTYRVVSVLP IQHQQDWLTGKEFKCKVNNKALPAPIEKTIISKAKGQTPREPQVYITLAPHREELAKDTVSVT | | |
| VEVRTANTKPKKEEQFNSTYRVVSVLP IQHQQDWLTGKEFKCKVNNKALPAPIERTISKAKGQTPREPQVYITLAPHREELAKDTVSVT | | |
| TEVHTAETKPKKEEQFNSTYRVVSVLP IQHQQDWLTGKEFKCKVNNKALPAPIERTISKAKGQTPREPQVYITLAPHREELAKDTVSVT | | |
| CH2 | | |
| CLVKGFFPSDIAVWESNGQPEN--NYKTTPPVLDSDGSFFFLYSKLTVDKSRWQQGNVFCSCVMHEALHNHYTQKSLSLSPGK | | |
| CLVKGFFPPDINVEWQRNGQPESEGTYATTPPQLDNDGTGYFLXSKXSVGKNTWQQGETFTCVVMHEALHNHYTQKSITQSSGK | | |
| CLVKGFFPADINVEWQRNGQPESEGTYANTPPQLDNDGTGYFLYSRLSVGKNTWQGETLTGVVMHEALHNHYTQKSITQSSGK | | |
| CLVKGFFFPADINVEWQRNGQPESEGTYANTPPQLDNDGTGYFLYSKLSVGKNTWQQGEVFTCVVMHEALHNHYTQKSITQSSGK | | |

WO 2005/037989

PCT/US2003/024918

FIG.24

28/53





Figure 25




WO 2005/037989

PCT/US2003/024918

30/53

FIG.26




WO 2005/037989

PCT/US2003/024918

31/53

FIG.27



32/53

FIG.28






FIG. 29



34/53

FIG.30



WO 2005/037989

PCT/US2003/024918

35/53


FIG. 31

| Name Identifier | Hinge Sequence | CH2 Sequence | CH3 Sequence | SEQ ID NO: |
|--|----------------------------|------------------------------------|---|------------|
| IgG WTH (CCC)
WTCH2CH3 | IgG1 WT Hinge (CCC) | Wild Type CH2 | Wild Type CH3 | |
| IgG MTH (SSS)
WTCH2CH3 | IgG1 Mutant Hinge
(SSS) | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| VH SER 11 IgG
MTH (SSS)
WTCH2CH3 | IgG1 Mutant Hinge
(SSS) | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| IgG (SSC)
WTCH2CH3 | IgG1 Mutant Hinge
(SSC) | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| IgG (SCS)
WTCH2CH3 | IgG1 Mutant Hinge
(SCS) | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| IgG (CSS)
WTCH2CH3 | IgG1 Mutant Hinge (CSS) | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| IgG MTH(SSS)
MTCH2WTCH3 | IgG1 Mutant Hinge
(SSS) | Mutant CH2 (IgG1)
Pro ? Ser 238 | Wild type CH3 (IgG1) | |
| IgAH IgGWTCH2CH3 | IgA Hinge | Wild type CH2 (IgG1) | Wild type CH3 (IgG1) | |
| IgAH IgACH2CH3 | IgA Hinge | Wild type CH2 (IgA) | Wild type CH3 (IgA) | |
| IgAH IgA-T4 | IgA Hinge | Wild type CH2 (IgA) | Truncated CH3 (IgA)
(deletion of 4 amino acids at
carboxy terminus) | |

WO 2005/037989

PCT/US2003/024918

FIG.32



WO 2005/037989

PCT/US2003/024918

37/53

FIG.33A




FIG.33B






FIG.33C



38/53


FIG.34



- ◆ 2H7 scFv WTH (CCC) WTCH2CH3
- 2H7 scFv MTH (CSS) WTCH2CH3
- ▲ 2H7 scFv MTH (SCS) WTCH2CH3
- * 2H7 scFv MTH (SSC) WTCH2CH3
- * 2H7 scFv VH11SER WTH (CCC) WTCH2CH3

39/53

FIG.35




WO 2005/037989

PCT/US2003/024918


40/53

FIG.36




41/53

FIG.37



42/53

FIG.38



WO 2005/037989

PCT/US2003/024918

43/53

FIG.39A





FIG.39B



WO 2005/037989

PCT/US2003/024918

44/53

FIG.40

